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“Let us keep looking in spite of everything. Let us keep searching 
It is indeed the best method of finding, and perhaps thanks to our efforts, 
the verdict we will give such a patient tomorrow 
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Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration 
(FTLD) are clinically distinct neurodegenerative diseases that are connected by 
genetic and pathological overlap. ALS patients present with muscle weakness 
and spasticity associated with degeneration of motor neurons in the motor 
cortex, brainstem, and spinal cord that ultimately leads to death. In contrast, 
patients with FTLD display cognitive dysfunction associated with degeneration 
of neurons in the frontal and temporal lobes of the brain. Despite being 
clinically distinct, 15% of individuals presenting FTLD also have ALS, whereas 
30% of individuals with ALS will develop FTLD. This implies that these two 
neurodegenerative diseases are part of a shared clinical spectrum. In recent 
years, several mechanisms have been proposed as contributory factors in the 
pathogenesis of neuron damage in ALS and FTLD, including excitoxicity, 
mitochondrial and energy metabolism failure, oxidative stress damage, 
altered glial cells, inflammation, cytoskeletal abnormalities, alterations in RNA 
metabolism, and altered TDP-43 metabolism, among others. However, it is 
poor known about the etiology of these disorders and their possible 
treatment. The objective of the investigations presented in this doctoral thesis 
is focused in the identification of new molecular alterations underlying motor 
and cognitive changes in post-mortem human spinal cord and brain samples 
of ALS patients and brain samples of FTLD-TDP patients compared with 
controls, combining microarray, mRNA, protein and enzyme assays studies. 
The obtained results have identified molecular alterations in ALS and FTLD of 
different biological functions and cellular pathways including changes in 
mitochondrial energy metabolism, neuroinflammation, neuronal structure, 
neurotransmission, axonal transport mechanisms and oligodendrocyte 
function; allowing in turn, the screening and identification of new candidate 











































































































Ageing, which all creatures must encounter, is a challenge to every living 
organism. In the human body, it is estimated that cell division and metabolism 
occur exuberantly until about twenty-five years of age. Beyond this time, 
subsidiary products of metabolism and cell damage accumulate and the 
phenotypes of ageing appear, causing appearance of disease in the long term. 
Among age-related diseases, neurodegenerative diseases (NDD) have drawn 
a lot of attention due to their lack of effective treatment, their irreversibility 
and the economic and social cost that they represent (Hung et al., 2010). 
Neurodegenerative disease is an umbrella term for a range of conditions that 
primarily affect the neurons in the human brain. Etymologically, the word 
neurodegeneration is composed of the prefix “neuro-,” which designates 
nerve cells, and “degeneration,” which refers to, in the case of tissues or 
organs, a process of losing structure or function, including death of neurons. 
In practice, NDD represent a large group of heterogeneous neurological 
disorders with variegated clinical and pathological expressions affecting 
specific subsets of neurons in specific functional anatomic systems, which 
arise for reasons that are not well-understood and progress in a relentless 
manner, affecting the structure and function of the central nervous system 
and/or peripheral nervous system (Przedborski et al., 2003).  
 






Intracellular protein aggregates are a common neuropathological feature of 
all neurodegenerative diseases, suggesting that these disorders might share 
cellular and molecular alterations (Bayer, 2013). These disorders are 
caracterized by the aberrant aggregation of a protein with physiological 
function in normal states. In all cases, proteins aggregate due to several 
combined factors including mutations in specific genes, changes in alternative 
splicing, enhanced protein production, aberrant post-translational 
modifications (e.g. phosphorylation, advanced glycation, deamidation, 
truncation) and altered protein clearance, which result in a change in the 
conformation of the protein different from its native condition with loss of 
binding partners, and leading to reticular stress, oxidative damage and 
inflammatory responses, among other reactions (Carrel and Lomas, 1997; 
Kovacs et al., 2010).  
 
Thus, altered proteins become pathologically active, aggregating and 
accumulating at different subcellular locations and resulting in a toxic gain or 
loss of function by interference with normal cellular processes (Nijholt et al., 
2011). It is important to note that the risk of self-association and aggregation, 
associated or not with a genetic mutation, is largely increased by proteins 
which are inherently able to undergo radical changes in their conformation 
(Carrel and Lomas, 1997).  
 
In addition to proteostasis network disturbances, proteinopathies include 
fundamental molecular abnormalities involved in basic mechanisms of 
neuronal loss and selective vulnerability. These include oxidative stress and 
free radical formation, mitochondrial dysfunction and impaired energectic 
metabolism, deoxyribonucleic acid (DNA) damage, neuroinflammation and 





axonal transport, among other mechanisms (Jellinger, 2010; Nijholt et al., 
2011). 
 
These common features allow grouping of these NDD under the term of 
“protein misfolding diseases” or “proteinopathies”, characterized either by a 
single type of proteinaceous aggregate or by two different aggregated 
proteins. However, proteinopathies are often mixed, making a definite 
diagnosis and therapy difficult.  
 
The period between the first events initiating neurodegeneration and the 
clinical manifestation may last for decades.  The aggregates accumulate early 
in the lifetime of the individual, but only manifest clinically in middle or late 
life (Skovronsky et al., 2006). Major clinical symptoms are cognitive decline, 
dementia and movement disorders, and combinations of them. Most cases 
are sporadic, but the evidence for genetic causative factors is very strong, as 
many of the disorders are closely linked to mutations that make the mutated 
protein more prone to misfold and aggregate (Bertram and Tanzi, 2005). 
Neverthless, the most common risk factors are ageing (Walker and LeVine, 
2000) and sometimes traumatic brain injury (DeKosky et al., 2010) in 
combination with other environmental and endogenous factors (Skovronsky 
et al., 2006).  
 
The most prevalent proteinopathy is Alzheimer's disease (AD) although many 
more exist, such as Parkinson's disease (PD), Lewy body disease (LBD), prion 
diseases, tauopathies, amyotrophic lateral sclerosis (ALS), frontotemporal 
lobar degeneration (FTLD), Huntigton’s disease, certain familial hereditary 
spinocerebellar ataxias, and many other disorders like familial British and 






Protein Disease type 
Aβ Alzheimer's Disease (AD) 
Tau 
Globular glial tauopathy (GGT), Corticobasal degeneration (CBD),  
Progressive supranuclear palsy (PSP), Argyrophilic grain disease (AGD), 
Pick disease (PiD), FTD and PD linked to chr-17 tauopathy (FTDP-17T), 
Primary age-related tauopathy (PART) 
TDP-43 
Frontotemporal lobar degeneration TDP-43 (FTLD-TDP), Motor neuron 
disease TDP-43 (MND-TDP/ALS), Frontotemporal lobar degeneration 
with motor neuron disease TDP-43 (FTLD-MND-TDP)  
FUS 
Motor neuron disease FUS (MND-FUS), Atypical FTLD with ubiquitinated 
inclusions (aFTLD-U), Neurofilament intermediate filament inclusion 
disease (NIFID), Basophilic inclusion body disease (BIBD) 
α-syn 
Parkinson's disease (PD), Dementia with Lewy bodies (DLB), Multiple 
system atrophy (MSA) 
PrP 
Creutzfeldt-Jakob disease (CJD), fatal insomnia (FI), Kuru, Gerstmann-
Sträussler-Scheinker disease (GSS), variably protease-sensitive 
prionopathy (vPSPr) 
TRD 
Huntington's Disease (HD), Spinocerebellar ataxia (SCA), Fragile X 
associated tremor and ataxia syndrome (FXTAS), Spinal and bulbar 
muscular atrophy (SBMA), Dentatorubral-pallidoluysian atrophy 
(DRPLA) 
Others 
Neuroserpinopathy, Heredetiray ferritinopathy, neurodegeneration 
with brain iron accumulation (NBIA), Hereditary amyloidoses 
Table I. List of major neurodegenerative disorders classified on the basis of their characteristic 
protein alterations. Abbreviations: alpha-synuclein (α-syn); Beta-amyloid (Aβ); Fused in 
sarcoma (FUS); Prion protein (PrP); triplet repeat diseases (TRD); modified from Kovacs 2016. 
 
As mentioned above, among the different protein aggregates, neuronal 
intracytoplasmic transactive response (TAR) DNA binding protein 43 (TDP-43)-
immunoreactive inclusions are neuropathological hallmarks of the majority of 
cases with ALS and, by definition, of all cases of FTLD-TDP, including cases with 
C9ORF72 mutated forms in both diseases.  
 
The present thesis is focused on the study of ALS, FTLD-TDP and c9FTLD (as  a 
particular form of genetic FTLD-TDP), which are classified according to the 
major component of their deposits, phosphorylated TDP-43 protein, as TDP-







1.2. TDP-43 proteinopathies 
 
Despite significant clinical, genetic and neuropathological overlapping, 
frontotemporal lobar degeneration (FTLD) with or without motor neuron 
disease and amyotrophic lateral sclerosis (ALS) have been historically 
considered as separate entities (Mackenzie and Feldman, 2005). However, this 
axiom changed when Neumann and colleagues (2006) revealed trans-
activation response element (TAR) DNA binding protein-43 (TDP-43) to be the 
major pathological protein in the inclusions of frontotemporal lobar 
degeneration with ubiquitin-positive inclusions (FTLD-U) with or without 
motor neuron disease, and in amyotrophic lateral sclerosis (ALS) (Neumann et 
al., 2006).  
 
This discovery provided the strongest evidence to date that these conditions 
are part of the same clinicopathological spectrum of disease unifying the 
majority of cases of FTLD with ubiquitin inclusions (FTLD-U) and ALS cases 
within the same spectrum (Neumann et al., 2006). Aggregates of TDP-43 have 
been identified in multiple brain areas in ALS as well as in FTLD-TDP 
throughout the central neurvous system (Brandmeir et al., 2008; Nishihira et 
al., 2009). Different studies have confirmed TDP-43 pathology in large cohorts 
of cases representing the most common forms of TDP-43 proteinopathy 
according to their clinical phenotype as well as to their morphological 
subtypes. The most common phenotypes are (i) pure ALS, (ii) pure FTD-TDP, 
and (iii) a combination of both in FTLD-MND (Geser et al., 2009). In addition, 
detailed reviews of the significance of clinical overlap and transition forms 
among ALS, ALS-FTLD-TDP, FTLD-MND and FTLD-TDP have been published 







1.2.1. TAR DNA-binding protein 43 structure 
 
Transactive response DNA-binding protein 43 (TDP-43) is a 414 amino acid 
nuclear protein encoded by the TARDBP gene on human chromosome 1 
(1p36.22) which contains six transcribed exons. The major protein form of 
TDP-43 is translated from exons 2–6, resulting in a 414 amino acid protein 
(Figure 1A). It is highly conserved and ubiquitously expressed in a variety of 
tissues including the nuclei of neurons and glial cells in the central nervous 












Figure 1. Structure of TDP-43 protein. (A) Schematic representation of TDP-43 aminoacid 
sequence. (B) TDP-43 binds to both DNA and to RNA. The small angle X-ray scattering (SAXS) 
envelope of TDP-43 dimer is fitted with the crystal structure of RNA recognition motif (hRRM1)-
DNA and mRRM2-DNA in the orientation allowing the DNA to form a continuous 5′–3′ strand, 
as it is bound from hRRM1 to mRRM2 in TDP-43. (C) Schematic representation of the domain 
structure of TDP-43 homodimer, which binds to a long UG-rich RNA via its RRM1 and RRM2 
domains. Adapted from Lee and McMurray, 2014. 
 
TDP-43 is physiologically active as a homodimer (Figure 1B and 1C). Each 
monomer contains two RNA-recognition motifs (RRM1: ~aa 106–176 and 
RRM2: ~aa 191–262) and a glycine-rich C-terminal region (GRR: ~aa 274–414) 
containing a Q/N-rich prion-like domain that allows it to bind single nucleic 
acid strands and proteins, respectively (Buratti et al., 2001; Wang et al., 2004). 





export signal (NES), which allows it to shuttle between the nucleus and the 
cytoplasm, although the protein is predominantly located in the nucleus 
(Coehn et al., 2011) (Figure 1A). 
 
1.2.2. TAR DNA-binding protein 43 function 
 
TDP-43 is a highly conserved, ubiquitously expressed heterogeneous nuclear 
ribonucleoprotein (hnRNP), mainly present in the nucleus, but it shuttles in 
and out of the cytoplasm and along axons. The physiological functions of TDP-
43 protein are wide and variegated, including its role in different cellular 
functions such as mRNA stability (Volkening et al., 2009; Ayala et al., 2011b), 
mRNA and miRNA processing (Buratti et al., 2010; Kawahara and Mieda-Sato, 
2012), mRNA transport (Godena et al., 2011; Wang et al., 2008) and negative 
regulation of alternative splicing (Buratti et al., 2001) (Figure 2). TDP-43 
regulates many non-coding and protein-coding RNAs, covering proteins 
involved in neuronal survival, and modulating the expression of genes relevant 
in neurodegenerative diseases (Tollervey et al., 2011), as well as mitochondrial 
transcripts which play a role in maintaining mitochondrial homeostasis 
(Izumikawa et al., 2017). Recently it has suggested that it may act as a neuronal 
activity-response factor, involved in the regulation of neuronal plasticity 
(Sephton et al., 2012). Moreover, thousands of RNAs are bound by TDP-43 in 
neurons (Sephton et al., 2011). For example, in human spinal motor neurons, 
TDP-43 acts as a low molecular weight neurofilament (hNFL) mRNA-binding 
protein (Strong et al., 2007). TDP-43 also acts as a neuronal activity response 
factor in dendrites of hippocampal neurons, suggesting possible roles in 







Additionally, in response to an oxidative insult or under stress conditions, TDP-
43 may contribute to cell survival, associating with stalled translation initiation 
complexes localized in stress granules (SGs) which are transient, dense, non-
membrane-bound aggregations (100-200 nm) in the cytosol composed of 
proteins and RNAs that appear when the cell is under stress, acting as sorting 
stations for mRNAs (Figure 2) (Nover et al., 1989). Nevertheless, stress 
granules can also precipitate the formation of toxic protein aggregates such as 
those seen during the progression of certain types of neurological disease 




















Figure 2. Schematic representation of TDP-43 functions in physiological conditions and main 






TDP-43 protein acts via its two RNA recognition motifs (RRM1 and RRM2), 
binding both mRNA and DNA molecules, predominantly within long introns 
and in the 3'UTR region of mRNAs, whereas the exon skipping, splicing and 
inhibitory activity, and SGs formation, require the glycine-rich C-terminal 
domain of TDP-43 that binds to several proteins, such as other members of 
the heterogeneous nuclear ribonucleoprotein family (Wang et al., 2004; 
Buratti et al., 2005). Notably, the identification of missense mutations in 
TARDBP gene in patients with ALS and FTLD has revealed that several 
mutations are located in the C-terminal glycine-rich domain, most of which is 
localized within the prion-like domain (Barmada et al., 2010), and encoded by 
exon 6 (Figure 2). It is worth stressing that exon 6 encodes ∼60% of the TDP-
43 protein and more than 70% of the entire mRNA transcript. In light of these 
observations, it is clear that exon 6 and its encoded glycine-rich domain are 
critical components of the TDP-43 protein (Pesiridis et al., 2009). 
 
1.2.3. TAR DNA-binding protein 43 regulation 
 
Little information exists about the factors that regulate TDP-43, and how post-
translational modifications affect TDP-43 function. Preliminary research 
identified specific TDP-43 residues that undergo phosphorylation under 
physiological conditions as well as multiple other predicted phosphosites. 
Based on their positions, the reported and predicted phosphosites may affect 
key TDP-43 processes, e.g. cellular trafficking and RNA interactions. Thus, it is 
hypothesized that TDP-43 is regulated by phosphorylation and that several 
disease-associated mutations or insults have the capacity to change the 
phosphorylation profile with deleterious consequences on protein function (Li 







Given its crucial function in the processing of thousands of RNA transcripts, 
the levels of TDP-43 protein are tightly controlled through autoregulation 
mechanisms, as the protein binds to and edits its own 3’ untranslated region 
mRNA leading to degradation of the TDP-43 transcript. A decrease in the 
cellular levels of TDP-43 results in decreased transcript editing and increased 
translation of TDP-43 protein. Similarly, if the levels of TDP-43 are too high, 
TDP-43 will bind to more transcripts and induce their degradation, thus 
decreasing the levels of soluble TDP-43 (Ayala et al., 2011b).  
 
1.2.4. TAR DNA-binding protein 43 oligomerisation and aggregation 
 
As a neurodegenerative disorder, the central histopathological hallmark of ALS 
and FTLD spectrum is the presence of TDP-43-immunoreactive inclusions or 
aggregates in degenerating neurons and oligodendrocytes. The origin of TDP-
43-positive histopathological inclusions in vivo is poorly understood. Under an 
acute insult, the recruitment of TDP-43 containing RNA complexes into SGs via 
a TDP-43 Q/N-rich C-terminal targeting domain is promoted. TDP-43 is 
selectively recruited into specific SGs depending on the type of stress 
condition. Once recruited to SGs, TDP-43 might have a physiological role in the 
regulation of TDP-43-dependent RNAs during acute stress. However, it is 
hypothesized that pathological factors such as prolonged stress or ageing 
could induce the formation of pathological SGs, representing persistent 
accumulation of coalesced SGs that form TDP-43 positive inclusions, 
characterized pathologically as TDP-43 aggregates in ALS and FTLD-TDP. The 
formation of pathological SGs can inhibit TDP-43 function via cytoplasmic 
sequestration of normal TDP-43 and/or initiate a toxic gain or loss of function 
leading to mitochondrial damage and other neuronal dysfunctions (Liu-






Biochemical analysis of insoluble protein extracts isolated from affected FTLD-
U and ALS tissue revealed a characteristic biochemical profile of TDP-43 with 
detection of disease-specific bands at ~25 kDa, ~45 kDa and a smear of high-
molecular-mass proteins in addition to the normal 43 kDa band (Zhang et al., 
2007). Further analysis demonstrated that this profile is due to N-terminal 
truncation, hyperphosphorylation and ubiquitination of TDP-43 in FTLD-U and 
ALS (Neumann et al., 2006), which shows characteristics of amyloid (Bigio et 
al., 2013).  
 
The abnormal TDP-43 together with normal TDP-43 translocates from the 
nucleus to the cytoplasm, giving rise to intracytoplasmic neuronal inclusions 
and aberrant neurites (Barmada et al., 2010).  The mechanism behind this 
redistribution is not known, and it could either be due to the translocation of 
TDP-43 from the nuclei to the cytoplasm, or to impaired TDP-43 cytoplasm to 
the nucleus shuttling process (Thorpe et al., 2008; Mackenzie et al., 2011; 
Geser et al., 2011). Additionally, CTF TDP-43 contains conformationally 
unstable structures that correspond to the prion-like domain and the glycine-
rich region with aggregation-prone properties (Zhang et al., 2009). Indeed, 
expression of an insoluble TDP-43 C-terminal fragment is sufficient for the 
recruitment to SGs (Liu-Yesucevitz et al., 2010). In this line, several studies 
have indicated that the glycine-rich C-terminal region mutations are required 
for TDP-43 association with SGs, most of which are localized in a prion-like 
domain (Barmada et al., 2010).  
 
Thus, SGs may represent a functional intersection of normal TDP-43 function 
and the pathological accumulation of TDP-43 inclusions, reflecting the 
potential for both loss and gain of function toxicity associated with TDP-43 






1.2.5. TAR DNA-binding protein 43 aggregates and Bunina bodies 
 
In sporadic and most familial ALS as well as in FTLD-TDP cases, there is a loss 
of nuclear TDP-43 and formation of pathological aggregates mislocalized in the 
cytoplasm (Giordana et al., 2010). Inclusions are widespread and not 
restricted to the spinal cord, motor nuclei of the brainstem, or frontal and 
temporal cortices, but also present in other brain regions such as 
hippocampus (Al-Chalabi et al., 2012). Neuronal cytoplasmic TDP-43-
immunoreactive inclusions (NCIs) and glial cytoplasmic inclusions (GCIs) in 
oligodendrocytes are present in the majority of cases with ALS (Neumann et 
al., 2006). Three types of neuronal TDP-43-immunoreactive inclusions have 
been described in FTLD with TDP-43 proteinopathy: (1) neuronal cytoplasmic 
inclusions (NCIs), (2) dystrophic neurites (DNs) and (3) neuronal intranuclear 
inclusions (NIIs). FTLD cases with MND overlap, also presenting glial 
cytoplasmic inclusions (GCIs) (Brandmeir et al., 2008). Three different types of 
TDP-43-immunoreactive cytoplasmic inclusions have been described in the 
upper and lower motor neurons, and other regions in patients with ALS-FTLD: 
skein-like inclusions (SLIs), round hyaline inclusions (HIs) and dot-like 
inclusions (Figure 3) (Mori et al., 2008). 
 
- Skein-like inclusions (SLI) are immunostained by anti-phospho-
TDP-43 and anti-ubiquitin antibodies. The SLI is basically a thready 
structure of a bundle of thick filaments. The threads may be present 
singly or in the form of networks or aggregates, occasionally forming 
single larger inclusions that resemble hyaline inclusions (HIs) (Figure 
4A and 4B). These features indicate that HIs and SLIs may be closely 
related (Mizusawa, 1993). The exact composition of such inclusions is 
not known, although proteins identified so far include, in varying 





peripherin, with the most prevalent being phospho-TDP-43 protein 
(Okamoto et al., 2008). This is the most common form of TDP-43-
positive inclusion in the lower motor neurons. They are found in the 
anterior horn cells of the spinal cord in patients with ALS and, to a 
lesser extent, in the hypoglossal and facial nuclei (Mori et al., 2008). 
Skein-like inclusions can be found in other brain regions and have been 
observed in certain spinocerebellar ataxias.  
 
- Round hyaline inclusions (HI) are usually round eosinophilic 
structures about 5-15 μm in diameter, with occasional spiculae in the 
marginal portion, that show immunoreactivitiy for TDP-43 and 
ubiquitin (Figure 3C) (Mizusawa, 1993; Piao et al., 2003). Hyaline 
inclusions are chiefly observed within the perikarya of both normal-
looking and chromatolytic anterior horn cells in the lumbar spinal cord, 
but some are detected in the axons and dendrites. Usually, a single 
inclusion is found in the perikaryon, but in rare cases two or more are 
noted (Sasaki et al., 1989). HIs are composed of various amounts of 
granule-associated thick filaments and neurofilaments, and are 
heterogeneous (Mizusawa, 1993). Several investigators have 
suggested that round hyaline inclusions may arise from dense compact 
areas of skein-like inclusions because of the ultrastructural and 
antigenic similarities between the two. HIs consist of dense cores with 
a rough peripheral halo lacking a limiting membrane, called Lewy 
body-like hyaline inclusions (LBHIs).  LBHIs are found in a small 
proportion of sALS cases as well as in patients with familial ALS (fALS) 
due to mutations in the Cu/Zu superoxide dismutase (SOD1) gene. 
LBHIs in sALS are immunopositive for TDP-43 and those in fALS with 






- Dot-like inclusions are small round perinuclear aggregates 
composed of granulo-filamentous structures that are immunoreactive 
to ubiquitin and TDP-43 and approximately 1-3 µm diametre, from 
which round inclusions appear to arise as mature inclusions (Figure 3D) 




















Figure 3. TDP-43 immunohistochemistry in the brain and spinal cord of patients with 
amyotrophic lateral sclerosis (ALS) and control subjects. (a) and (b) skein-like inclusions in the 
anterior horn cells. Dense compacted area (arrowhead) is also evident (b). (c) Round hyaline 
inclusion, spicular inclusion in the anterior horn cell. (d) Dot-like inclusions in the anterior horn 
cell. (e) Early thread-like structures scattered in the cytoplasm of anterior horn cell. (f) Higher 
magnification view of the area in (e) showing straight or wavy linear wisps. (g) Punctate granules 
in the spinal anterior horn. Note that nuclear TDP-43 immunoreactivity is absent. (h) Circular 
inclusion in the putamen. (i) and (j) Granular cytoplasmic staining in the neostriatal small 
neurons. Punctate granules in the spinal anterior horn (k) and motor cortex (l). Note that 
nuclear TDP-43 immunoreactivity is preserved (l) (bars 10 µm). Adapted from Mori et al., 2008. 
 
In some cases, TDP-43 proteinopathy is manifested as clearing of the nucleus 
and/or diffuse, or as granular cytoplasmic TDP-43 despite the absence of 
clearly cytoplasmic inclusions (Figure 3E-K) (Alves-Rodrigues et al., 1998; 
Neumann et al., 2006). Morphologically, the diffuse cytoplasmic TDP-43 
immunoreactivity may be divided into two types: (i) diffuse punctate 





cytoplasm in the brainstem and spinal cord (Figure 3G), and (ii) granular 
cytoplasmic immunoreactivity as a fine or coarse granular perikaryal staining 
in the cerebral cortex and basal ganglia (Figure 3I-J) (Cairns et al., 2007; 
Brandmeir et al., 2008). Both ‘diffuse punctate cytoplasmic staining’ and 
‘granular cytoplasmic immunoreactivity may represent incipient TDP-43 
inclusion formation or ‘pre-inclusions’ (Cairns et al., 2007; Davison et al., 2007; 
Dickson et al., 2007; Brandmeir et al., 2008; Fujita et al., 2008). 
 
Additionally, other structures called Bunina bodies (BBs) may be found in the 
cell bodies of motor neurons in ALS (Okamoto et al., 1993; Sasaki and 
Maruyama, 1994) and occasionally in dendrites (Kuroda et al., 1990). BBs 
consist of small round eosinophilic inclusions with a diameter of 1-5 μm, 























Figure 4: Bunina bodies in the anterior horn cells in the lumbar cord of amyotrophic lateral 
sclerosis. (A) HE staining; (B) Klüver-Barrera staining; (C) cystatin C immunoreactivity is seen in 
the Bunina bodies in an anterior horn cell and its dendrites; (D) transferrin immunoreactivities 





These aggregates are composed of cystatin C, transferrin- and sortilin-related 
receptor CNS expressed 2 (SorCS2), and they partially colocalize with 
peripherin, but are negative for TDP-43 (Figure 4) (Okamoto et al., 1993; 
Mizuno et al., 2011; Miki et al., 2018). Ultrastructurally, these inclusions 
consist of electron-dense, granular material with membranous vesicular 
structures, and they are thought to originate in the Golgi apparatus or rough 































2.1. Discovery of ALS  
 
ALS is considered the third most common adult-onset neurodegenerative 
disease (Hirtz et al., 2007). It is described as a progressive, paralytic disorder 
characterized by degeneration of motor neurons in the primary motor cortex, 
motor neurons of the lower brainstem and spinal cord (Rowland and Shneider, 
2001; Al-Chalabi et al., 2016). The first reports of this disorder in terms of 
motor symptoms bring us back to the second half of the 1800s. The first 
description of the disease, by Charles Bell, dates back to at least 1824 
(Rowland, 2001). In 1869, Jean-Martin Charcot, through careful clinical 
observation and meticulous work in the laboratory detailing the 
pathophysiology of the illness, deduced the relationship between the clinical 
signs and neuropathological findings at autopsy.  
 
Charcot's work on amyotrophic lateral sclerosis classified neurological entities 
formerly considered as unrelated disorders to be expressions of the same 
disease, including primary amyotrophy and primary lateral sclerosis. In 
addition, these studies contributed to understanding of spinal cord and brain 
stem anatomy, and to the organization of the normal nervous system (Goetz, 
2000). The term amyotrophic lateral sclerosis was introduced in 1874, when 
Charcot’s works were compiled into a collection entitled ‘Oeuvres Completes’ 





(Rowland, 2001; Kumar et al., 2011). The term ‘amyotrophic’ comes from the 
Greek word amyotrophia, where a- means ‘no’, myo- refers to ‘muscle’, and 
trophia to ‘nourishment’. Amyotrophia therefore means ‘no muscle 
nourishment’ which describes the characteristic atrophy of the disused muscle 
tissue. The second term, ‘lateral’, identifies the motor tracts of the spinal cord. 
Finally, ‘sclerosis’ describes the scarring that degeneration leads to in the 
motor tracts (Rowland, 2001; Ferrari et al., 2011).  
 
Nowadays, ALS is still referred to as Charcot's disease worldwide, as the 
original description of the clinical and pathological findings has virtually 
remained unaltered (Tan and Shigaki, 2007). In the United States it is 
commonly referred to as ‘Lou Gehrig’s disease’, for the baseball great who 
succumbed to the illness in 1941. 
 
2.2. Epidemiology of ALS and nomenclature of MNDs 
 
ALS has an annual incidence of 3 to 5 cases per 100,000 people, and it is 
globally fairly uniform, although there are rare foci in which ALS is more 
common (Robberecht and Philips, 2013). There appears to be no ethnic or 
racial predisposition to ALS. Prior to the age of 65 or 70, the incidence of ALS 
is higher in men than in women, but thereafter the gender incidence is equal. 
ALS has an age distribution that peaks in the seventh to eighth decades.  
 
Therefore, the incidence and prevalence of ALS increase with age. However, 
many different etiologies of ALS have been described including juvenile forms 
(Elman and McCluskey, 2012). The following scheme summarizes different ALS 








Idiopatic motor neuron disease 
- Sporadic amyotrophic lateral sclerosis (sALS). 
- sALS with frontotemporal lobar degeneration. 
- sALS-parkinsonism-dementia complex Western Pacific. 
- Parkinsonism-dementia-sALS Guadeloupe forms. 
- Monomeric motor neuron disease. 
- ‘Madras-type’ motor neuron disease. 
- Post-polio syndrome. 
Autosomal dominant 
- Familial ALS (fALS). 
Distal spinal muscular atrophy. 
Juvenile-onset ALS. 
fALS with frontotemporal lobar degeneration. 
Autosomal recessive  
- Spinal muscular atrophy (SMA) linked to chromosome 5q13. Deletions of exons 
7 and 8 of the SMN1 gene; clinical manifestations depend on the number of 
copies of the SMN2 gene. 
Type I: Werdnig-Hoffmann disease. 
Type II: Intermediate. 
Type III: Kugelberg-Welander disease. 
- Fazio-Londe disease (FLD). 
- Juvenile forms of ALS. 
X-linked  
- Kennedy syndrome (spinal and bulbar muscular atrophy with gynaecomastia, 
testicular atrophy and reduced fertility): expansion at the CAG trinucleotide 
repeat in exon 1 of the androgen receptor (AR) located at Xq11-q12157t. 
Autosomal dominant, recessive or X-linked 
- Non.5q SMA (autosomal dominant or recessive: SMA-plus: with 
pontocerebellar hypoplasia, with respiratrory distress, with myoclonus 
eiplepsy, distal, scapulohumeral). 
- Hereditary spastic paraplegia (HSP) or Strümpell-Lorrain syndrome. 
Heterogeneous group associated with mutations in 19 different genes: 
restricted involvement of the upper motorneuron. 
Table II. List of main motor neuron diseases classified on the basis of their etiology. 







2.3. Clinical symptoms of classical ALS forms 
 
The clinical hallmark of ALS is the combination of upper and lower motor 
neuron signs and symptoms. Motor neurons are grouped into upper 
populations (UMN) in the motor cortex, and lower populations in the brain 
stem and spinal cord (LMN) which innervate muscle. When the failing of 
corticospinal (upper) motor neurons happens, weakness with slowness, 
hyperreflexia, abnormal reflex such as Babinski's sign, and spasticity result 
from degeneration of frontal motor neurons located in the motor strip 
(Brodman area 4) and their axons traversing the corona radiata, internal 
capsule, cerebral peduncles, pontine base, medullary pyramids, and 
corticospinal tracts of the spinal cord (Rowland, 1998; Ferguson and Elman, 
2007; Elman and McCluskey, 2012). When lower motor neurons become 
affected in the brainstem and spinal cord, excessive electrical irritability, 
leading to spontaneous muscle twitching (fasciculations) is followed by 
neuron degeneration and loss of synaptic connectivity with target muscles, all 
of which results in muscular weakness and atrophy (Rowland, 1998; Ferguson 
and Elman, 2007; Elman and McCluskey, 2012). Usually, these clinical signs 
begin insidiously with focal weakness but spread relentlessly to involve most 
muscles. Patients experience difficulty in moving, swallowing (dysphagia), and 
speaking or forming words (dysarthria), culminating in diaphragm 
involvement that leads to death due to respiratory paralysis after 3 to 5 years 
from the onset of symptoms (Elman and McCluskey, 2012). 
 
The start of ALS may be so subtle that the symptoms are overlooked (Kiernan 
et al., 2011). Differences in site and segment of onset, pattern and speed of 
spread, and the degree of upper and/or lower motor neuron dysfunction 
produce a disorder that is remarkably variable among individuals (Elman and 





affected first, with this debut known as ‘limb onset’, in which neurons in the 
brain and in the spinal cord start to die first. People first experience 
awkwardness when walking or running; tripping or stumbling may be 
experienced and this is often marked by walking with a ‘dropped foot’ which 
drags gently on the ground. Or there may be arm onset, marked by difficulty 
with tasks requiring manual dexterity such as buttoning a shirt, writing, or 
turning a key in a lock (Turner et al., 2010). In about 25% of cases, muscles in 
the throat are affected initially because motor neurons in the medulla 
oblongata start to die first. This form is called ‘bulbar onset’. Initial symptoms 
include difficulty in speaking and swallowing. Speech may become slurred, 
nasal in character, or quieter. The difficulty in swallowing may be 
accompanied by loss of tongue mobility (Jawdat et al., 2015). Finally, a smaller 
proportion of patients, about 5% of cases, experience a respiratory debut 
(‘respiratory-onset’), in which the intercostal muscles that support breathing 
are affected first (Kiernan et al., 2011). 
 
In addition, during the past two decades, a link between ALS and 
frontotemporal executive dysfunction that may precede or follow the onset 
of upper and/or lower motor neuron dysfunction has been called ALS or MND 
with dementia: ALS-D or MND-D (Ringholz et al., 2005; Murphy et al., 2007a 
and 2007b; Takeuchi et al., 2016). It has been recognized that up to 50% of 
patients with ALS have at least some evidence of frontal-executive cognitive 
deficits and behavioural abnormalities (Phukan et al., 2007) leading ultimately 
to dementia in about 15-20% of patients. The presentation of dementia may 
be dramatic and initially suggestive of a psychiatric disorder because of change 
in personality, impairment of judgment and development of obsessive 
behavior. It may also manifest as a disorder of language in the form of primary 
progressive aphasia (also semantic aphasia or semantic dementia). Short-term 





disease (Phukan et al., 2007; Logroscino et al., 2010; Bang et al., 2015; Ng et 
al., 2015). Since these behavioral alterations correlate with autopsy evidence 
of degeneration of the frontal and temporal lobes, the condition is designated 
frontotemporal dementia (FTD). 
 
In contrast, certain motor neurons are usually spared in ALS, which means that 
some functions are preserved. Most patients retain extraocular movements, 
and bowel and bladder control. With disease progression, patients may 
develop problems with urge incontinence and constipation because of weak 
abdominal musculature, but sphincter control generally is unaffected. Since 
the disease primarily involves motor neurons, sensory function typically is 
preserved, although a minority of patients complain of some numbness and 
paresthesia. Abnormalities have been reported in sensory nerve conduction 
studies in a small number of patients with ALS, but these findings often reflect 
the presence of an unrelated, coexistent condition (Isaacs et al., 2007). 
Involvement of other spinal tracts, in addition to the pyramidal pathways, is 
not unocommon in certain familial forms linked to SOD1 mutations.  
 
2.4. Diagnosis and treatment of ALS 
 
ALS diagnosis is based primarily on clinical examination in conjunction with 
electromyography, to confirm the extent of denervation, and laboratory 
testing, to rule out reversible disorders that may resemble ALS (Armon, 2018). 
When the disease has progressed clinical symptoms and signs and neurologic 
examination may provide sufficient evidence for the diagnosis. Specifically, 
the diagnosis of ALS is made possible by: (1) history, physical and appropriate 
neurological examinations to ascertain clinical findings which may suggest 
suspected, possible, probable or definite ALS; (2) electrophysiological 





clinically involved regions, identify LMN degeneration in clinically uninvolved 
regions and exclude other disorders; (3) neuroimaging examinations to 
ascertain findings which may exclude other disease processes; (4) clinical 
laboratory examinations, determined by clinical judgement, to ascertain 
possible ALS related syndromes; (5) neuropathologic examinations, where 
appropriate, to ascertain findings which may confirm or exclude sporadic ALS, 
coexistent sporadic ALS, ALS-related syndromes or ALS variants; and (6) 
repetition of clinical and electrophysiological examinations at least six months 
apart to ascertain evidence of progression (Brooks et al., 1994).  
 
The criteria for the diagnosis of ALS was stablished in a consensus document 
called the “El Escorial ALS Diagnostic Criteria” in 1990. In accordance with this 
document formulated by the World Federation of Neurologists in 1994 and 
modified in 1998, the definitive diagnosis of ALS is based on clinical and 
electrophysiological examination; in addition to the required clinical criteria, 
laboratory and imaging tests (Escorial Revisited) (Brooks et al., 1994 and 
2001). Essentially, the criteria classify patients into four categories of 
certainty: 'definite', `probable' and `possible', by taking into account their 
clinical, electrophysiological, neuroimaging, laboratory and neuropathological 
information (Table III). 
 
Criteria Clinical presentation 
Definite ALS 
It is defined on clinical grounds alone by the presence of UMN as well 
as LMN signs in the bulbar region and at least two of the other spinal 
regions or the presence of UMN and LMN signs in three spinal regions 
(cervical, lumbosacral and thoracic). The important determinants of 
the diagnosis of definite ALS in the absence of electrophysiological, 
neuroimaging and laboratory examinations are the presence of UMN 
and LMN signs together in multiple regions. 
Probable ALS 
It is defined on clinical grounds alone by UMN and LMN signs in at 
least two regions. While the regions may be different, some UMN 
signs must be rostral (above) the LMN signs. Multiple different 









It is defined when clinical signs of UMN and LMN dysfunction are in 
only one region, or when UMN signs alone are present in one region, 
and LMN signs defined by EMG criteria are present in at least two 
regions, with proper application of neuroimaging and clinical 
laboratory protocols to exclude other causes. Monomelic ALS, 
progressive bulbar palsy without spinal UMN and/or LMN signs and 
progressive primary lateral sclerosis without spinal LMN signs 
constitute special cases which may develop LMN or UMN signs to 
meet the criteria for probable ALS with time or be subsequently 
confirmed at autopsy by specific LMN and UMN neuropathologic 
findings. 
Possible ALS 
It is defined when clinical signs of UMN and LMN dysfunction are 
found together in only one region or UMN signs are found alone in 
two or more regions; or LMN signs are found rostral to UMN signs 
and the diagnosis of Clinically Probable ALS-Laboratory-supported 
cannot be proven by evidence on clinical grounds in conjunction with 
electrodiagnostic, neurophysiologic, neuroimaging or clinical 
laboratory studies. Other diagnosys must have been excluded to 
accept a diagnosis of Clinically possible ALS. 
Table III. Diagnostic certainty based on Revised El Escorial criteria. Abbreviations: LMN: lower 
motor neuron; UMN: upper motor neuron. Adapted from Brooks et al., 1994 and 2001. 
 
Although there is no known cure for ALS, the drugs Rilutek (riluzole) and 
Radicava (edavarone) may slow the progression of the disease. Rilutek is 
indicated to buffer glutamate excitotoxic pulses in ALS, whereas Radicava is 
used to counteract the excessive oxidative stress observed in this disorder. 
These are short-term treatments with a slight effect on disease progression; 
they do not reverse the damage caused by the disease but they can slow the 
deterioration of function, prevent complications, and increase the comfort 
and independence of patients. 
 
In the years that followed the discovery of these two drugs, over 60 molecules 
have been investigated as possible treatments for ALS (Table IV). Despite 
significant research efforts, the majority of human clinical trials have failed to 
demonstrate clinical efficacy. Only oral masitinib and intravenous edaravone 
have emerged as promising new drugs with beneficial effects in clinical trials 











1-2; 3 Failure 
Berry et al., 2013; Cudkowicz 
M. et al., 2013 
Memantine Oral ALSFRS 2-3 Failure de Carvalho et al., 2010 
Riluzole Oral Survival 3 Mixed* 
Bensimon et al., 1994, 2002; 
Lacomblez et al., 1996 
Talampanel Oral ALSFRS-R 2 Failure 
Pascuzzi et al., 2010; Teva, 
2010 
Anti-inflammatory 
Celecoxib Oral MVIC 2-3 Failure Cudkowicz et al., 2006 
Erythropoietin i.v. DTP 2; 3 Failure Lauria et al., 2009 
Copaxone s.c. ALSFRS-R 2; 2-3 Failure 
Gordon et al., 2006; 
Meininger et al., 2009 
Minocycline Oral ALSFRS-R 1-2; 3 Failure 
Gordon et al., 2004, 2007; 




ALSFRS-R 1; 2 Failure Miller et al., 2014, 2015 
Pioglitazone Oral Survival 2 Failure Dupuis et al., 2012 
Valproic acid Oral DTP 3 Failure Piepers et al., 2009 
Anti-oxidative 
Coenzyme Q10 Oral ALSFRS-R 2 Failure 
Ferrante et al., 







Rosenfeld, 2001; Groeneveld 
et al., 2003; Shefner et al., 
2004; Rosenfeld et al., 




ALSFRS-R 2; 3 Mixed** 
Yoshino and Kimura, 2006; 
Abe et al., 2014; Palumbo et 
al., 2016; Sakata et al., 2016; 
Tanaka et al., 2016 a,b 
Neuroprotective 
Dexpramipexole Oral CAFS 2; 3 Failure 
Cudkowicz et al., 2011; 
Cudkowicz et al., 2013; Bozik 
et al., 2014 
Olesoxime Oral Survival 2-3 Failure Lenglet et al., 2014 




2; 3 Failure 
Lacomblez et al., 





1-2; 3 Failure 
Bradley, 1995; Kasarskis et 
al., 1999 




Miller et al., 1993, 1996; ALS 
CNTF Treatment Study 









Lai et al., 1997; Borasio et al., 
1998; Sorenson et al., 2008 
CSF1R inhibition 








Fornai et al., 2008; 
Verstraete et al., 
2012; Morrison et al., 2013 
Tirasemtiv Oral ALSFRS-R 2 Failure Shefner et al., 2016 
 
Table IV. List of drugs and compounds tested in human ALS clinical trials. *Two out of three 
late-stage trials reported negative results; ∗∗: two out of three Phase 3 trials reported negative 
results; $: statistical significance reached on multiple efficacy endpoints based on the results of 
interim analysis with 192 patients (50% of enrolled patients); £: only one pilot early phase trial 
reported statistical significance on efficacy endpoints, all subsequent large-scale follow-up 
studies failed to reproduce these positive results. Abbreviations: AALS, Appel ALS Rating Scale; 
ALSFRS-(R), The ALS Functional Rating Scale (Revised); CAFS, combined assessment of function 
and survival; DTP, time to death, tracheostomy or persistent assisted ventilation; %FVC, forced 
vital capacity; MMT, manual muscle test; MVIC, maximum voluntary isometric contraction; 
CSF1R, colony stimulating factor 1 receptor; i.m., intramuscular i.v., intravenous; s.c., 
subcutaneous. Adapted from Petrov et al., 2017. 
 
Generally, complementary treatment is used in ALS to help control symptoms, 
including treatment with drugs such as baclofen or diazepam, which may help 
control spasticity; gabapentin, which may be prescribed to help control pain; 
and trihexyphenidyl or amitriptyline, which may help patients swallow saliva, 
among other drugs or functional adapatations indicated for other possible 
symptoms. Control of respiration with respiratory assistance devices, and 
control of alimentation using gastrostomy and alimentary perfusion, are 
usually employed at advanced stages of the disease. Various devices are used 
to facilitate communication in the absence of oral language and very reduced 
hand movement.   
 
2.5. Neuropathology of ALS 
 
In most ALS cases, no gross abnormalities are observed in the brain. In 
contrast, the spinal cord often reveals atrophy of the anterior nerve roots and 





show atrophy of the precentral gyrus (Ellison et al., 2012). In patients with 
dementia, atrophy of the frontal and/or temporal cortex may be seen (Murphy 
et al., 2007a,b; Ellison et al., 2012); the atrophy is more marked in patients 
with overlapping ALS-frontotemporal lobar degeneration (ALS-FTLD). The core 
pathological finding in ALS is motor neuron death in the motor cortex and 
spinal cord including degeneration and loss of Betz cells in the motor cortex, 
large motor neurons in the anterior horn of the spinal cord and cranial motor 
nuclei of the lower brainstem (Hammer et al., 1979; Nihei et al., 1993). 
Although it is known that motor neurons degenerate and die in ALS, it is not 
clear how this degeneration begins and progresses (Saberi et al., 2015). 
Microscopic changes include loss of myelinated axons in the lateral and 
anterior pyramidal tracts of the spinal cord, reduced number of fibers in the 
anterior roots of the spinal cord and cranial motor nerves of the lower 
brainstem, and altered nerve-motor junctions in skeletal muscles (Ellison et 
al., 2012). These observations are in agreement with morphometric studies of 
the spinal anterior horn that show a global reduction of all neurons in the 
anterior horn including large alpha motor neurons (Stephens et al., 2006). 
Other pathological features of ALS include vacuolization, large empty spaces 
near neurons and spongiosis. These changes in neurons are accompanied by 
astrocytic gliosis, oligodendroglial alterations, and microglial activation in 
target regions. Axonal balloons filled with aggregates of abnormal filaments 
are particularly common in the anterior horn of the spinal cord in rapid forms.   
 
As detailed above, the central histopathological hallmark of ALS is the 
presence of cytoplasmic inclusions composed of abnormal forms of TDP-43 
protein. Staging of TDP-43 pathology in ALS has been proposed in line with 
similar categorization stages in other neurodegenerative disorders 
(Brettschneider et al., 2013). In stage 1, abnormal TDP-43 inclusions are 





anterior horn of the spinal cord and certain motor nuclei of the brain stem. In 
stage 2, abnormal TDP-43 extends to neurons of the reticular formation of the 
brain stem and deep nuclei of the cerebellum. In stage 3, TDP-43-
immunoreactive inclusions are also noted in the prefrontal cortex and basal 
ganglia. In stage 4, the hippocampal formation and the anteromedial areas of 
the temporal cortex show TDP-43-immunoreactive inclusions. However, 
recent refinements of this staging identify oligodendroglial TDP-43-
immunoreactive inclusions as early pathological events in the spinal cord in 
ALS. Involvement of the oculomotor nuclei and Onuf’s nucleus may occur at 
advanced stages of the disease categorized as stage 5 (Brettschneider et al., 
2014b). Brainstem nuclei that remain free of pTDP-43 pathology include the 
noradrenergic locus coeruleus and the serotoninergic nuclei of the raphe. 
 
2.6. Etiology: sporadic and familial ALS  
 
ALS is categorized into two forms. The most common form is sporadic (90–
95%) which has no obvious genetically inherited component (sALS), although 
mutations in selected genes may occur in some patients. The remaining 5-10% 
of cases make up familial-type ALS (fALS) linked to mutations in various genes 
(Greenway et al., 2006; Abhinav et al., 2007; Valdmanis et al., 2008). The 
pattern of inheritance varies depending on the gene involved. The inheritance 
in most cases is autosomal dominant. However, some carriers do not develop 
clinical symptoms, and variability exists among unaffected individuals within 
the same family. ALS may be inherited with an X-linked dominant pattern. In 
these cases, males tend to develop the disease earlier and have a decreased 
life expectancy compared with females. Less frequently, ALS is inherited in an 
autosomal recessive pattern. Since parents of a particular affected person may 
be not affected, autosomal recessive ALS is often mistaken for sporadic ALS 





caused by mutations in SOD1, 4-5% of fALS results from mutations in TARDBP 
and FUS genes, more than 30% of fALS cases are associated with C9ORF72 
repeat expansions, and the remaining genetic cases are caused by mutations 
in alsin (ALSIN), senataxin (SETX), spatacsin (SPG11), vesicle associated 
membrane protein associated protein B (VAPB), angiogenin (ANG), factor 
induced gene 4 (FIG4) and optineurin (OPTN) genes, among other genes 
summarized in Table V (Chen et al., 2013). 
 
fALS Chr. locus Gene Protein Onset Inheritance 
ALS1 21q22.1 SOD1 Cu/Zn SOD-1 Adult AD/AR 
ALS2 2q33-2q35 ALSIN Alsin Juv AR 
ALS3 18q21 Unknown Unknown Adu AD 
ALS4 9q34 SETX Senataxin Juv AD 
ALS5 15q15-21 SPG11 Spatacsin Juv AR 
ALS6 16p11.2 FUS Fused in Sarcoma Juv/Adu AD/AR 
ALS7 20ptel-p13 Unknown Unknown Adu AD/AR 
ALS8 20q13.3 VAPB VAPB Adu AD 
ALS9 14q11.2 ANG Angiogenin Adu AD 




ALS11 6q21 FIG4 PI 5-phosphatase Adu AD 
ALS12 10p13 OPTN Optineurin Adu AD/AR 
ALS14 9p13.3 VCP VCP Adu AD 
ALS15 Xp11 UBQLN2 Ubiquilin 2 Adu/Juv XD 
ALS16 9p13.2-21.3 SIGMAR1 SIGMAR1 Juv AR 
ALS-FTD1 9q21-22 unknown unknown Adu AD 
ALS-FTD2 9p21 C9ORF72 C9ORF72 Adu AD 
Table V. Several mutated genes have been identified in fALS patients. Abbreviations: VAPB 
Vesicle associated membrane protein associated protein B, VCP valosin-containing protein, 
SIGMAR1 Sigma non-opiod intracellular receptor, C9ORF72 Chromosome 9 open reading frame 
72, AD Autosomal dominant, AR Autosomal recessive. 
 
2.6.1. ALS1/ Superoxide dismutase 1 (SOD1) 
SOD1, which maps to chromosome 21q22.1, was the first gene identified as 
causative of fALS, as revealed by linkage analysis in autosomal dominant fALS 





present with limb onset, starting predominantly in the lower limbs rather than 
the upper. A few cases also start with bulbar symptoms. However, SOD1 
mutant ALS cases show wide individual variation regarding the age of onset, 
severity, rate of disease progression, and duration. Several mutations have 
been found in all 5 exons affecting the functional domains of SOD1, 
predominantly in patients bearing missense mutations, followed by a small 
percentage of nonsense mutations, insertions and deletions. Mutations in 
SOD1 have been reported in ~20% of fALS and in ~1-4% of sALS (Pasinelli and 
Brown, 2006).  
 
2.6.2. ALS6/fused in sarcoma (FUS) mutations 
ALS patients with ALS6 mutations are characterized by variable age at onset 
from 26 to 80 years (Pasinelli and Brown, 2006). Most cases show LMN 
predominance without bulbar region involvement, and no cognitive 
impairment. The locus for ALS6 has been mapped to chromosome 16p11.2 
encoding FUS (Sapp et al., 2003). FUS gene encodes for a DNA/RNA binding 
protein that has multiple domains; the domain at N-terminus plays a role in 
transcriptional activation of the gene. Mutations at the C-terminus disrupt the 
transport of FUS protein into the nucleus, which leads to cytoplasmic 
localization of FUS and to the formation of stress granules (Bosco et al., 2010; 
Dormann et al., 2010). To date, more than 50 FUS mutations have been 
identified in ~4% cases of fALS and ~1% of sALS cases (Lanson and Pandey, 
2012). Histopathological analysis of this type of ALS case with mutant FUS 
illustrates distinctive FUS positive and TDP-43 negative inclusions (Bäumer et 
al., 2010).  
 
2.6.3. ALS10/ TAR DNA binding protein (TARDBP) mutations 
Mutations of gene TARDBP were first reported in fALS cases in 2008. TARDBP-





onset. The age of onsert is variable (30–77 years), as is disease duration. Since 
its discovery, more than 40 mutations have been identified in various ethnic 
groups, with an incidence of ~4-5% in fALS and up to 2% in sALS. However, it 
is not clear how TARDBP mutations cause motor neuron degeneration, 
although mechanisms of loss of nuclear function and gain of toxic function 
have been proposed (Sreedharan et al., 2008).  
 
2.6.4. ALS-FTD1 and ALS-FTD2 (C9ORF72 mutations) 
ALS-FTD1 is an adult-onset, autosomal dominant disorder linked to 
chromosome 9q21-q22 which presents with the symptoms of both fALS and 
fFTD (Hosler et al., 2000; Pasinelli and Brown, 2006).  The causal genetic defect 
is variable hexanucleotide GGGGCC repeat expansions in the chromosome 9 
open reading frame 72 (C9ORF72) gene (DeJesus-Hernandez et al., 2011). 
Cases with ALS-FTD2 mutation have both p62/ubiquitin- and TDP-43-positive 
inclusions. p62-ubiquitin inclusions are particularly visible in the cerebellar 
cortex. C9ORF72 repeat expansions are the most frequent genetic cause of 
fALS and fFTD-TDP, accounting for approximately 34.2% and 25.9% of the 
cases, respectively (Van Blitterswijk et al., 2012). Patients bearing C9ORF72 
mutations manifest FTD and ALS as well as other features including psychosis, 
akinetic-rigid symptoms and cerebellar signs (Rademakers et al., 2012). 
Detailed description of this mutated gene is provided in the Part 3 of this 
thesis. 
 
2.7. Animal models of ALS 
 
Animal models of ALS provide a unique opportunity to uncover the molecular 
players involved in the pathology, which might be amenable to therapeutic 
intervention. Although much work has been carried out to generate new 





that enterely recapitulates the human disease. Therefore, although various 
animal models have been developed to investigate ALS disease, human post-
mortem tissue remains the gold standard.  
 
Small-animal models, such as Caenorhabditis elegans, Drosophila and 
zebrafish, can be used for unbiased forward genetic screens. However, rodent 
models are believed to mimic human disease more closely (Van Damme et al., 
2017). The transgenic rodent models most commonly used in ALS reaserch are 
those bearing mutations in SOD1, TARDBP, FUS and C9ORF72 (Turner and 
Talbot et al., 2008; Gendron and Petrucelli, 2011; Philips and Rothstein, 2015; 
Nolan et al., 2016) , as described below. 
 
2.7.1. SOD1-G93A transgenic mice 
 
The first breakthrough in the development of rodent models to study ALS 
came in the early 1990s with the identification of missense mutations in SOD1 
as a cause of autosomal dominant fALS (Rosen et al., 1993). SOD1 is a 153 
amino acid located in the cytoplasm and mitochondria which functions in a 
dimeric state. SOD1 protein attaches to copper and zinc to catalyse the 
breakdown of harmful reactive oxygen species (ROS), and converts superoxide 
radicals to hydrogen peroxide, thereby preventing oxidative stress (Roberts et 
al., 2007). Due to the damaging effects of ROS and their association with 
neurodegenerative diseases, it was originally proposed that pathogenic 
mutations in SOD1 might cause ALS because of decreased dismutase activity. 
Subsequent investigation failed to correlate mutant SOD1 activity with 
pathogenicity (Borchelt et al., 1995). Deficiency of SOD1 in Sod1 knock-out 
mice (Sod1−/−) does not result in motor dysfunction, at least up to 6 months 
of age (Reaume et al., 1996). Thus, the significant loss of motor neurons in 





of-function. Accordingly, with this gain of function, wild type SOD1 may play a 
role in ALS pathogenesis (Deng et al., 2006; Bosco et al., 2010; Graffmo et al., 
2012); over-expression of human wild-type SOD1, at a level similar to that 
seen in the SOD1G93A mouse model, can cause progressive motor neuron 
degeneration (Graffmo et al., 2012), and abnormal axonal and mitochondrial 
structure (Jaarsma et al., 2000 and 2006). 
 
More than 150 different mutations have been found in this gene throughout 
all coding regions (Battistini et al., 2005) but animal model studies have been 
focused on the mutation containing a substitution of glycine to alanine at 
position 93, abbreviated as SOD1-G93A, which is overexpressed (15-20 copies) 
under control of the human SOD1 promoter (Gurney et al., 1994). This 
mutation retains SOD1 enzymatic activity (Gurney et al., 1994) although it 
does not bind copper ions as effectively as wild-type SOD1 (Pratt et al., 2014). 
For the past twenty years, since the first of such models became available in 
1994, SOD1 transgenic mice, mainly SOD1-G93A, followed by G37R, G85R and 
G86R models, have been used extensively to characterize the biology of ALS 
as well as to explore specific benefits of potential therapies, albeit with 
questionable success (Gurney et al., 1994). More particularly, SOD1 G93A has 
been widely used to study motor neuron cell death. 
 
The original SOD1 mutant lines have diverged into a family of strains with 
different genetic backgrounds manifested with particular clinical aspects such 
as variable age of onset and rate of disease progression (Gurney et al., 1994). 
Development of ALS-like symptoms in these mice is known to be largely 
dependent on four factors: (i) SOD1 mutation; (ii) transgene expression level; 
(iii) gender and (iv) genetic background (Heiman-Patterson et al., 2011; 
Mancuso et al., 2012a and 2012b). In our experiments, we used the well-





shows a milder phenotype and relative long survival rate compared with mice 
with SJL/J background. The later show aggressive phenotype and shorter 
lifespan.  
 
Although the SOD1-G93A transgene is widely expressed, pathology in this 
model is largely restricted to the spinal cord, especially in the lumbar region, 
the brainstem, the descending spinal tracts and the neuromuscular junctions. 
Various pathogenic mechanisms have been recognized including protein 
misfolding and aggregation precedening MN death (Johnston et al., 2000; 
Chattopadhay and Valentine, 2009), together with mitochondrial 
vacuolization (Dal Canto and Gurney, 1995), Lewy body-like inclusions (Dal 
Canto and Gurney, 1995), aberrant neurofilamant processing, neurofilament-
positive inclusions (Tu et al., 1996), axonal transport deficits, Golgi 
fragmentation (Mourelatos et al., 1996),  astrogliosis and microgliosis (Philips 
and Rothstein, 2014), glutamate-mediated excitotoxocity and reduced 
metabolic support to motor neurons from their surrounding glial cells (Boillée 
et al., 2006). SOD1-G93A mutant mice also show degeneration of 
neuromuscular junctions at the age of about 47 days (Frey et al., 2000; Pun et 
al., 2006). This is followed by spinal motor neuron death with about a 50% 
reduction in the cervical and lumbar segments at the end-stage of the disease 
(Chiu et al., 1995; Bento-Abreu et al., 2010).  
 
2.8. Molecular pathways affected in ALS 
 
Several molecular and cellular mechanisms, such as oligodendrocyte 
dysfunction, oxidative stress, excitotoxicity, proteostasis disturbance, 
mitochondrial dysfunction, defective axonal transport, alteration in RNA/DNA 
mechanisms and glial activation, have been proposed as key players in ALS 





these mechanisms precisely contribute to selective motor neuron 
vulnerability and degeneration is not understood. The mechanisms are not 
mutually exclusive and it seems probable that they all participate to some 
extent in disease progression, suggesting that ALS is a multifactorial disorder 
with a poorly understood primary factor. 
 
2.8.1. Glial cells: microglia, astrocytes and oligodendrocytes 
 
The central nervous system is a complex organ composed of neurons, which 
represent 10% of the total number of cells, and glia, representing 90% of the 
total cell number. Glial cells were discovered in 1856 by the pathologist Rudolf 
Virchow in his search for a ‘connective tissue’ in the brain. The term derives 
from Greek word γλία that means ‘glue’ and suggests the original impression 
that they were the glue of the nervous system (Purves et al., 2001). Glia play 
an active role in many processes, maintaining tissue homeostasis, supplying 
nutrients and oxygen to neurons, supporting neurotransmission, participating 
in adult neurogenesis, and providing immune surveillance, among a pleiad of 
functions (Rasband, 2016; Jäkel and Dimou, 2017).  
 
Glial cells in the central nervous sytem are subdivided into four major groups: 
(A) astrocytes, (B) oligodendrocytes, (C) microglia and (D) ependymal cells 
(Figure 5) (Von Bartheld et al., 2016; Jäkel and Dimou, 2017). These different 
types of cells participate in these processes in a coordinated form, interacting 
with neurons and infiltrating peripheral immune cells as part of their 
regulation of inflammatory responses in the central nervous system. In the 
brain, this inflammatory response, termed neuroinflammation, is a 
fundamental response generated to protect the central nervous system. 
However, uncontrolled or prolonged neuroinflammation is potentially 





injury, there is a non-specific reactive change in glial cells in response to 
damage, called gliosis, which is one of the most important features in 
neuroinflammation and includes proliferation or hypertrophy of several 



























Figure 5: Glial cells of the CNS. Representative drawings of four different types of glial cells in 
central nervous system: (A) astrocytes (IHC anti-GFAP), (B) microglia (IHC anti-IBA1), (C) 
oligodendrocytes (IHC anti-MOG) and (D) ependymal cells (H&E stain). Abbreviations:  GFAP-
glial fibrillary acidic protein; H&E-hematoxylin and eosin; IHC-immunohistochemistry; IBA1- 




Microglia play an important role as resident immunocompetent and 
phagocytic cells in the central nervous system in the event of injury and 





Franz Alexander Nissl who named them ‘rod cells’ for their rod‐shaped nuclei 
and considered them as reactive neuroglia. However, Pío del Rio Hortega was 
who advanced microglia as a distinct cell type apart from astrocytes and 
oligodendrocytes after his studies of brains from young animals using his silver 
carbonate staining method in 1919, recognizing them as cells of mesodermal 
origin (Del Rio-Hortega, 1919). Microglia emerge from two sources: 
erythromyeloid precursors of the embryonic yolk sac, and myeloid 
progenitors. These precursor cells invade the developing brain during the 
embryonic, fetal, or perinatal stages, and they are transformed from actively 
phagocytic globoid-ameboid cells into resting ramified microglia (Sievers et al., 
1994; Ginhoux et al., 2013). These cells are identified by the expression of 
monocytic markers, such as α-M-β2 integrin (or CD11b/CD18 and MAC-1), IgG 
receptors (CD16/CD32), ionized calcium-binding adaptor protein-1 (Iba-1), 
and the major histocompatibility complex (MHC) (Hendrickx et al., 2017).  
 
In agreement with Hortega’s original description, microglia have been 
classically described as existing in two states, resting and activated. ‘Resting’ 
microglia exhibit a highly ramified morphology characterized by motile 
processes that constantly monitor their immediate surroundings by extending 
and retracting their processes to maintain homeostasis (Davalos et al., 2005; 
Nimmerjahn et al., 2005). This constant movement of microglial processes 
while the soma remains stationary is called microglial motility. The 
unexpected finding of microglial process motility led scientists to investigate 
and identify new roles in the non-pathological brain (Kettenmann et al., 2013), 
showing active involvement in the phagocytosis of synaptic elements during 
the entire lifespan, and the formation of learning-dependent synapses in the 
mature brain, as well as in the maturation and plasticity of excitatory synapses 






In contrast, when microglia encounter a substance that they sense is foreign 
or indicative of harm, they enter into an ‘activated’ state with ameboid 
morphology. As macrophage-like cells of the brain, active microglia regulate 
innate central nervous system immunity and initiate appropriate responses. 
Concretely, the term activation includes a range of different ‘activated’ states. 
It is now recognized that activated microglia can exist broadly in two different 
states (Colton et al., 2009). The first is classical activation (phenotype M1), 
which is identified by the production of inflammatory cytokines and reactive 
oxygen species (ROS). 
Figure 6. The schematic 
image illustrates most of 
the physiological 
functions of microglia. 
Microglia contribute to 
healthy nervous system 
physiology in several ways. 
They provide cues and 
remove inappropriate 
synapses during 
development, and they 
secrete neurotrophins and 
cytokines to support and 
maintain neural networks 
in the mature nervous 
system. In addition, they 
rapidly sense ATP 
signalling via receptors 
such as P2Y purinoceptor 
12 (P2Y12) and migrate to 
areas of damage, where 
they proliferate and 
phagocytose apoptotic 
cells and any other 
damaged tissue to aid 
repair. Indeed, activation 
of microglia following CNS 
damage or disease induces 
a respiratory burst, which 
is necessary for an efficient 
innate immune response. 
Adapted from Pocock and 






Using a full array of immune receptors, such as toll-like receptors (TLRs), 
nucleotide-binding oligomerization domains (NODs), NOD-like receptors and 
many scavenger receptors (Ransohoff and Perry, 2009; Ransohoff and Brown, 
2012), microglia are able to recognize harmful stimuli and respond by 
producing inflammatory cytokines such as TNFα, IL-6, IL-1β, interferon-γ 
(IFNγ), and several chemokines (Boche et al., 2013). Further, there is a state 
of alternative activation (phenotype M2) in which microglia take an anti-
inflammatory phenotype involved in wound repair and debris clearance 
(Gordon, 2003). In contrast with proinflammatory M1 cells, alternatively 
activated macrophages express cytokines and receptors that are involved in 
inhibiting inflammation and restoring homeostasis. This includes production 
of IL-10 to downregulate inflammatory cells, extracellular matrix protecting 
proteins like YM1, a heparin-binding lectin (Chang et al., 2001); FIZZ1, which 
promotes deposition of extracellular matrix (Raes et al., 2002); ornithine, 
which promotes proliferation; CD206, a mannose receptor for phenotype M2 
inducer IL-4 (Stein et al., 1992); polyamines for wound repair; and higher levels 
of receptors associated with phagocytosis, such as scavenger receptors (CD68 
antigen) (Martinez et al., 2009; Varin and Gordon, 2009). Thus, it makes sense 
that during neurodegenerative disease, in which neuroinflammation is a 
prominent feature and potential contributor to disease, the alternatively 




Astrocytes are arguably the most numerous and diverse neuroglial cells in the 
central nervous system, compromising nearly 35% of the total cell population 
(Liberto et al., 2004; Sofroniew, 2005). After the first description of glial cells 
by Virchow in 1856, the cellular nature of glial cells was recognized soon after 





and Verkhratsky, 2012). Nevertheless, the detailed morphological analysis of 
glial cells began after Camillo Golgi’s had developed black staining reaction 
and produced drawings of stained glial cells in 1872 (Golgi, 1873 and 1903).I It 
was not until 1891 that Michael von Lenhossek introduced the term astrocyte, 
in which astron means ‘star’ while kytos means ‘cell, to define the star-like 
cells.  
 
Astrocytes are present in all regions of the central nervous system. However, 
they are not uniform; their functions and morphology differ depending largely 
on their location, subtypes, and developmental stage. In healthy brain, the 
most prevalent are the protoplasmic astrocytes that are found throughout the 
grey matter and, as first demonstrated using classical silver impregnation 
techniques, they exhibit several stem branches that give rise to many finely 
branching processes in a uniform globoid distribution (Ramon y Cajal, 1909). In 
contrast, fibrous astrocytes are found throughout the white matter and 
exhibit many long fiber-like processes, and are in physical contact with 
oligodendrocytes while playing a crucial role in myelinization and support of 
the white matter (Ramon y Cajal, 1909; Lundgaard et al., 2013). 
 
Although originally defined as gap fillers for the neuronal network, astrocytes 
play a number of active roles in the brain (Figure 7). They provide trophic and 
metabolic support for neurons in conditions of energy depletion, when 
glucose expenditure exceeds availability, by releasing lactate from glycogen 
stores, forming the astrocyte neuron lactate shuttle (Zwingmann et al., 2000; 
Bouzier-Sore et al., 2002). Astrocytes also have high concentrations of anti-
oxidant molecules such as vitamin E, ascorbate, and glutathione (GSH) 
(Dringen et al., 2000; Shih et al., 2003). The interaction between astrocytes 
and neurons is required for the maintainence of the synaptic homeostasis, 





(Bergami et al., 2008; Bogen et al., 2008). Although astrocytes are electrically 
nonexcitable, with a constant resting membrane potential, contact at the 
synaptic level is necessary in the assembly of tripartite synapses along with 
the pre- and postsynaptic neurons. Astrocytes modulate transmission by 
releasing chemical transmitters (Araque et al., 2001; Fields and Stevens-
Graham, 2002). The interaction between developing neurons and astrocytes 
plays an important role in neuronal replacement, including dendritic growth 
and axon guidance, effective synapse formation and removal of unwanted 
synapses (Seri et al., 2001; Bundesen et al., 2003; Sanai et al., 2004; Petros et 














Figure 7. Schematic representation of the various functions attributed to astrocytes. 
Abbreviations: BBB: blood-brain barrier, GS: glutamine synthetase, GLAST: glutamate aspartate 
transporter, GLT1: glutamate transporter 1; adapted from Frago and Chowen, 2017. 
 
Moreover, astrocyte contact with other central nervous system cells is 
important for several biological functions in the brain. Astrocytes are able to 
regulate the specialized roles of the endothelial cells that line cerebral 





permeability to nutrients such as glucose (Leybaert, 2005). Astrocytes regulate 
the function of oligodendrocytes (Ishibashi et al., 2006; Yamaguchi et al., 
2008). In addition, astrocytes respond to all forms of nervous system damage 
and disease, showing a variety of changes in gene expression, cellular 
structure and function in the processes of ‘astrogliosis’ and ‘reactive 
astrocytosis’ (Sofroniew, 2014).  
 
Reactive astrocytes increase cell body size and thickness of astrocytic 
processes. In addition, branching of astrocyte processes becomes complex 
and is reorganized with increasing reactivity (Wilhelmsson et al., 2006). 
Increased numbers of astrocyte processes and a polarization occur toward the 
injury site or toxic aggregates (Bardehle et al., 2013). Reactive astrocytes show 
a broad heterogeneous graded spectrum of reactivity that in function of the 
inury can be classified into two main types, ‘A1’ and ‘A2’. A1 astrocytes are 
partially induced by micrcoglial secreted cytokines, such as the interleukin 1α 
(Il-1α), tumour necrosis factor (TNF) and complement component 1, 
subcomponent q (C1q) (Zhang et al., 2014; Bennett et al., 2016). A1 astrocytes 
highly upregulate many classical complement cascade genes, rapidly killing 
neurons and mature differentiated ‘harmful’ oligodendrocytes.By contrast, A2 
reactive astrocytes upregulate many neurotrophic factors, which promote 
survival and growth of neurons, as well as thrombospondins, which promote 
synapse repair. This upregulation suggests that A2s might have ‘helpful’ or 
reparative functions. 
 
The first modern description of a ‘reactive astrocyte’ occurred during the 
1970s, after the discovery of the intermediate filament protein glial fibrillary 
acidic protein (GFAP)- a routine identifier of astrocytes in the healthy and the 
pathological central nervous system. Histologically, astrocytes can be 





GFAP, such as vimentin or other markers such as the astrocyte specific 
glutamate transporters, glial L-glutamate transporter 1 (GLT1) and L-
glutamate/L-aspartate transporter (GLAST) (also known as EAAT1) (Walz, 
2000). Other markers for astrocytes have varying specificities: S-100b (calcium 
binding protein), aquaporin 4 (AQ4), brevican, G-protein coupled receptor 37-
like1 (gpr371R), aldehyde dehydrogenase 1 family-member L1 (ALDH1L1), and 
anti-low-affinity nerve growth factor receptor-p75 (NGFRp75), among others 




Oligodendrocytes represent highly specialized glial cells in the central nervous 
system that closely interact with the axons of neurons. The first systematic 
description of oligodendrocytes was provided by Pío Del Río Hortega in an 
article published in 1928 (Del Río Hortega, 1928). However, the complete story 
of this discovery begun in 1921 when he described microglia as the third 
element, mentioning the existence of oligodendrocytes as a new neuroglia cell 
type , the interfascicular glia, made up of cells showing very fine processes and 
arranged in groups along axonal tracts (Del Río Hortega, 1921). He used the 
term ‘oligodendroglia’ as in his observervations, glial cells with very few 
processes or branches, present in white matter, were also diffusely distributed 
in all regions of the central nervous system, and commonly grouped next to 
neurons in grey matter. Four different types were described by Pio del Río-
Hortega as detailed in recent reviews (Pérez-Cerdá et al., 2015; Ferrer, 2018):  
 
- Type I: small round cell bodies and large numbers of very fine cellular 
processes associated with thin myelinated fibers in the grey matter and 





- Type II: cuboidal with a few thick processes which 
trap axons longitudinally in the white matter. 
- Type III: one or two long cellular processes and present in the brain stem 
and spinal cord. 
- Type IV: elongated cell body and unique long processes running in parallel 
to thick axons in the white matter of the brain stem and spinal cord.  
 
Perineuronal oligodendroglial cells are called ‘perineuronal satellites’ whereas 
another subtype includes oligodendroglial cells localized in the proximity of 
small blood vessels and called, for this reason, ‘perivascular satellites’. 
 
One year later, using metallic silver impregnations, Del Río Hortega proposed 
that these cells were functionally similar to Schwann cells in the central 
nervous system (Del Río Hortega, 1922), and he predicted their relationship 
with myelination processes, their involvement in neuronal trophism, and their 
ectodermal origin (Del Río Hortega, 1928).  
 
The most typical characteristic of this cell type is the ability to generate a 
compact multilayered myelin sheath around the axon (Figure 8) (Nonneman 
et al., 2014). The myelin sheath is made up of thick concentric membrane 
bilayers of about 12 nm in periodicity formed by alternating electron-dense 
(major dense line of myelin) and electron-light (intra-period line of cytoplasm) 
membranes tightly connected at their edges by thigh junctions between the 
electron-dense layers (Baumann and Pham-Dinh, 2001; Simons and Trotter, 
2007). Myelin is composed of lipids, including cholesterol (26%); 
glycosphingolipids, in particular galactocerebrosides and sulphatides (24%); 
plasmalogens (20%); phospholipids and gangliosides, particularly GM4; and 
proteins (30%) (Kursula, 2001 and 2008; Chrast et al., 2011; Saher and Stumpf, 





myelin sheath are proteolipid protein (PLP), including its isoform DM20, and 
myelin basic protein (MBP). Other less abundant proteins are 2’,3’-cyclic 
nucleotide-3’phosphodiesterase (CNP), myelin oligodendrocyte glycoprotein 
(MOG), myelin-associated glycoprotein (MAG), myelin/oligodendrocyte 
basicprotein (MOBP), oligodendrocyte myelin glycoprotein (OMgp), 
myelin/oligodendrocyte specific protein (MOSP), transferrin (TF), carbonic 
anhydrase, claudin 11, connexins 32 and 47 (Cx32 and Cx47) and tetraspan-2, 














Figure 8: Schematic representation of oligodendrocyte structure and functions. (1) A typical 
CNS myelinated fiber from the spinal cord observed by transmission electron microscopy (TEM). 
(2) Diagrammatic representation of current concepts of the molecular organization of compact 
CNS myelin. The apposition of the extracellular (Ext) surfaces of the oligodendrocyte cell 
membranes to form the intraperiod (IP) line is shown in the upper part of the figure. The 
apposition of the cytoplasmatic (Cyto) surfaces of the membranes of the myelin-forming cells 
with the major dense (MD) line are shown in the lower part of the figure. This diagram does not 
include CNP, MAG and other quantitatively minor proteins of isolated myelin, because they do 
not play a major structural role in most of the compact myelin. (3) Oligodendrocytes provide 
lactate to axons via the periaxonal space and remove K+ ions. Abbreviations: PLP: proteolipid 
protein; MBP: myelin basic protein; MCT1/2: monocarboxylate transporter ½. Adapted from 






Individual neuronal axons are myelinated by consecutive oligodendrocytes 
arranged in line, separating each segment from the next by a gap, the so-called 
node of Ranvier. Ranvier’s nodes are enriched in certain myelin- and axon-
derived proteins, such as netrin, contactin 1 and 2, neurofascin 155, 
neurofascin 186 and contactin-associated proteins (Caspr), which interact to 
bind the myelin sheath to the axon at the free borders of myelin, together 
with extracellular matrix proteins (Rasband, 2011; Thaxton, 2011; Arancibia-
Carcamo and Attwell, 2014). 
 
Myelin sheath makes fast and efficient propagation of action potentials 
possible over long distances along the axons through saltatory conduction due 
to the interruption of the myelin sheath at regular distances by the nodes of 
Ranvier. At these nodes of Ranvier, electrical activity can be generated in order 
to propagate the action potential efficiently from one node of Ranvier to the 
next (Poliak and Peles, 2003). Nodes are enriched in voltage-gated sodium 
channels and potassium-gated channels Nav 1.6, Nav 1.1, KCNQ2/3, Kv 3.1, 
Kv1.1/1.2; and postsynaptic density protein 93/95 (PSD 93/95) which are all 
crucial for saltatory nerve conduction (Poliak and Peles, 2003). 
 
Another important function of the oligodendrocytes is their ability to provide 
neurons with energy support. Monocarboxylates, including lactate, pyruvate 
and keton bodies, are a class of essential energy substrates for the central 
nervous system. These energy substrates are transported across membranes 
by monocarboxylate transporters (MCTs). The most abundant lactate 
transporter in the CNS is monocarboxylate transporter-1 (MCT1), mainly 
expressed by oligodendrocytes at high levels (Lee et al., 2012; Morrison et al., 
2012). Abnormalities in one of these two functions cause a number of 






Most oligodendrocytes develop during embryogenesis and early postnatal life 
in restricted periventricular germinal regions. In the adult brain, 
oligodendrocyte formation is associated with glial-restricted progenitor cells, 
known as oligodendrocyte progenitor cells (OPCs), that may be called NG2-glia 
because of their expression of proteoglycan GSPG4 (NG2) (Dawson et al., 
2003). Differentiation of OPCs to oligodendrocytes depends on the availability 
of certain growth and survival factors, such as platelet-derived growth factor 
A (PDGF)-A, fibroblast growth factor 2 (FGF-2), insulin-like growth factor 1 
(IGF-1), ciliary neurotrophic factor (CNTF) and neurotrophin 3 (NT-3) (Barres 
et al., 1992). Early stages of oligodendrocyte lineage are identified by the 
expression of Olig1, Olig2 and Nkx2.2 (Liu et al., 2007). PDGF-Rα, NG2, Olig1, 
Olig2, Sox 10 and A2B5 are OPC differentiation and pre-oligodendrocyte 
markers. Loss of PDGF-Rα and NG2, and increased expression of surface lipid 
sulfatide, galactocerebroside and CNP, together with Olig1 and Olig2 
transcription factor, are characteristic markers of immature oligodendrocytes 
(Marinelli et al., 2016). After oligodendrocyte differentiation, myelination is 
triggered by myelin regulatory factor (MYRF) which is expressed in post-
mitotic oligodendrocytes (Cahoy et al., 2008), loosing the expression of myelin 
proteins that have MYRF binding motifs in their promoters (Emery et al., 
2009). At this time, oligodendrocytes also produce sulfatides and 
galactocerebrosides as the main lipid components of myelin (Bradl and 
Lassmann, 2010). 
 
2.8.1.1. Neuroinflammation in ALS 
  
A common characteristic of neurodegenerative disorders is the occurrence of 
a neuroinflammatory reaction consisting of activated glial cells, mainly 
microglia and astrocytes, and infiltrated active T cells, evidencing the 





presymptomatic phase of ALS (Kang et al., 2013; Philips and Rothstein, 2014; 
Komine and Yamanaka, 2015; Liu and Wang, 2017). In neurodegenerative 
diseases, the neuroinflammatory reaction is not transient, but sustained, 
probably because of the persistent presence of precipitating factors, turning 
it into a hazardous process and contributing to neuronal damage. Chronically 
activated microglia and astrocytes, as well as infiltrating immune cells, 
represent prominent pathological findings in affected central nervous system 
areas of patients and animal models of neurodegenerative disorders such as 
ALS (McCombe and Henderson, 2011). 
 
Despite not being immune cells, astrocytes are a potential source of both pro- 
and anti-inflammatory cytokines, actively contributing to the immune 
response. Data in post-mortem tissues of ALS patients reveal changes in the 
morphology of astrocytes together with reactive astrogliosis surrounding both 
upper and lower motor neurons (Schiffer et al., 1996). Increased numbers of 
GFAP- and ALDH1L1-immunoreactive astrocytes locate in the dorsal horn and 
at sites where fibres of the corticospinal tract enter the grey matter; and they 
are particularly notable in the grey matter of the ventral horn of the spinal 
cord where astrocytes normally express GFAP at very low levels (Philips and 
Robberecht, 2011). In the brain, astrocytosis occurs in both cortical grey 
matter and subcortical white matter, and it is not restricted to the motor 
cortex (Kushner et al., 1991; Nagy et al., 1994). 
 
Additionally, reactive astrocytes in post-mortem tissue from ALS cases also 
show increased immunoreactivity for calcium-binding protein S100, and they 
express inflammatory mediators (Shobha et al., 2010), such as cyclo-
oxygenase-2 (COX-2), prostaglandin E2, leukotriene B4, nitric oxide (NO), 
inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase 





Corroborating these data, mutant hSOD1 transgenic mice show a similar 
pattern of reactive astrogliosis, although the time course of astrogliosis, 
relative to motor neuron degeneration and the onset of symptoms, seems to 
vary in different models (Wong et al., 1995; Bruijn et al., 1997; Hall et al., 1998; 
Howland et al., 2002). 
 
Microgliosis occurs in the motor cortex, the motor nuclei of the brainstem, 
along the corticospinal tract, and in the ventral horn of the spinal cord where 
microglia might interact with T-cell infiltrates (Kawamata et al., 1992). It has 
been reported that injured MNs and astrocytes in ALS release misfolded 
proteins and activate, through CD14, toll-like receptor (TLR) 2, TLR4, and 
scavenger receptor dependent pathways (Appel et al., 2011; Zhao et al., 
2013). Once microglia are activated, they display distinct plastic phenotypes, 
with either neurotoxic or neuroprotective function, depending on the state of 
activation and disease stage. At early slow progressive stages of ALS, microglia 
display an M2 phenotype with upregulated expression of tissue repair and 
regeneration molecules, like CD206 and Ym1; overexpression of neurotrophic 
factors such as IGF-1, BDNF or GDNF and secretion of anti-inflammatory 
mediators IL-10 and TGFB; and interaction with protective signals such as 
CD200 and fractalkine (CX3CL1) (Appel et al., 2011; Blasco et al., 2013). As ALS 
progresses, MNs release signals which induce microglia to acquire M1 
phenotype which enhances the secretion of NOX2, ROS and proinflammatory 
cytokines (e.g., TNF-α, IL-1, INFy and IL-6) (Beers et al., 2011; Liao et al., 2012). 
 
Microglial activation is associated with infiltration of helper T cells and 
cytotoxic T cells. Concomitant with increased infiltration of inflammatory T 
cells, parenchymous microglia acquire properties of antigen-presenting cells, 
as revealed by the upregulation of certain expression markers such as CD11c 





This suggests that these microglial cells interact closely with the T-cell 
infiltrates (Philips and Robberecht, 2011). Infiltrated T cells can both damage 
and protect neurons. At early stages of ALS, the immune profile is 
characterised by increased regulatory T cells, upregulation of anti-
inflammatory cytokines and activation of neuroprotective microglia (M2) cells. 
Transition to pro-inflammatory effector T cells and cytokines along with 




















Figure 9. General overview of the cross-talk between motor neurons, astrocytes, and immune 
cells in ALS context. Neuroinflammation, characterized by the appearance of reactive 
astrocytes and microglia as well as macrophage and T-lymphocyte infiltration, appears to be 
highly involved in the disease pathogenesis, highlighting the involvement of non-neuronal cells 
in neurodegeneration. There appears to be cross-talk between motor neurons, astrocytes, and 
immune cells, including microglia and T-lymphocytes, which are subsequently activated. 





Thus, in ALS, astrocytes, microglia and peripheral immune cells are involved 
exerting either deleterious or protective effects on MN survival depending on 
the stage of the disease, but the mechanism is far from being fully elucidated 
(Figure 9). Moreover, it remains to be clarified whether neuroinflammation is 
a consequence of motor neuron injury or actively contributes to the 
development and progression of the disease. 
 
2.8.1.2. Myelin and oligodendrocyte alterations in ALS 
 
The involvement of non-neuronal glial cells, such as microglia and astrocytes, 
is a well-studied aspect of ALS pathology. However, the oligodendrocytes and 
their progenitor cells are glial cell types that have been largely ignored for 
years in the context of ALS (Nonneman et al., 2014). However, recent studies 
have demonstrated that motor neuron degeneration in ALS is intimately 
linked to oligodendroglial cell dysfunction.  
 
Recent studies have postulated oligodendroglial TDP-43-immunoreactive 
inclusions to be an early pathological event in the spinal cord in ALS 
(Brettschneider et al., 2014a). Specifically, oligodendroglial TDP-43-
immunoreactive inclusions are present in the anterior horn of the spinal cord 
and in the motor, sensory and premotor cortex, but not in the corpus 
callosum, cingulum or lateral tracts of the spinal cord (Fatima et al., 2015). 
 
In addition to the presence of inclusions, myelin abnormalities and 
demyelination are present in the motor cortex and grey matter of the ventral 
spinal cord of ALS patients, in both sporadic and familial ALS patients (Kang et 
al., 2013). The levels of myelin-related proteins progressively decrease during 
disease (Niebroj-Dobosz et al., 2007), most prominently the decrease in MBP. 





degeneration, unless it occurs in combination with oligodendroglial injury or 
inflammation (Nave, 2010b). 
 
Besides myelin defects, oligodendrocytes also fail to supply axons with 
metabolic energy substrates. MCT1 expression levels are predominantly 
decreased in the ventral horn of the spinal cord grey matter of symptomatic 
SOD1-G93A mice and significally decreased in the motor cortex of ALS 
patients, while unaffected brain regions show normal MCT1 levels (Lee et al., 
2012). 
 
Furthermore, in mutant SOD1-G93A mice, evidence indicates that 
oligodendrocytes start to degenerate before the first symptoms of motor 
neuron degeneration become apparent, increasing with disease progression, 
and showing oligodendrocytes with thickened, irregularly shaped cell bodies, 
enlarged cytoplasm and elongated reactive processes, known as dysmorphic 
oligodendrocytes. In addition, clear markers of the apoptotic state are 
observed in dysmorphic oligodendrocytes, such as cleaved caspase-3 
immunoreactivity and chromatin condensation (Kang et al., 2013).  
 
Nevertheless, mature oligodendrocytes are not the only cells in their lineage 
affected in ALS patients. NG2+ oligodendroglial precursor cells also show 
reactive changes, with augmentation of NG2 immunoreactivity and thick 
hypertrophic NG2+ processes (Philips et al., 2013). Oligodendrocyte 
degeneration with disease progression is offset by increased proliferation and 
differentiation of NG2+ glial cells into oligodendrocytes, thereby maintining 
the overall number of oligodendrocytes. In this manner, the density of 
oligodendrocytes remains constant in ALS, although newly generated 








The brain, which accounts for only 2% of body weight, consumes 20% of the 
total oxygen (O2) breathed in. A major reason for the high oxygen uptake by 
the brain is the vast amounts of ATP needed for its normal activity, maintaining 
the intracellular ion homeostasis and powering its ~86 billion neurons and 
their unfathomably complex connectome spanning trillions 
of synapses abetted by ~250–300 billion glial cells (Carey, 2002; Cobley et al., 
2018).  
 
Mitochondria are responsible for the production of most of the cell's ‘energy 
currency’ in the form of ATP, the end-product of pathways involving oxidation 
of substrates. The mitochondrion is a double-membrane-bound organelle 
found in most eukaryotic organisms. The term 'mitochondrion' is derived from 
a Greek words 'mitos', which means 'thread', and ‘chondrion’, which means 
'granule'. The first observations of intracellular structures that probably 
represented mitochondria were published in the 1840s (Ernster and Schatz, 
1981), but it was not until 1957 that, based on evidence accumulated over 
years by different authors about its different functions, Philip Siekevitz dubbed 
them ‘powerhouse of the cell’ (Siekevitz, 1957).  
 
Mitochondria, frequently 0.75 and 3μm in diameter, vary considerably in size, 
structure and number, depending on the organism, tissue, and cell type. The 
organelle is composed of compartments that carry out specialized functions 
(Wiemerslage and Lee, 2016). These compartments include (Figure 10): 
 
(i) Outer mitochondrial membrane (OMM) is a smooth lipid bilayer 
composed of equal amounts of phospholipids and proteins, specifically a 





mitochondrial membrane -40 (TOMM40) or -70 (TOMM70), with most of 
them being porins, like the voltage-dependent anion channel 
(VDAC). OMM is freely permeable to nutrient molecules, ions and energy 
molecules like the ATP and ADP. 
 
(ii) Inner mitochondrial membrane (IMM) is a phospholipid bilayer with a 
complex structure turned into a number of repeated folds known as the 
cristae. This folding helps to increase the surface area inside the organelle 
hosting the main proteins of ETC involved in the production of ATP. IMM is 
strictly permeable to oxygen and ATP, and also helps regulate the transfer 
of some metabolites. 
 
(iii) Intermembrane space (IMS) is the space between the outer and inner 
membrane of the mitochondria; it has the same composition as the cell's 
cytoplasm. It tends to have a low pH because of the proton gradient, which 
occurs when protons are pumped from the mitochondrial matrix into the 
intermembrane space during ETC. 
 
(iv) Matrix is the viscous space within the IMM. The mitochondrial matrix 
contains the mitochondria's DNA, ribosomes and molecules linked to 
energy production, such as soluble enzymes, small organic molecules, 
nucleotide cofactors and inorganic ions. 
 
Additionally, the mitochondrion contains mitochondrial DNA (mtDNA), which 
is organized as several copies of a single, usually circular, chromosome, coding 
information for 13 mitochondrial proteins (Friedman and Nunnari, 2014). 
Mitochondria are involved in a myriad of functions, including biosynthesis of 
amino acids and steroids, β-oxidation of fatty acids, maintenance of cytosolic 





modulation of reactive oxygen species (ROS) and acting centrally in apoptosis, 
among others (Davis and Williams, 2012). However, as noted before, the most 


















Figure 10: Mitochondrion structure. (A) Coloured transmission electron microscope image of a 
thin section of mammalian tissue; mitochondria displaying their matrix, membranes and 
ribosomes. (B) Schematic structure of a mitochondrion, showing its two specialized 
membranes. The inner membrane is highly convoluted so that a large number of infoldings 
called cristae are formed. 
 
2.8.2.1. Mitochondria’s energy metabolism 
 
Energy production is accomplished through the mitochondrial electron 
transport chain (ETC) which consists of four enzyme complexes (complex I to 
complex IV) embedded in the IMM that transfer electrons from donors like 





transfer, the ETC pumps protons into the IMS, generating a gradient across the 
IMM that the ATP synthase exploits to drive adenosine triphosphate (ATP) 
synthesis (chemiosmosis) (Mitchell, 1961; Wallace, 2013; Birsoy et al., 2015). 
This process is called oxidative phosphorylation (OXPHOS) and is fueled using 
electron donors generated in the mitochondrial matrix by the tricarboxylic 
acid (TCA) cycle and fatty acid β-oxidation or by cytosolic glycolysis (Birsoy et 
























Figure 11: The electron transport chain has four protein complexes (C-I to C-V). The transfer 
of electrons creates hydrogen ions that get pumped across a proton gradient in the 
mitochondrial matrix and the intermembrane space. During chemiosmosis, there are more 





these ions will travel across ATP synthase, catalyzing the phosphorylation of ADP to ATP. 
Legend: (7.1.1.2) NADH dehydrogenase (ubiquinone); (1.3.5.1) succinate dehydrogenase; 
(7.1.1.8) cytochrome bc1 complex; (1.9.3.1) cytochrome C oxidase; (7.1.2.2) ATP synthase; 
(7.2.2.19) proton pump; (7.1.2.1) proton transport ATPase. 
 
1. Complex I (C-I) receives two electrons from NADH molecule. C-I is 
composed of flavin mononucleotide (FMN), a prosthetic group derived 
from vitamin B2 also called riboflavin, and an iron-sulfur (Fe-S)-containing 
enzyme, known as NADH dehydrogenase (Sharma et al., 2009). Fourteen 
central subunits represent the minimal form of C-I; these are assigned to 
functional modules for NADH oxidation and ubiquinone reduction, and 
they pump hydrogen ions across the membrane from the matrix into the 
intermembrane space, establishing and maintaining an ion gradient 
between the two compartments separated by the inner mitochondrial 
membrane. The enzymatic core is composed of seven hydrophobic 
subunits (ND1–ND6 and ND4L) encoded by the mitochondrial genome 
(Chomyn et al., 1985) in combination with seven nuclear-encoded subunits 
(NDUF) divided into different subtypes (Iα, Iβ, Iλ, and Iγ) (Sazanov et al., 
2000). In addition, there are assembly proteins, which mediate complex I 
assembly and maintain the complex I stability including NDUFAF1, 
NDUFAF12L, AIF, NDUFS4, ECSIT and C6orf66, among others. 
 
2. Complex II (C-II), also known as succinate dehydrogenase (SDH) 
complex, directly receives FADH2 from mitochondrial matrix, which does 
not pass through C-I. SDH is comprised of four subunits (SDHA, SDHB, 
SDHC, and SDHD) encoded by nuclear DNA, and unlike other mitochondrial 
complexes, lacks subunits encoded by the mitochondrial genome. SDH 
transfers electrons from succinate via its [Fe–S] clusters to ubiquinone 
(UbQ). Thus, UbQ receives the electrons derived from complex II but also 
receives electrons derived from NADH from C-I. Once ubiquinone is 





complex in the electron transport chain (Kluckova et al., 2013; Bezawork-
Geleta et al., 2017). C-II has also a role in the ETC and the tricarboxylic acid 
(TCA) cycle where SDH oxidises the metabolite succinate to fumarate, thus 
linking the two essential energy-producing processes of the cell (Kluckova 
et al., 2013). 
 
3. Complex-III (C-III), also called cytochrome oxidoreductase, is a 
multiheteromeric enzyme composed of 11 different subunits (Schagger et 
al., 1986), one encoded by mitochondrial DNA and 10 by nuclear genes. 
These 11 subunits constitute the monomeric module of a symmetric dimer, 
which constitutes the functionally active form of the enzyme. The complex 
is embedded in the mitochondrial inner membrane, spanning from the 
matrix to the inter-membrane space. Three of these subunits contain the 
catalytic centers: cytochrome b (MT-CYB), cytochrome c1 (CYC1) and the 
Rieske protein (UQCRFS1). Additionally, cytochrome b contains two heme 
moieties, the low potential (bL) and the high potential (bH) heme b; CYC1 
binds a c-type heme group and the Rieske Iron Sulfur Protein subunit (ISP) 
that contains a 2Fe-2S cluster (UQCRFS1). Heme groups act as prosthetic 
groups, helping in the electron transition process (Fernández-Vizarra and 
Zeviani, 2015). The exact function of the other eight supernumerary 
subunits (UQCRC1, UQCRC2, UQCRH, UQCRB, UQCRQ, Subunit 9, UQCR10 
and UQCR11) remains to be established (Xia et al., 2013).  
 
C-III shunts the electrons coming from ubiquinol across the intermembrane 
space to cytochrome c, which brings electrons to the next complex. 
Oxidation of ubiquinol at C-III requires the donation of those two electrons 
to the single electron carrier cytochrome c. The first electron transfer at 
complex III is to the Reiske iron-sulfur center protein (RISP). This electron 





This one electron transfer from ubiquinol results in the unstable radical 
ubisemiquinone (Q•-) which can donate its unpaired electron to oxygen to 
generate superoxide within the Q-cycle. However, under most 
circumstances, the unpaired electron of ubisemiquinone is transferred to 
the two heme groups of cytochrome b (Heme bL and Heme bH). The two 
hemes have different electron affinities because they are located in 
different polypeptide environments. Heme bL is located closer to the 
intermembrane space and has a lower affinity for electrons than Heme bH, 
which is located closer to them matrix side. Ubisemiquinone transfers its 
electron to bL to form ubiquinone. Heme bL in turn donates an electron to 
Heme bH, which subsequently reduces another molecule of ubiquinone, 
forming ubisemiquinone. The Q-cycle at this stage is only half complete as 
only one electron from ubiquinol has been transferred to cytochrome c. 
After a second round of the Q-cycle, two molecules of ubiquinol have been 
oxidized on the intermembrane side of the inner membrane and two 
molecules of cytochrome c have been reduced on the matrix side of the 
inner membrane. The total balance produces the exchange of 4H+ to the 
mitochondrial intermembrane space (Kramer et al., 2004; Chandel, 2010). 
 
4. Complex IV (C-IV) or cytochrome C oxidase (COX) is the last electron 
acceptor of the respiratory chain. COX is a multimeric complex formed by 
14 polypeptide subunits, three of which are encoded by mitochondrial DNA 
and which are the catalytic subunits that carry out the electron transport 
function (MT-CO1, MT-CO2 and MT-CO3), whereas the remaining 11 are 
encoded by nuclear DNA (COX4-COX8, some of them with different forms) 
(Balsa et al., 2012). Subunits are combined with prosthetic groups 
(heme a and heme a3, one in each of the two cytochromes), three ion 
copper metallic centers, and three copper ions (a pair of CuA and one CuB 





receives an electron from each complex III molecule, and transfers these 
to one oxygen molecule, converting molecular oxygen to two molecules of 
water. The cytochromes hold an oxygen molecule very tightly between the 
iron and copper ions until the oxygen is completely reduced. The free 
energy released as the electrons move to an even lower energy state is 
used to pump even more protons into the intermembrane space, further 
strengthening the transmembrane difference of proton electrochemical 
potential that the ATP synthase then uses to synthesize ATP (McEwen et 
al., 2011). 
 
5. Complex V (C-V), also known as ATP synthase or FoF1 ATPase, consists 
of two main subunits, Fo and F1, which have a rotational motor mechanism 
allowing for ATP production. Fo and F1 create a pathway for proton 
movement across the membrane. The flow of these protons down the 
gradient turns the rotor and stalk of the ATP synthase, which makes it 
possible for a phosphate group to join with adenosine diphosphate (ADP), 
forming ATP (Velours et al., 2000).  
 
F1 is composed of three copies of each of subunits α (ATP5A1, ATPAF2) and 
β (ATP5B, ATPAF1, C16orf7), and one each of subunits γ (ATP5C1), δ 
(ATP5D) and ε (ATP5E) (Jonckheere et al., 2012). There is a substrate-
binding site on each of the α and β subunits; those on β subunits are 
catalytic, while those on α subunits are regulatory. The remaining F1 
subunits (γ, δ, ε) form part of the stalks with diverse regulatory functions. 
The α/β subunits undergo a sequence of conformational changes, induced 
by the rotation of the γ subunit, leading to the formation of ATP (Leyva et 
al., 2003). In contrast, Fo has mainly hydrophobic regions that consist of 8 
c subunits forming a ring and one copy each of a (ATP6, ATP8), b (ATP5F1), 





conferring protein (OSCP) subunits, together with the accessory subunits e 
(ATP5ME), f (ATP5MF), g (ATP5MG) and A6L (ATP8) that form the 
peripheral stalk which lies to one side of the complex. The ring has a 
tetramer shape with a helix-loop-helix protein that goes though 
conformational changes when protonated and deprotonated, pushing 
neighboring subunits to rotate andcausing the spinning of Fo which then 
also affects conformation of F1, resulting in the switching of states of α and 
β subunits (Jonckheere et al., 2012). 
 
Considering the intense energy demands and limited regenerative capacity of 
neurons, improper functioning of mitochondria energy mechanisms and the 
remaining biological functions can trigger devastating effects on neuronal 
survival.  
 
2.8.2.1.1. Energy failure in ALS 
 
Besides their ability to convert nutrients into ATP, mitochondia are crucial in 
intermediate metabolism, maintaining cellular calcium homeostasis and 
functioning as gatekeepers in the intrinsic apoptotic pathways. Because of the 
multiple functions of mitochondria, alteration of their properties might confer 
an intrinsic susceptibility to long-lived post-mitotic cells, such as motor 
neurons, and to aging and cellular stress (Cozzolino and Carrì, 2012).  
 
Mitochondrial abnormalities are pathological hallmarks in spinal cord of ALS 
patients (Afifi et al., 1966). Specific, structurally altered and aggregated 
mitochondria with swollen and vacuolated appearance were one of the first 
changes observed in ALS patient motor neurons and in Bunina body- 
containing cells (Hart et al., 1977; Atsumi, 1981; Sasaki and Iwata, 2007). sALS 





neurofilaments. Morphologically, abnormal mitochondria are also 
consistently reported in animal and cell models of ALS, mainly manifested as 
mitochondrial fragmentation (Jaarsma et al., 2000; Bendotti et al., 2001; 
Martin et al., 2007; Martin, 2007). 
 
Direct evidence that disruption of mitochondrial structure may contribute to 
ALS comes from the discovery of causative mutations in the mitochondrial 
protein coiled-coil-helix-coiled-coil-helix domain containing 10 (CHCHD10) 
which is localised to contact sites between the inner and outer mitochondrial 
membranes (Bannwarth et al., 2014). ALS-associated mutations in CHCHD10 
disrupt mitochondrial cristae and have profound effects on mitochondrial 
structure (Genin et al., 2016). Deformation and loss of mitochondrial cristae 
have also been reported in C9orf72-related ALS and FTD (c9ALS/FTD) patient 
fibroblasts (Dafinca et al., 2016; Onesto et al., 2016), and in vitro and in vivo in 
SOD1-G93A mouse (Kirkinezos et al., 2005). In addition, part of misfolded 
mutant SOD1 protein is located on the cytoplasmic surface of mitochondria. 
Axonal mitochondria of motor neurons are primary targets (Vande Velde et 
al., 2011).  Mutant SOD1 motor neurons have impaired mitochondrial fusion 
processes in cell bodies and axons, showing smaller mitochondrial size, 
reduced density and defective membrane (Magrané et al., 2012). 
 
The electron transport chain is also affected in ALS patients, although the well-
known difficulty in obtaining well-conserved, large collections of samples and 
the heterogeneity of tissues have, at times, complicated the interpretation of 
results. For instance, increased activity of complex I was found in a first study 
on post-mortem brain tissue (Bowling et al., 1993) which may represent a 
compensatory event against the deficiency of mtDNA encoded enzyme 
cytochrome c oxidase observed in some ALS patients (Yamamoto et al., 1989; 





and fALS patients, the decrease in citrate synthase activity parallels the 
decrease in the activity of respiratory chain complexes (Fujita et al., 1996; 
Borthwick et al., 1999; Wiedemann et al., 2002). This suggests loss of 
mitochondria in ALS spinal cords and increased mitochondrial DNA damage 
(Swerdlow et al., 1998). Alteration of ETC also occurs in ALS skeletal muscle, 
mainly manifested by severe deficiency of respiratory chain complex I and 
complex IV. This has been interpreted to mean either that sALS patients have 
primary mitochondrial DNA damage in muscle fibers or that these alterations 
are secondary to muscle fiber denervation and atrophy (Wiedemann et al., 
1998). 
 
Mitochondria are also key players in the buffering of intracellular calcium, 
which in prolonged excess results in the activation of pro-oxidant and 
apoptotic factors (Choi, 1988; Dawson et al., 1991). Depletion of 
mitochondrial calcium-buffering ability is particularly deleterious to neurons 
and skeletal muscle, whose normal functioning involves frequent influxes of 
calcium to generate action potentials. Likewise, both ALS patients and mouse 
models have increased intracellular calcium concomitant with mitochondrial 
damage (Curti et al., 1996; Siklos et al., 1996; Damiano et al., 2006). It is not 
clear whether decreased mitochondrial buffering capacity precedes cytosolic 
Ca2+ overload or vice-versa, since these processes reciprocally enhance each 
other (Dykens, 1994; Carriedo et al., 2000). Indeed, glutamate-receptor 
mediated neurotoxicity has been linked to overload of mitochondrial calcium 
and ROS production in cultured spinal motor neurons from transgenic ALS 
animals (Carriedo et al., 2000).  
 
Together, these studies demonstrate that changes in mitochondrial function 






2.8.2.2. Mitochondria and oxidative stress 
 
Under normal physiological conditions, the mitochondrial electron flow leads 
to the formation of superoxide anion (O2–) subproduct, the primary oxygen 
free radical produced by mitochondria. Superoxide is a reactive oxygen 
species (ROS), a natural product of the oxygen metabolism that has important 
roles in cell signaling and homeostasis (Devasagayam et al., 2004). Reactive 
oxygen molecules include superoxide radical (O2−), hydroxyl radical (OH-) and 
hydrogen peroxide (H2O2) (Chandra et al., 2015). However, under 
environmental stress, ROS levels can increase dramatically, triggering the 
deleterious condition known as oxidative stress (OS), which reflects an 
imbalance between the systemic manifestation of ROS and a biological 
system's ability to readily detoxify the reactive intermediates and to repair the 
resulting damage (Figure 12) (Betteridge, 2000). In the case of oxidative stress 
induced by superoxide molecule, it interferes with the electron transport 
chain, dramatically increasing superoxide production. Mitochondria are highly 
vulnerable to the action of ROS, which are able to interfere with multiple 
components of the respiratory chain (Murphy, 2009), with the heme-
containing molecule COX1 of the complex 4 of the respiratory chain being the 
most vulnerable (Mahad et al., 2008). Oxidation of respiratory chain 
components results either in functional inhibition or in increased degradation 
of the respective proteins, leading to partial dysfunction of energy 
metabolism. In addition, mitochondrial DNA mutations and deletions may be 
induced by free radicals (Campbell et al., 2010). Moreover, superoxide radicals 
can rapidly react with nitric oxide (NO) to generate cytotoxic peroxynitrite 
anions (ONOO–) (Figure 12). Peroxynitrite anions belong to reactive nitrogen 
species (RNS) that act together with reactive oxygen species to damage cells, 





to protein damage via the formation of nitrotyrosine and lipid oxidation 
(Barber et al., 2006). 
 
While these partially reduced oxygen species can attack iron sulfur centers in 
a variety of enzymes, superoxide is rapidly converted within the cell to 
hydrogen peroxide (H2O2) by the superoxide dismutase enzymes (SOD1, SOD2 
and SOD3) (Figure 12). However, hydrogen peroxide can react with reduced 
transition metals, via the Fenton reaction, to produce the highly reactive 
hydroxyl radical (OH), a far more damaging molecule to the cell (Yim et al., 
1990). Oxidative injury leads to tissue degeneration in the central nervous 
system through various mechanisms. First, it may directly oxidize lipids, 
proteins and DNA, thus interfering with the function of these molecules and 










Figure 12. Generation of reactive oxygen and nitrogen species (ROS and RNS). This overview 
shows the major reactions (not fully balanced) generating ROS and RNS (only peroxynitrite) and 
the antioxidant (scavenging) proteins catalyzing the reduction of superoxide anion (O2-) and 
hydrogen peroxide (H2O2). It also indicates that ferrous iron (Fe2+) contributes to catalyzing the 
formation of hydroxyl radicals; SOD, superoxide dismutase; OH- , hydroxyl radical; NO- , nitric 
oxide; ONOO-, peroxynitrite. Adapted from Tomanek, 2015. 
 
The oxidative stress can be effectively neutralized by enhancing cellular 
defenses in the form of antioxidants. Certain enzymatic antioxidants work by 
breaking down and removing free radicals, converting dangerous oxidative 
products to hydrogen peroxide and then to water, in a multi-step process in 





example, to reduce hydroxyl radical damage, the antioxidant enzymes 
catalase and glutathione peroxidase act on hydrogen peroxide molecules, 
converting them to oxygen and water (Figure 12) (Lü et al., 2009; Nimse and 
Pal, 2015).  
 
Other antioxidants are those compounds which act by raising the levels of 
endogenous antioxidant defenses, such as the expression of gene coding for 
detoxyfing enzymes like superoxide dismutase (SOD), catalase (CAT) and 
glutathione peroxidase (GSHPx), or by directly interfering with free radical 
chain reactions  (Nimse and Pal, 2015). Examples of non-enzymatic 
antioxidants are vitamin C, vitamin E, plant polyphenol, carotenoids and 
glutathione, among others (Lü et al., 2009).  
 
2.8.2.2.1. Oxidative stress in ALS 
 
The vast majority of neurons are more susceptible to oxidative stress than 
other cellular populations because they are post mitotic cells, and damage 
accumulates throughout life (Shaw and Eggett, 2000). Markers of oxidative 
stress are found in post-mortem brains from patients with different 
neurodegenerative disorders (Sayre et al., 2001). However, motor neurons in 
particular are highly specialised cells; likely, this specialisation renders them 
vulnerable to oxidative stress injury. The unusually high energy demand of the 
motor neuron must be supported by mitochondria with the side-effect of 
increased ROS generation (Shaw and Eggett, 2000). In addition, free radical 
production is a major cause of aging (Lenaz et al., 2002). 
 
In ALS, there is substantial evidence to support the hypothesis that oxidative 
stress is one mechanism by which motor neuron death may occurs. In sporadic 





et al., 1995) and motor cortex (Ferrante et al., 1997), and increased 3-
nitrotyrosine levels, a marker for oxidative damage mediated by peroxynitrite, 
are observed in both sporadic and SOD1 familial ALS patients (Beal et al., 
1997). Protein and lipid oxidation markers are localised in motor neurons, 
reactive astrocytes and microglia/macrophages in the grey matter neuropil of 
sporadic ALS patients (Shibata et al., 2001). Oxidative damage to DNA, 
measured by levels of 8-hydroxy-2′-deoxyguanosine (8-OHdG), are found 
elevated in whole cervical spinal cord from ALS patients (Fitzmaurice et al., 
1996). These facts became more persuasive with the discovery of superoxide 
dismutase 1 (SOD1) mutations that cause disease in a significant minority of 
fALS cases. However, the precise mechanism(s) by which mutant SOD1 leads 
to motor neuron degeneration has not been defined, and the results of trials 




Neuronal excitotoxicity that culminates in neuronal death is a hallmark of 
cellular responses to major stresses such as those that occur in 
hypoxia/ischemia injury and in neurodegenerative diseases (Prentice et al., 
2015). The excitotoxicity concept was coined by John Olney in 1969 (Olney, 
1969), based on the observations that those amino acids that induce neuronal 
death were the ones known to activate excitatory amino acid (EAA) receptors 
(Olney, 1978). Overactivation of these receptors causes excitotoxicity by 
allowing high levels of calcium ions to enter the cell (Manev et al., 1989). The 
excitatory effects of glutamate are exerted via the activation of three major 
types of ionotropic receptors and several classes of metabotropic receptors 
linked to G-proteins. The major ionotropic receptors activated by glutamate 
are N-methyl-D-aspartic acid (NMDA), α-amino-3-hydroxy-5-methylisoxazole-





ion channels permeable to various cations (Danysz and Parsons, 2003). As to 
metabotropic (mGluR) receptors, they mediate slow synaptic responses, 
owing to their coupling with intracellular G-proteins. For example, the mGluR1 
and mGluR5 subunit subtypes are coupled to the inositol trisphosphate 
(IP3)/Ca2+ signal transduction pathway and can thus affect protein kinase 
activation and stimulation of Ca2+ release from neuronal stores, both of which 
can trigger delayed cell death processes (Friedman, 2006). Excessive calcium 
influx into cells activates a number of enzymes, including phospholipases, 
endonucleases and proteases, such as calpain. These enzymes go on to 
damage cell structures such as components of the cytoskeleton, membranes 
and DNA (Berliocchi et al., 2005), leading to cell death (Figure 13). 
 
Under physiological conditions, during glutamatergic neurotransmission, a 
depolarizing impulse on the presynaptic neuron triggers a transient spike in 
the concentration of glutamate in the synaptic cleft that activates ionotropic 
glutamate receptors present on the postsynaptic neuron. Activation of these 
glutamate receptors results in the influx of sodium ions into the cell, leading 
to depolarization and ultimately, if the threshold is achieved, to the generation 
of an action potential at the axon hillock of the postsynaptic neuron (Van Den 
Bosch et al., 2006; Sirohi and Kuhn, 2017). In addition to Na-K channel 
activation, activation of NMDA receptors also allows conductivity of Ca2+ ions 
that trigger a signaling cascade which helps to modulate the strength of the 
synapse. Additionally, NMDA receptors may also be hyperactivated if the 
ambient glycine levels in the synaptic cleft are disturbed due to malfunctioning 
of the glycine transporters (GlyT1) (Sirohi and Kuhn, 2017). 
 
Thus, regulation of glutamatergic transmission is a complex process, 
dependent on fine-tuning of extracellular glutamate levels-reuptake and 





individual neurons. Neurons have evolved to finely regulate their excitability 
and maintain appropriate output, although a dramatic or prolonged 





















Figure 13. Glutamate neurotransmission, homeostasis, and excitotoxicity in the brain. A 
glutamate-driven chemical synapse along with a neighboring astrocyte and an activated 
microglia is shown. Different pathological insults, many of them occurring in ALS, lead to the 
unprovoked and sustained presence of glutamate in the synaptic cleft and chronic activation of 
NMDAR, resulting in neuronal damage. Abbreviations: (NMDAR) N-methyl-d-aspartate 
receptor; (AMPAR) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; (EAAT) 
excitatory amino acid transporter; (vGLUT) vesicular glutamate transporter; (Xc−) cystine-
glutamate antiporter; (GlyT1) glycine transporter; (TCA) tricarboxylic acid (cycle); (ROS) reactive 
oxygen species; (OONO−) peroxynitrite; (TNF-α) tumor necrosis factor alpha; (IL-1β) interleukin-






In neurodegenerative conditions, such as those associated with ALS and other 
neurodegenerative disorders, glutamate homeostasis may be disturbed by a 
variety of mechanisms such as (i) oxidative stress, mitochondrial dysfunction, 
or energy deficiency (via loss of ATP-dependent Na+/K+ pumps), which may 
cause chronic or excessive release of glutamate from presynaptic neurons; (ii) 
release of large amounts of glutamate from activated microglia mediated by 
Xc antiporters; and (iii) reduction of glutamate clearance from synaptic clefts 
due to compromised activity of EAATs on astrocytes, either due to the 
presence of ROS and inflammatory cytokines produced by activated microglia 
or to damage in the astrocytes themselves (Sirohi and Kuhn, 2017). 
 
The excess of glutamate overactivates glutamatergic receptors, including 
NMDA receptors, leading to Ca2+ overload in cells, and in consecuence, causing 
excitotoxicity which rapidly leads to cell death or prolonged pathologic 
changes via calcium-dependent effectors. These efectors include  endoplasmic 
reticulum (ER) stress and mitochondrial overload (Van Damme et al., 2005), 
high level generation of ROS and RNS, and loss of mitochondrial membrane 
potential which in turn increase cell vulnerability (Le Masson et al., 2014).  
 
2.8.3.1. Excitotoxicity in ALS 
 
Motor neuron injury caused by EAA may explain how motor neurons can be 
selectively damaged by a disturbance of the glutamate neurotransmitter 
system, in spite of the fact that EAA receptors are widely distributed 
throughout the central nervous system. Three cell-specific molecular features 
of human motor neurons may render this cell group particularly susceptible to 
calcium-mediated toxic events following glutamate receptor activation (Shaw 
and Ince, 1997). The first feature is the low expression of mGluR2 and the 





permeable AMPA receptors (Tomiyama et al., 2001). mGluR2 may help to 
mediate the survival of neurons, as activation of mGluR2 increases the 
phosphorylation of tau and reduces oxidative stress-mediated cytotoxicity in 
neuronal cells (Lee et al., 2009). The second feature is the fact that human 
motor neurons that are vulnerable in ALS do not express the calcium-binding 
proteins parvalbumin and calbindin D28K (Ince et al., 1993). These proteins 
buffer intracellular calcium and protect neurons from calcium-mediated injury 
following activation of glutamate receptors. A direct relationship exists 
between cellular calcium buffering capacity and resistance to glutamate 
neurotoxicity (Mattson et al., 1989). Finally, the third fact is linked to selective 
reduced expression of the astrocytic glutamate transporter EAAT2, which 
mediates prompt clearance of glutamate from the synaptic cleft after firing 
(Maragakis et al., 2004). Both sALS and fALS patients, and mutant SOD1 mice, 
have decreased levels of functional EAAT2 protein (also known as GLT1), and 
increased circulating glutamate in the CSF (Rothstein et al., 1995; Fray et al., 
1998; Sasaki et al., 2000; Howland et al., 2002). Work in transgenic mice 
confirms the importance of EAAT2/GLT1-mediated glutamate clearance to 
motor neuron health. Deletion of this gene is sufficient to induce progressive 
neurodegeneration (Rothstein et al., 1996), and genetically encoded (Guo et 
al., 2003) or exogenously stimulated EAAT2/GLT1 overexpression (Rothstein 
et al., 2005) delays the onset of clinical symptoms in ALS mouse models. The 
mechanisms by which EAAT2/GLT1 is downregulated in ALS are not yet 
understood, and it is not clear whether decreased mRNA synthesis/stability is 
a factor. 
 
These three molecular features may, in combination, render human motor 
neurons particularly susceptible to calcium toxicity following AMPA receptor 
activation (Shaw and Ince, 1997). The most important argument for the role 





properties against disease progression, has anti-excitotoxic properties and 
inceases survival by a few months (Bensimon et al., 1994; Lacomblez et al., 
1996). However, the properties of riluzole are not limited to anti-excitotoxic 
activity.  
 
2.8.4. Axonal transport 
 
Intracellular trafficking of cargoes is an essential process in maintaining the 
structure and function of all mammalian cell types, but especially of neurons 
because of their extreme axon/dendrite polarization (De Vos and Hafezparast, 
2017). Motor neurons are highly specialized cells with extensive dendritic 
arbors and axonal processes that can extend up to 1 m from the cell body 
(Ström et al., 2008). The ability of motor neurons to maintain this specialized 
morphology depends on the cytoskeletal structure and the continous 
transport of proteins and organelles for long distances to and from the cell 
body.  
 
Microtubules (MTs), intermediate filaments (IF) and microfilaments, as 
components of the cytoskeleton, contribute to the morphology and function 
of neurons, but it is almost entirely on microtubules that axonal transport 
depends (Maday et al., 2014; Clark et al., 2016). Microtubules are polarized 
tubulin polymers with fast growing plus ends and more stable minus ends, 
organized in a generally radial array in the soma with plus ends directed 
toward the cell surface. In the axon, parallel microtubules form a unipolar 
array with plus-ends oriented outward (Burton and Paige, 1981; Stepanova et 
al., 2003), while in dendrites microtubule organization is more complex, with 






Neurofilaments (NF), a type of intermediate filament abundantly found in 
neuronal cytoplasm, also act as structural components assembled into an 
intracellular scaffold, which provides mechanical stability to axons. Moreover, 
neurofilaments determine axonal caliber, which in turn is essential for the 
rapid speed of neuronal signal propagation (Lobsiger and Cleveland, 2009). In 
a pathological context, NF are also important because their accumulation is 
one of the pathological hallmarks of various MNDs including ALS (Ikenaka et 
al., 2012). Neurofilaments consist of light (NF-L), medium (NF-M), and heavy 
(NF-H) subunits, in equal proportion, and their assembly mainteins vulnerable 
large-caliber motor axons (Kawamura et al., 1981; Julien, 1997).  
 
Thus, using cytoskeletal rails, axonal transport is able to mediate the 
movement of cargoes, such as proteins, mRNA, lipids, membrane-bound 
vesicles and organelles mostly synthesised in the cell body (De Vos and 
Hafezparast, 2017). In the axon and dendrites, transport occurs 
bidirectionally, depending on the polarity of the rails being transported from 
the cell body to the periphery, in a process known as anterograde transport, 
and from the periphery to the cell body, in a molecular system called 
retrograde transport. The major components of axonal transport are a group 
of specialized motor proteins that govern cargo transport along the 
cytoskeletal networks of microtubules and actin filaments. These are kinesin, 
dyenin and myosin proteins (Hirokawa, 1998; Cheney and Baker, 1999).  
 
The human kinesin superfamily contains 45 members (Hirokawa et al., 2009), 
subdivided into 15 subfamilies, which are termed kinesin 1 to kinesin 14B 
according to the results of phylogenetic analyses (Lawrence et al., 2004; 
Hirokawa et al., 2009). Kinesin acts as a tetramer of two heavy chains (KHC) 
and two light chains (KLC) mainly composed of motor and coiled-coil/cargo 





Kinesin components comprise three major groups depending on the position 
of the motor domain within the molecule: N-terminal motor domain KIFs (N-
KIFs), middle motor domain KIFs (M-KIFs) and C-terminal motor domain KIFs 
















Figure 14. Kinesin protein. (A) Kinesin tetrameric structure. (B) The domain structure of the 
major kinesins. In general, kinesins comprise a kinesin motor domain and a coiled-coil domain. 
There are also gene specific domains, such as the pleckstrin homology (PH) domain of KIF1A 
and KIF1Bβ, the CAP-Gly domain of KIF13B and the WD40 repeats of KIF21A. N-kinesins drive 
microtubule plus end-directed transport, while C-kinesins drive minus end-directed transport 
and M-kinesins depolymerize microtubules. Only the kinesin 13 family contains M-kinesins and 
only the kinesin 14A and 14B families contain C-kinesins. All other families consist of N-kinesins. 
Abbreviattions: (aa) amino acids; (PX) phox homology. Adapted from Cooper and Hausman, 
2006 and Hirokawa et al., 2009. 
 
Kinesin is the major motor for anterograde transport supplying distal axons 
with newly synthesized proteins and lipids, like synaptic proteins and neurite 
elongation components (Hirokawa et al., 1991); kinesin also participates in the 





lysosomes, membrane organelles, and granular-like particles  (Hirokawa et al., 
2009; Maday et al., 2014).  
 
Dyneins are a superfamily of cytoskeletal mechanoenzymes that move along 
microtubules in cells, converting the chemical energy stored in ATP to 
mechanical work, allowing the transport of various cellular cargos. Dyenins 
comprise two major groups: (i) axonemal dyneins and (ii) cytoplasmic dyneins 
(Karki and Holzbaur, 1999). Axonemal dyneins regulate microtubule sliding in 
the axonemes of cilia and flagella, whereas cytoplasmic dynein facilitates 
movement of organelles and other cargo necessary for cellular function. Each 
molecule of the dynein motor is a complex protein assembly composed of 
many smaller polypeptide subunits. Dynein consists of a huge protein complex 
containing multiple polypeptide subunits: two heavy chains (∼520 kDa) with 
ATPase activity and generating movement along the microtubules, two 
intermediate chains (∼74 kDa), four intermediate light chains (∼33–59 kDa) 
and several light chains (∼10–14 kDa) (Figure 15A) (Pfister et al., 2005).  
 
Cytoplasmic and axonemal dynein contain some of the same components, but 
they also contain some unique subunits. Axonemal dyneins might include as 
subunits the axonemal dynein heavy chain subunits (DNAH1, DNAH2, DNAH3, 
DNAH5, DNAH6, DNAH7, DNAH8, DNAH9, DNAH10, DNAH11, DNAH12, 
DNAH13, DNAH14, DNAH17), the axonemal dynein intermediate chain 
subunits (DNAI1, DNAI2), the axonemal dynein light intermediate chain 
subunits (DNALI1) and the axonemal dynein light chain subunits (DNAL1, 
DNAL4), whereas cytoplasmatic dyneins may include as subunits the 
cytoplasmic dynein heavy chain subunits (DYNC1H1, DYNC2H1), the 
cytoplasmic dynein intermediate chain subunits (DYNC1I1, DYNC1I2), the 





DYNC2LI1) and the cytoplasmic dynein light chain subunits (DYNLL1, DYNLL2, 













Figure 15. Dynein protein. (A) Dynein complex tetrameric structure. (B) Representation of 
dynactin complex tetrameric structure. The dynactin filament is shown by Arp1 (red) and β-
actin (light purple). It is capped by Arp11 (yellow) and p62 (orange) and p25/p27 (brown) on the 
pointed end and by CapZ α–β (green) on the barbed end. p150 is found both in the shoulder 
complex (blue) and in the extended coiled coil (CC) (gray), at the end of which is its microtubule-
binding CAP-Gly domain (blue). (C) Cartoon of the functional complex between dynein and 
dynactin complexes moving a cargo toward microtubule minus end. The dynein motor domains 
(blue) point toward the minus end of the microtubule, whereas the rest of the dynein motor 
and dynactin (red) extends toward the microtubule plus end. BICD2 (yellow) stabilizes the 
interaction between dynein and dynactin and also provides a link to cargo. Adapted from 
Cooper and Hausman, 2006 and Reck-Peterson, 2015. 
 
Cytoplasmic dynein moves toward the minus ends of microtubules. Therefore, 
it conveys cargo retrogradely in the axon and distal dendrites, while in the 
proximal dendrites it conveys cargo to both the periphery and the cell center 
because of the mixed polarity of the microtubules (Hirokawa et al., 1990; 
Kamiya, 2002). Retrograde transport is required to maintain homeostasis by 
removing aging proteins and organelles from the distal axon for degradation 





also important to provide forces and displacements in mitosis, and drive the 
beat of eukaryotic cilia and flagella (Roberts et al., 2013). 
 
Dynein often works in association with dynactin (Schroer, 2004), a 23-subunit 
protein complex that acts as a co-factor of the microtubule motor cytoplasmic 
dynein-1. Dynactin consists of three major structural domains: (1) sidearm-
shoulder: DCTN1/p150Glued, DCTN2/p50/dynamitin, DCTN3/p24/p22; (2) the 
Arp1 filament: ACTR1A/Arp1/centractin, actin, CapZ; and (3) the pointed end 
complex: Actr10/Arp11, DCTN4/p62, DCTN5/p25, and DCTN6/p27 (Figure 15B 
and C) (Schroer, 2004). Dynactin can be considered as a ‘dynein receptor’ that 
modulates binding of dynein to cell organelles that are to be transported along 
microtubules (Vaughan and Vallee, 1995). 
 
Myosin superfamily motor proteins use the energy of ATP hydrolysis to 
generate force and movement along actin filaments for short-range, 
dispersive distribution of vesicles, and/or organelles to the cell periphery. 
They are classified into 18 classes (Foth et al., 2006). Concretely, myosin motor 
proteins play significant roles in cell movement, muscle contraction, 
cytokinesis, membrane trafficking and signal transduction. Most myosins form 
a dimer and consist of a motor domain, a neck region, and a tail region 
(Hirokawa et al., 2010). Actin filaments also have a polarity; the barbed end 
(the growing end) points to the plasma membrane in the presynaptic and 
postsynaptic regions (Hirokawa et al., 2010). 
 
2.8.4.1. Axonal transport impairment in ALS 
 
Because of the decreased motility of motor proteins or their decreased 
binding to motor proteins, various cargos of motor proteins are accumulated 





dynein-mediated axonal transport occurs in ALS patients and in transgenic 
animal models (Breuer et al., 1987; Breuer and Atkinson, 1988; Collard et al., 
1995; Sasaki and Iwata, 1996; Williamson and Cleveland, 1999; Ligon et al., 
2005). Among related genes with dysregulated expressions, dynactin-1 is also 
markedly and widely downregulated in sALS motor neurons (Jiang et al., 
2005). Furthermore, dynactin-1 downregulation precedes the accumulation 
of phosphorylated-neurofilament (Jiang et al., 2007). This change in sALS 
seems to be specific to motor neurons, as dynactin-1 expression is preserved 
in neurons in the dorsal nucleus of Clarke and the intermediolateral nucleus in 
the spinal cord, Purkinje cells of the cerebellum, and cortical neurons in the 
occipital cortex (Ikenaka et al., 2012).  
 
Additionally, mutations in the retrograde motor complex dynein and in the 
dynein interacting complex dynactin cause motor neuron degeneration in 
humans and mice (Hafezparast et al., 2003; Puls et al., 2005). For example, the 
potential involvement of cytoplasmic dynein in ALS is further highlighted by 
the identification of a number of alterations in the motor-binding domain of 
dynactin subunit p150Glued (DTCN1) in ALS patients (Münch et al., 2004). Other 
mutations associated with fALS and axonal transport are found in genes 
coding for charged multivesicular body protein 2B (CHMP2B) and 
synaptobrevin-associated membrane protein B (VAPB) (Nishimura et al., 2004; 
Parkinson et al., 2006). 
 
Accumulation of neurofilaments is a long-recognized hallmark of ALS 
pathology in humans and mouse models and contributes to the selective 
vulnerability of long, large-caliber motor axons (Carpenter, 1968; Gurney et 
al., 1994; Bruijn et al., 2004). Concretely, SOD1 mutants have impaired slow 
axonal transport with axonal accumulations of neurofilaments and tubulin 





accumulations, consistent with a failure in axonal transport, are observed in 
patients with ALS (Muñoz et al., 1988). Thus, misassembly of neurofilaments 
due to altered expression, mutation or deficient transport of individual 
subunits results in their accumulation, further hindrance of axonal transport, 
and eventual motor neuron death (Beaulieu et al., 1999; Millecamps et al., 
2006).  
 
Defects in kinesin and the dynein/dynactin axonal transport also result in 
abnormal accumulation of mitochondria and autophagosomes, among others 
(Hirokawa et al., 2010). Mitochondria accumulate in the axons of spinal motor 
neurons in mouse mutant SOD1 models (Collard et al., 1995; Magrané and 
Manfredi, 2009), and in sALS patients (Sasaki and Iwata, 1996), suggesting an 
impairment of axonal transport in ALS. Indeed, defective axonal transport of 
mitochondria in sciatic nerves is observed during the presymptomatic stage in 
mutant SOD1 models (Bilsland et al., 2010). Something similar happens with 
the accumulations of autophagosomes in sALS human post-mortem tissue and 
animal models of ALS (Sasaki, 2011). 
 
2.8.5. Proteostasis clearance systems 
 
Protein homeostasis, also known as proteostasis, is the correct balance 
between production and degradation of proteins that is essential for the 
health and survival of cells. Proteostasis requires an intricate network of 
protein quality control pathways that works to prevent protein aggregation 
and maintain proteome health throughout the lifespan of the cell (Webster et 
al., 2017). 
 
Proteins are only slightly stable at physiological temperatures. This fact, 





means that proteins are constantly exposed to the high probability of 
unfolding and misfolding; in consequence, the process of cellular proteostasis 
is highly demanding (Schubert et al., 2000; Hipp et al., 2014). Proteins are 
constantly turned over to ensure a steady supply of functional proteins. Newly 
synthesized proteins fold into their specific three-dimensional shape co-
translationally as the nascent polypeptide chain emerges from the ribosome. 
The specific three-dimensional structure of a protein, which is in part 
determined by its amino acid sequence, is crucial to its function (Webster et 
al., 2017).  
 
Under normal conditions, cells have efficient protein quality control 
machinery that is able to detect and handle misfolded proteins. This is 
accomplished by a number of cytosolic and endoplasmatic reticulum resident 
folding factors that aid in this calibrated system, including effectors such as 
chaperones and co-chaperones of the heat shock protein (Hsp) family, 
peptidyl prolyl cis/trans isomerases, and oxidoreductases (Braakman and 
Bulleid, 2011), which recognize wrongly folded proteins, help in their 
refolding, prevent their aggregation and provide aid to repair damaged 
proteins. In the event that all attempts to repair and correctly refold the 
proteins fails, then these chaperones also actively mediate their removal to 
prevent protein aggregation and proteotoxic stress (Ruegsegger and Saxena, 
2016). 
 
Eukaryotic cells have two major pathways of protein degradation: (i) the 
proteasome and (ii) the lysosome. The proteasome is a multimeric ATP-
dependent protease complex that selectively recognizes ubiquitinated 
substrates, forming the ubiquitin-proteosome system (UPS). Degradation by 
the proteasome requires protein unfolding and relies on chaperones to 





Concretely, UPS employs polyubiquitin chains to label proteins for proteolysis 
and a vast array of ubiquitin-activating (E1), ubiquitin-conjugating (E2), and 
ubiquitin-ligase (E3) enzymes to assure protein turnover in a tightly regulated 














Figure 16. The scheme shows the main steps of the ubiquitin-proteasome pathway. 1) E1 
binds to ubiquitin by consumption of one ATP to AMP in order to activate it. 2) The ubiquitin-
carrier enzyme E2 takes over the ubiquitin from E1. 3) E2 transfers the ubiquitin to a protein 
substrate bound to the ubiquitin ligase, E3. 4) The ubiquitin chain is extended. Each step of the 
extension can be reversed by a deubiquitinating enzyme. 5) A ubiquitinated protein bound with 
either 1, 2, 3 or 4 ubiquitin molecules binds to the 26 S proteasome in order to be degraded. At 
degradation of the substrate the ubiquitin molecules are released by deubiquitinating enzymes. 
Adapted from Sino Biological web. 
 
Autophagy is a crucial lysosome-dependent protein degradation process, in 
which cytosolic materials such as long-lived proteins and aggregate-prone 
pathogenic proteins, as well as damaged organelles, are eliminated by 
enclosing them within a double membrane vesicle termed as an 
‘autophagosome’. The autophagosome ultimately fuses with lysosome to 
degrade the isolated materials (Mizushima and Komatsu, 2011). Autophagy is 





chaperone-mediated autophagy (CMA). Macroautophagy (here onwards 
termed autophagy) is associated with the bulk degradation of cytoplasmic 
components via the formation of autophagosomes, whereas microautophagy 
is a process that involves the direct uptake and degradation of cytoplasmic 
components by lysosomes, without the formation or involvement of transport 
vesicles (Glick et al., 2010). In the case of CMA, the presence of a consensus 
pentapeptide sequence, Lys-Phe-Glu-Arg-Gln, is required in the substrate 
protein to which the chaperone Hsp70 binds, followed by the recognition of 
the substrate-chaperone complex by LAMP2A. The entire complex is then 
unfolded, moved across lysosomal membranes and eventually degraded 
















Figure 17. The scheme shows the autophagy mechanism. (a, b) Cytosolic material is 
sequestered by an expanding membrane sac, the phagophore, (c) resulting in the formation of 
a double-membrane vesicle, an autophagosome; (d) the outer membrane of the 
autophagosome subsequently fuses with a lysosome, exposing the inner single membrane of 
the autophagosome to lysosomal hydrolases; (d) the cargo-containing membrane compartment 





Taking into account the important role played by autophagy and proteosome 
in the clearance of damaged or misfolded proteins, it is not surprising that 
disturbances in any of the mechanisms described above induce the cellular 
stress that is commonly observed in neurodegenerative disorders (Koga and 
Cuervo, 2011). Moreover, the ability of cells to maintain proteostasis declines 
with aging, thereby promoting the aberrant protein folding and aggregate 
deposition and facilitating the development and progression of various 
diseases, including neurodegenerative diseases (Takalo et al., 2013). 
Furthermore, neuronal cells appear to be particularly vulnerable to 
disturbances in proteostasis because they are long-lived post-mitotic cells that 
are not able to dilute out protein aggregates during cell divisions (Son et al., 
2012).  
 
2.8.5.1. Proteoasis disturbance in ALS 
 
A hallmark feature in affected tissues of ALS is the presence of pathological 
protein aggregates. This fact suggests defective proteostasis mechanisms as 
possible causative players in ALS pathology. The discovery of ALS genes linked 
to UPS and autophagy (C9ORF72, VCP, UBQLN2, OPTN, and TBK1) supports its 
dysfunction as part of the etiology of the disease, explaining alterations in 
protein quality control, trafficking and degradation, and maintaining protein 
homeostasis (Blokhuis et al., 2013; Peters et al., 2015).  
 
The insoluble protein aggregates observed in ALS and FTD are mainly 
composed of TDP-43 and, in a low percentatge of cases, FUS protein 
(Neumann et al., 2006; Vance et al., 2009). Upon stress by missfolding, mutant 
forms of both proteins are ubiquitinated and recruited into cytoplasmic stress 
granules, where they aggregate with stress granule components in an 





Chen et al., 2016). The accumulation of these ubiquitin-positive inclusion 
bodies in sALS and fALS cases, also observed in several disease models, has 
been linked to UPS dysfunction (Bendotti et al., 2012), due to the catalytic 
activity of the proteasome shown to be significantly reduced in sALS tissue 
(Kabashi et al., 2012). In addition, there are several pieces of evidence, 
accumulated over years, that mutant SOD1 models also present proteoasis 
disturbances. Aggregation of SOD1 has toxic effects on the two major protein 
degradation mechanisms. Mutant SOD1 also forms toxic oligomers (Urushitani 
et al., 2002), which further adopt a conformation to prevent ubiquitin-
mediated degradation and accumulate as aggregates to induce stress 
response in cells (Atkin et al., 2006; Niwa et al., 2007). 
 
Other ALS-associated proteins are involved in proteoastasis impairment, such 
as valosin-containing protein (VCP), which functions as an ATP-driven 
chaperon involved in the maturation of ubiquitin containing autophagosomes, 
playing an important role in the regulation of ER stress. VCP mutations lead to 
suboptimal functioning of these quality control mechanisms, thereby 
damaging proteostasis (Wojcik et al., 2006; Yamanaka et al., 2012). Another 
example is mutations in VAPB gene, coding for Vesicle-Associated Membrane 
Protein-Associated Protein B/C, causing ER stress and impairment of 
proteasome function (Moumen et al., 2011).  
 
Autophagy enhancement has been reported in ALS patients and mouse 
models (Morimoto et al., 2007; Li et al., 2008; Hetz et al., 2009; Sasaki, 2011) 
accompanied by alterations at different steps of this pathway either in 
transport of cargo in autophagosome formation or in lysosome-mediated 
degradation (Zhang et al., 2011). A direct role for TDP-43 has been identified 
in regulating transcription factor EB (TFEB) gene expression (Xia et al., 2006), 





lysosomal hydrolases, membrane proteins and other genes involved 
in autophagy (Sardiello et al., 2009). Under physiological conditions, both UPS 
and autophagy are actively involved in the clearance of TDP-43, which is 
dependent on the solubility of TDP-43. Soluble form of TDP-43 is preferentially 
degraded by the UPS, whereas the removal of oligomeric TDP-43 and TDP-43 
aggregates is achieved via autophagy. In fact, functional UPS and autophagy 
are able to clear macro-aggregates in vitro that mimic the pathological 
features of the aggregates in patients (Scotter et al., 2014). Yet loss of TDP-43 
leads to enhanced nuclear translocation of TFEB, thereby impairing the fusion 
of autophagosomes with lysosomes (Xia et al., 2006). 
 
Similarly, loss of optineurin function, which occurs in membrane and vesicle 
trafficking, results in protein aggregation that in turn leads to the appearance 
of severe motor axonopathy. Mutations in optineurin impair autophagy-
facilitated degradation of misfolded proteins, as well as inhibiting 
autophagosome formations, thereby contributing to proteostasis impairment 
and concomitant aggregate formation and accumulation (Shen et al., 2015). 
In the same manner, mutations in C9ORF72 gene result in defective regulation 
of endosomal trafficking and autophagy. Loss of C9orf72 function diminishes 
the transport of proteins from the plasma membrane to the Golgi, and 
changes the ratio of autophagosome marker light chain 3 (LC3-II):(LC3-1) (Farg 
et al., 2014). 
 
2.8.6. RNA processing 
 
Gene expression is tightly regulated by complex pathways by which RNA is 
generated, stored, transported, and translated (Lagier-Tourenne and 
Cleveland, 2009; Verma, 2011; Ling et al., 2013). Transcription is the first step 





template for complementary base-pairing, when an enzyme called RNA 
polymerase II catalyzes the formation of a pre-mRNA molecule, which is then 
processed to form mature mRNA (Clancy and Brown, 2008). After 
transcription, alternative splicing occurs in cellular machines called 
spliceosomes, which are a complex of small nuclear ribonucleoproteins 
(snRNPs) and additional proteins. Alternative splicing is a regulated process 
during gene expression that results in a single gene coding for multiple 
proteins. In this process, particular exons of a gene may be included within or 
excluded from the final processed messenger RNA produced from that gene 
(Black, 2003). The resulting mRNA is a single-stranded copy of the gene, which 
must then be translated into a protein molecule. Consequently, the proteins 
translated from alternatively spliced mRNAs will contain differences in their 
amino acid sequence and, often, in their biological functions. Specifically, 
neurons and glial cells in the brain take great advantage of these different 
strategies to diversify their repertoires. 
 
After the process of transcription in the cell's nucleus, mature mRNA 
molecules must leave the nucleus and travel to the cytoplasm, where the 
ribosomes are located. Translation machinery resides within a specialized 
organelle called the ribosome.  The ribosome molecules translate this code to 
a specific sequence of amino acids. The ribosome is a multi-subunit structure 
containing rRNA and proteins. It is the ‘factory’ where amino acids are 
assembled into proteins. 
 
2.8.6.1. Aberrant RNA processing in ALS 
 
RNA processing is essential for normal and properly regulated gene 
expression; therefore, defects at all or some levels of gene regulation can 





Bentmann et al., 2013; Anderson and Ivanov, 2014). Recent studies have 
shown that mutations in RNA-binding proteins (RBPs) are a key cause of 
several human neuronal-based diseases (Liu et al., 2017). RBPs are essentially 
required at all levels of RNA processing in both the nucleus and cytoplasm 
where transcription, splicing, RNA stabilization and RNA degradation occur. A 
notable example of RBP defects is found in familial and sporadic cases of ALS 
and FTD, the TDP-43 protein. The involvement of TDP-43 in RNA-related 
pathways is strong. Since its discovery, TDP-43 has been described as an RNA-
processing protein with roles in multiple steps of RNA regulation including 
RNA transcription, splicing, transport, translation and microRNA production 
(Lagier-Tourenne et al., 2010). 
 
TDP-43 participates in RNA transcription in human brain (Thorpe et al., 2008; 
Lagier-Tourenne et al., 2010) and in several cell culture systems (Ayala et al., 
2008); this is conducted by direct interaction with RNA through two RNA 
recognition motif (RRM) protein domains, used to mediate their binding to 
euchromatin in nuclear DNA. TDP-43 directly interacts with the 
heterogeneous nuclear ribonucleoprotein complex, which regulates RNA 
splicing and transport (D’Ambrogio et al., 2009). TDP-43 is associated with 
other splicing factors in the spliceosome, and its depletion or overexpression 
affects the splicing pattern of specific targets (De Conti et al., 2015). 
 
Furthermore, TDP-43's major interactor protein, hnRNP A2, is a crucial 
component of splicing regulation. TDP-43 is known to affect the splicing of 
apolipoprotein A-II (APOA2) and survival motor neuron (SMN) transcripts. 
SMN mutation is the underlying cause of human spinal muscular atrophies, 
another form of MND (Bose et al., 2008). Notably, TDP-43’s RNA targets also 
include genes linked to synaptic function, neurotransmitter release and the 





(MAPT) and ataxin 1 and 2 (ATXN1/2). However, the magnitude of its specific 
RNA targets in nerve cells remains poorly understood. Approximately,1/3 of 
all transcribed RNAs harbor TDP-43 binding sites, which is consistent with the 
critical functions of TDP-43 in regulating RNA splicing and transport (Luquin et 
al., 2009). However, the mechanism of protein-RNA interaction is not known 
(Polymenidou and Cleveland, 2011; Sephton et al., 2011).  
 
Heterokaryon assays have also demonstrated the function of TDP-43 as 
shuttle between the nucleus and the cytoplasm (Belly et al., 2005; Feiguin et 
al., 2009; Lagier-Tourenne et al., 2010). Indeed, TDP-43 is present in variable 
amounts in the cytoplasm, where it is involved in regulating mRNA’s fate in 
space and time, controlling its subcellular localization, translation and 
degradation. In the neuronal cytoplasm, TDP-43 is found in RNA-transporting 
granules that translocate to dendritic spines upon specific neuronal stimuli 
(Belly et al., 2005; Fujii et al., 2005). The loss of TDP-43 reduces branching as 
well as synaptic formation in Drosophila neurons, suggesting that TDP-43 also 
plays a role in the modulation of neuronal plasticity by altering mRNA 
transport and local protein translation in the neurons (Feiguin et al., 2009).  
 
2.8.6.2. Dysfunctional miRNA processing in ALS 
 
miRNAs are defined as 21-25 nucleotide single-stranded RNAs (ssRNAs), which 
are produced from hairpin shaped precursors (Ambros et al., 2003). A number 
of miRNAs are known for functions in diverse processes including cell 
proliferation, cell death, fat metabolism, neuronal patterning, hematopoietic 
differentiation and immunity (He and Hannon, 2004).  
 
miRNAs are synthesized from primary miRNAs (pri-miRNAs) in two stages by 





the cytoplasm (Kim et al., 2009). The pri-miRNA is processed within the 
nucleus to a precursor miRNA (pre-miRNA) by Drosha enzyme. Next, the 
transport of pre-miRNAs to the cytoplasm is mediated by exportin-5 (EXP-5). 
In the cytoplasm, pre-miRNA are further processed to become mature miRNAs 
by Dicer and, subsequently, loaded onto the Argonaute (Argo) protein to be 
incorporated into the effector RNA-induced silencing complex (RISC), which 
degrades or translationally silences mRNA (Verma, 2011).  
 
In the context of ALS, TDP-43 associates with DROSA (Hicks et al., 2000; Feiguin 
et al., 2009). Additionally, TDP-43 is involved in the cytoplasm cleavage step 
of miRNA biogenesis as evidenced by its association with proteins known to 































































3.1. FTLD definition 
 
Frontotemporal lobar degeneration (FTLD) is a pathological process 
underlying frontotemporal dementia (FTD); FTLD is the second most common 
cause of early-onset dementia after Alzheimer disease (Forman et al., 2006). 
FTLD is clinically and pathologically a heterogeneous syndrome, characterized 
by progressive decline in behaviour and/or language associated with 
degeneration of the frontal and anterior temporal lobes (Forman et al., 2006a; 
Rabinovici and Miller, 2010).  
 
3.2. Epidemiology of FTLD 
 
FTD prevalence ranges from four to fifteen per 100,000 inhabitants under the 
age of 65, as reported in European and US epidemiological studies (Rabinovici 
and Miller, 2010).  The age of onset can vary widely from the third to the ninth 
decade (Ratnavalli et al., 2002; Hodges et al., 2003; Johnson et al., 2005; 
Dickerson, 2016). Median survival in FTLD is 6-11 years from symptom onset, 
and 3-4 years from diagnosis, with a shorter survival and more rapid cognitive 
and functional decline than in Alzheimer’s disease (Hodges et al., 2003; 
Roberson et al., 2005). Sex distribution in FTLD appears to vary depending on 
the clinical syndrome, with most studies reporting a male preponderance in 





behavioural-variant, whereas others report male predominance in the 
semantic-variant and female predominance in the nonfluent variant 
(Ratnavalli et al., 2002; Hodges et al., 2003; Roberson et al., 2005). 
 
3.3. Clinical symptoms of FTLD 
 
FTD usually presents in the patient’s mid-life, preserving, at the beginning, 
memory, navigational skills and other aspects of general intellect. Three main 
clinical syndromes of FTD have been defined (Warren et al., 2013): 
 
(i) Behavioural-variant frontotemporal dementia (bvFTLD) manifests with 
progressive decline in interpersonal and executive skills with altered 
emotional reactions and a variety of abnormal behaviours such as apathy, 
disinhibition, obsessions, rituals and stereotypies. This clinical syndrome is 
closely associated with frontal-predominant cortical degeneration 
(Rascovsky et al., 2011).  
 
(ii) Semantic variant of primary progressive aphasia (svPPA) manifests 
with progressive breakdown of semantic memory that stores knowledge 
about objects and concepts. Typically, semantic dementia initially affects 
highly elaborate knowledge of vocabulary as well as the meaning of words. 
This syndrome is associated with bilateral anterior temporal degeneration 
(Hodges and Patterson, 2007). 
 
(iii) Nonfluent variant of primary progressive aphasia (nfvPPA) manifests 
with progressive breakdown in language output with effortful non-fluent 
speech (Rohrer et al., 2010). In some patients, speech sound (phonemic) or 
articulatory (phonetic, speech apraxic) errors are the dominant feature, 





with terse telegraphic phrases. This syndrome is associated with left 
perisylvian cortical atrophy (Rabinovici and Miller, 2010). 
 
Additionally, disturbances of motor function are common, including clinical 
symptoms and signs of three disorders that are part of the FTD spectrum:  
corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and 
amyotrophic lateral sclerosis (ALS) (Bott et al., 2014). Therefore, ALS may be 
associated with cognitive impairment characteristics of FTLD, thus suggesting 
that ALS and FTLD might be different manifestations of a single disorder.  
 
FTD decline differs from one person to another. Persons suffering from FTD 
show muscle weakness and coordination problems, leaving them in need of a 
wheelchair or remaining bedbound. Muscular alterations may cause problems 
of swallowing, chewing, moving and controlling bladder and/or bowels. 
Causes of death include urinary tract and/or lung infections (Bott et al., 2014).  
 
3.4. Diagnosis and treatment of FTLD 
 
FTD diagnosis is based on clinical examination, followed by complementary 
analysis including magnetic resonance imaging (MRI) and positron emission 
tomography (PET) (Kipps et al., 2009). Nowadays, there is no treatment for 
any of the frontotemporal subtypes. Selective serotonin re-uptake inhibitors 
can be used to control disinhibition and compulsive behavior (Swartz et al., 
1997).  
 
3.5. Neuropathology of FTLD 
 
Neuropathological changes in brains affected by FTD are atrophy in the frontal 





spongiosis in the upper cortical layers, and astrocytic gliosis; the white matter 
shows variable reduction and myelin pallor. 
 
FTLD was initially classified into two different types: (a) FTLD-MAPT, linked to 
the presence of tau-positive inclusions, and (b) FTLD-U, linked to tau-negative, 
ubiquitin-positive inclusions. However, this classification has been refined, 
establishing three main different types of FTLD: (1) FTLD-MAPT, (2) FTLD-TDP 
and (3) FTLD-FUS. Before the discovery of TDP-43 agreggates in 2006, most 
tau-negative FTLD cases were collectively termed FTLD-U. After the discovery, 
the majority of cases became FTLD-TDP43 because TDP43 was the main 
protein accumulated in ubiquitin-positive inclusions.  
 
In 2009, mutations in FUS were identified as causative in some familial ALS 
cases; further studies demonstrated that most tau-negative and TDP-43-
negative inclusions were FUS positive, thereby establishing the third group, 
FTLD-FUS (Hasegawa, 2017). Notably, the neuropathology underlying FTLD is 
a tauopathy (tau-positive) in approximately 45% of patients, while in about 
50% of patients the underlying pathology is FTLD-TDP (ubiquitin-positive but 
tau- and α-synuclein-negative); a minority of cases are FUS-positive or positive 
for other proteins (Geser et al., 2009). Thus, the most common form of tau-
negative FTLD is associated with neuronal inclusions composed of TDP-43 
(FTLD-TDP-43) (Josephs et al., 2009).  
 
3.5.1. Histopathology of FTLD-TDP 
 
TDP-43 is the most specific and sensitive marker to detect the characteristic 
protein aggregates of FTLD-TDP, forming neuronal cytoplasmic inclusions 
(NCIs), dystrophic neurites (DNs) and neuronal intranuclear inclusions (NIIs) 
































Figure 18. Typical examples of TDP43-immunoreactivity with pTDP43 and iTDP43 in FTLD. In 
sections immunostained with anti-phosphorylated TDP43 antibodies (pTDP43), nuclear staining 
is not observed in normal neurons (A). Typical examples of pTDP43-immunoreactive pre-
inclusions (C), NCI I, NII (G) and long DN (I, the inset shows a short DN) are seen in FTLD-TDP43 
cases. In sections stained with anti-non-phosphorylated TDP43 antibodies, normal neurons 
demonstrate TDP43 nuclear staining (B). Loss of nuclear staining is accompanied by NCIs and 
NIIs in FTLD-TDP43 cases (D, F, H). TDP43-immunoreactive long DN (J, inset shows a short DN). 
Scale in H (equivalent for A-G), scale in J (equivalent for I). Adapted from Tan et al., 2013. 
 
FTLD-TDP is categorized into four subtypes depending on the morphology of 
TDP-43 inclusions, laminar distribution, and relative proportion of dystrophic 
neurites versus neuronal cytoplasmic inclusions (Figure 19) (Mackenzie et al., 






- Type A shows abundant short dystrophic neurites (DN) and compact oval 
or crescent-shaped neuronal cytoplasmic inclusions (NCI), predominantly 
in layer II/III of the neocortex. Moderate numbers of granular NCI are 
present in the dentate granule cells of the hippocampus. TDP-43-
immunoreactive glial cytoplasmic inclusions (GCI) are present in the 
cerebral white matter, and in affected subcortical regions including the 
striatum, thalamus and substantia nigra. Cases with this pathology usually 
present with either bvFTD or nfvPPA. 
 
- Type B shows moderate numbers of compact or granular neuronal 
cytoplasmic inclusions (NCI) in both superficial and deep cortical layers 
with few or no pre-inclusions and delicate wispy neurites which are often 
more abundant in the superficial cortical laminae. Characteristic, and 
almost exclusive to type B, is the presence of neuronal cytoplasmic 
inclusions (NCI) in lower motor neurons (LMN), even in the absence of 
clinical features of ALS. Glial cytoplasmic inclusions (GCI) in 
oligodendrocytes of the cerebral white matter, medulla and spinal cord are 
common.  
 
- Type C includes abundance of tortuously long neurites, predominantly in 
the superficial cortical laminae, with few or no neuronal cytoplasmic 
inclusions (NCI). Neuronal intranuclear inclusions (NII) and glial cytoplasmic 
inclusions (GCI) are uncommon. Variable numbers of neuronal cytoplasmic 
inclusions (NCI) are present in the hippocampus, usually with a compact 
round morphology. This is the most common pathology found in cases 






- Type D shows abundance of lentiform neuronal intranuclear inclusions 
(NII) and few short dystrophic neurites (DN) in the neocortex, not restricted 
to any cortical layer, with only rare neuronal cytoplasmic inclusions (NCI). 
 
Recently, the sequential distribution of TDP-43 pathology has been proposed 


















Figure 19. llustration of the harmonized classification system used for FTLD-TDP 
subtyping.  Cases with moderate-to-numerous TDP43-immunoreactive NCI and short DN 
predominantly in the cortical layers II/III are assigned to type A. Cases with moderate to 
numerous TDP43-immunoreactive NCIs and sparse DNs across all cortical layers are assigned to 
type B. Cases with long dystrophic neurites in the upper layers, and NCIs, are assigned to type C. 
Cases with numerous lentiform NII are assigned to type D. From Tan et al., 2013. 
 
3.5.1.1. Genetics of frontotemporal lobar degeneration TDP-43 
 
FTD is genetically complex and can present as sporadic or familial, often with 
autosomal dominant inheritance (Chow et al., 1999). Conventional linkage 
studies have identified different chromosomal loci and a number of mutated 
genes including those coding for TAR DNA-binding protein (TARDBP), 
progranulin (PGRN), valosin containing protein (VCP), and charged 





chromosome 9p (C9ORF72), among other minoritary mutations in other 
genes. 
 
3.5.1.1.1. TARDBP mutations 
TDP-43 gene mutations are rare in FTLD, despite this protein’s being present 
in the pathological inclusions of most cases (FTLD-U) (Neumann et al., 2006).  
Mutations in TARBP are more common in fALS. 
 
3.5.1.1.2. PGRN mutations 
Mutations in PGRN account for ~5–10% of all FTLD cases (Baker et al., 2006; 
Cruts et al., 2006). PGRN, located on chromosome 17q21, is composed of a 
noncoding region and 12 coding exons. PGRN encodes a 593 amino acid 
precursor protein having a signal peptide followed by 7.5 tandem repeats of 
12 cysteinyl granulin motifs (He and Bateman, 2003). The 
secreted progranulin is subjected to proteolysis by extracellular proteases like 
elastase that cleave progranulin to generate granulin, a process regulated by 
secretory leukocyte protease inhibitor (SLPI) (Zhu et al., 2002; He and 
Bateman, 2003). PGRN protein is a widely expressed, multifunctional, high 
molecular weight secreted growth factor, which plays significant roles in 
development, tumorigenesis, wound repair and inflammation by activating 
signaling pathways that control cell cycle progression and cell motility (Ahmed 
et al., 2007). In the periphery, progranulin and granulin regulate the 
inflammatory cascade through opposing effects, with progranulin being anti-
inflammatory while granulin is pro-inflammatory. The exact function 
of PGRN in CNS is unknown, although it may be involved in neurotrophic 
activity and neuroinflammation (He et al., 2003; Ahmed et al., 2007). 
 
To date, more than 60 different pathogenic mutations in 163 families have 





pathogenic PGRN mutations including heterozygous deletions create 
functional null alleles and retain or degrade the unspliced transcript within the 
nucleus, preventing the translation of PGRN, and thus ultimately resulting in 
the reduction of secreted PGRN. Nevertheless, the ubiquitinated neuronal 
inclusions in the affected regions of brain do not show immunoreactivity 
to PGRN but to TDP-43-immunoreactivity in NCIs, NIIs and DNs (Baker et al., 
2006; Cruts et al., 2006; Mackenzie et al., 2006b). 
 
3.5.1.1.3. VCP mutations 
FTD associated with inclusion body myopathy and Paget’s disease of bone 
(IBMPFD) is a rare multi-system disorder linked to chromosome 9p21-12. The 
gene responsible for this is VCP; the coding protein acts as a molecular 
chaperone associated with several cellular functions including ubiquitin-
dependent protein degradation, cell cycle regulation and apoptosis (Watts et 
al., 2004). Most of the VCP mutations are located within or near the ubiquitin-
binding domain (Watts et al., 2004). VCP mutations produce numerous 
lentiform NIIs and DNs (Forman et al., 2006b). Similar to other FTLD-U 
subtypes, TDP-43 is the major protein constituent of these inclusions 
(Neumann et al., 2006). 
 
3.5.1.1.4. CHMP2B mutations 
Genome-wide linkage analysis in different families with dementia has revealed 
rare complex mutations in the CHMP2B gene on chromosome 3p11 (Skibinski 
et al., 2005). The protein encoded by this gene is a component of the 
endosomal secretory complex required for transport (ESCRT) type III (Skibinski 
et al., 2005; Momeni et al., 2006). The disease segregating mutation results in 
aberrant splicing of exon 6, producing a truncated protein (Skibinski et al., 
2005). Dysfunction of the ESCRT results in the inability of multi-vesicular 





endosomes and reduced protein turnover (Babst et al., 2002). Carriers of 
CHMP2B mutations show ubiquitinated inclusions negative for TDP-43 (Holm 
et al., 2007). Besides FTD, CHMP2B mutations can also cause additional 
phenotypes including ALS and FTD-ALS (Parkinson et al., 2006). 
 
The identification of a common genetic locus for FTD and ALS (shown above) 
reinforces the molecular link between FTD and ALS. Thus, the genetic overlap 
between these two clinical entities suggests that diagnostic genetic screening 
in FTD-ALS should include both FTD-related and ALS-related genes including, 
PGRN, VCP, CHMP2B and TARDBP gene, among other minor prevalent genes 
(Aswathy et al., 2010). Among these, the strongest link between the two 
disorders is mutations located in C9ORF72 gene, causing ALS, FTLD and 
concomitant forms.  
 
3.5.1.1.5. C9ORF72 mutations 
Phenotypical overlap exists between FTD and amyotrophic lateral sclerosis, 
with as many as 30% of FTD patients developing clinical symptoms of motor 
neuron dysfunction (Lomen-Hoerth et al., 2002), and 50% of ALS cases 
displaying at least some evidence of frontal-executive cognitive deficits 
(Phukan et al., 2007). The link between ALS and FTD is supported by the 
identification of a non-coding “GGGGCC” (G4C2) hexanucleotide repeat 
expansion in the first intron or promoter region of the C9ORF72 gene on 
chromosome 9p21 in fALS and fFTD. Mutations in C9ORF72 are the most 
common genetic abnormality in familial and sporadic FTLD/ALS, being found 
in at least 8% of sALS and sFTLD cases and more than 40% of fALS and fFTLD 
cases (Dejesus-Hernandez et al., 2011; Renton et al., 2011).  
 
In a normal population, wild-type alleles are, on average, three of these 





persons with the repeat expansion mutation, expansion sizes vary 
considerably between individual cases, with tens, hundreds or even thousands 
of these repeat units being present (Dejesus-Hernandez et al., 2011; Renton 
et al., 2011). Nevertheless, the lower threshold required to initiate 
pathogenesis is poorly defined. An individual with intermediate repeat length 
(30 units) exhibits some C9orf72-associated pathological phenotypes in the 
absence of clinical manifestations (Gami et al., 2015), suggesting that 30 
repeats may lie on the border between mild abnormalities and full-blown 
disease. Expansions of less than 30 repeats are not typically associated with 
disease, but a minority of ALS cases with 20-22 repeats have been described 
(Byrne et al., 2014). The inheritance of the C9ORF72 mutation is autosomal 
dominant, although reduced penetrance occurs in some cases (Bigio, 
2012; Van Blitterswijk et al., 2012). Repeat expansion is unstable, increasing 
in repeat number over generations (Vance et al., 2006). 
 
C9orf72 repeat expansions also manifest pathologically as proteinaceous 
inclusions of the RNA/DNA-binding protein TDP-43, as in other forms of the 
clinicpathological spectrum. Thus, C9orf72 repeat expansion as a common 
genetic cause of ALS of FTD further highlights the extensive clinical, genetic 
and pathological overlap between these two conditions, suggesting that the 
two diseases represent opposite ends of a continuous clinical spectrum, with 
C9orf72 mutations at the heart of this spectrum, increasing the risk of 
developing FTD and/or ALS (Barker et al., 2017). In addition to TDP-43-positive 
inclusions, patients with C9orf72 mutations show TDP-43-negative and p62-
positive inclusions mainly in the cerebellum. C9orf72-immunoreactive 








- C9orf72 function 
 
C9orf72 protein is found in many regions of the brain, in the cytoplasm of 
neurons as well as in presynaptic terminals. Differential use of transcription 
alternative start and termination sites generates three RNA transcripts from 
C9orf72 DNA. These encode two protein isoforms consisting of a long isoform 
(isoform A) of approximately 54 kDa derived from variants 2 and 3, and a short 
isoform (isoform B) of approximately 24 kDa derived from variant 1 (Figure 20) 














Figure 20. C9orf72 RNA transcript variants. Schematic representation of the C9orf72 gene and 
RNA transcript variants. Exons are depicted as blue boxes and the location of the GGGGCC 
repeat expansion is shown in purple. Differential selection of transcription start and termination 
sites generates three different RNA transcripts. Variant 1 encodes a short protein isoform 
(isoform B) whereas variants 2 and 3 encode a longer protein isoform (isoform A). Presence of 
the repeat expansion favors transcription from exon 1a, increasing the proportion of transcripts 
containing the repeat expansion. Adapted from Barker et al., 2017. 
 
The normal function of the C9orf72 protein remains obscure, but the major 





neoplastic cells) domain. DENN-domain containing proteins function as 
guanine nucleotide exchange factors (GEFs), regulating GTPase-mediated 
membrane trafficking pathways. In cells, C9orf72 co-localizes with Rab 
proteins 7 and 11 suggesting its involvement in the regulation of vesicular 
membrane traffic (Zhang et al., 2012; Levine et al., 2013). C9orf72 is also 
implicated in the formation of autophagosome (Webster et al., 2016) and in 
the removal of aggregated proteins via the autophagy receptor p62 (Sellier et 
al., 2016).  
 
Recent genetic and cell biological studies indicate that C9orf72 protein 
functions in lysosomes as part of a tri-molecular complex with Smith-Magenis 
chromosome region 8 (SMCR8) (Amick and Ferguson, 2017) and WD repeat-
containing protein 41 (WDR41) proteins (Sullivan et al., 2016), both regulators 
of autophagy. The important role for C9orf72 in lysosomes is supported by 
defects in the lysosome morphology and mTOR complex-1 (mTORC1) signaling 
arising from knocking out C9orf72 in diverse model systems. Moreover, 
C9orf72 knockdown in murine models produces an altered immune response 
(Atanasio et al., 2016) characterized by the accumulation of lysosomal vesicles 
within macrophages, implying a role for the C9orf72 protein in the regulation 
of late endosomal/lysosomal trafficking in macrophages and microglia 
(O’Rourke et al., 2016). Collectively, these findings define C9orf72-containing 
protein complex and lysosomal sites of action as central to C9orf72 function 
(Amick and Ferguson, 2017). 
 
- C9orf72 repeat toxicity 
 
There are currently three major hypotheses to explain how such repeat 
expansions could be pathogenic in fALS and fFTLD. The presence of a large 





expression leading to loss of C9orf72s still undefined normal cellular function. 
Several groups have shown that mRNA levels of at least one 
C9ORF72 transcript are decreased in fFTLD and fALS (Dejesus-Hernandez et 
al., 2011; Renton et al., 2011; Gijselinck et al., 2012), suggesting a potential 
loss of function.  
 
In addition, RNA-mediated toxicity contributes to disease pathophysiology. 
C9orf72 repeat RNA is bidirectionally transcribed, from both the sense (G4C2)n 
and the antisense (G2C4)n DNA strand (Zu et al., 2013), forming punctate 
nuclear aggregates termed RNA foci. Early reports indicate that transcribed 
repeats lead to accumulation of repeat-containing RNA foci in patient tissues 
(Dejesus-Hernandez et al., 2011). Multiple nuclear, and more rarely, 
cytoplasmic, sense and anti-sense RNA foci have been identified in patient-
derived cells throughout the CNS in expansion carriers (Gendron et al., 2013; 









Figure 21. (A) Dipeptide repeat proteins. The figure shows the dipeptide repeat proteins 
generated by GGGGCC repeat-associated non-ATG (RAN) translation. The sense strand 
generates poly-GA, poly-GP and poly-GR , and the antisense strand generates poly-GP, poly-PA 
and poly-PR. (B) c9FTD/ALS neuropathology. Sense and antisense RNA foci are a common 
feature in the brains of patients with c9FTLD and/or c9ALS. a,b) Representative images show 
neurons from the frontal cortex of a patient with C9FTD/ALS, containing multiple sense (red; 
part A) and antisense (green; part B) foci in nuclei (stained blue with DAPI). Scale bar: 2.5 μm. 
c) TAR DNA-binding protein 43 (TDP-43) pathology in a patient with C9FTD/ALS. Arrow indicates 





concomitant depletion of nuclear TDP-43. Scale bar: 50 μm. d) Dipeptide repeat protein (DPR) 
pathology in a patient with C9FTD/ALS. Inclusions consisting of sense and antisense DPRs. 
Arrows indicate neuronal cytoplasmic inclusions of poly-GA protein. Scale bar: 50 μm. Adapted 
from Barker et al., 2017. 
 
The RNA toxicity hypothesis postulates that sense and antisense G4C2 repeats 
accumulate in nuclear RNA foci where they sequester essential RBPs (hnRNP-
A1, hnRNP-A3, hnRNP-H, ADARB2, Pur-a, ASF/SF2, ALYREF and nucleolin), thus 
impairing their ability to regulate their RNA targets and culminating in a range 
of RNA misprocessing events. 
 
Additionally, sense and antisense C9ORF72 RNA repeats translate by an 
unconventional form of translation, repeat-associated non-AUG initiated 
translation (RAN translation). RAN translation of (G4C2) and (C4G2) results in 
the synthesis of five dipeptide repeat protein (DPR) species: poly-GA, poly-GP 
and poly-GR, from the sense transcript, and poly-GP, poly-PR and poly-PA, 
from the antisense transcript (Figure 21A). All five DPR species form 
ubiquitinated inclusions, which spread in different brain regions; these 
inclusions are more abundant in the cerebellum, hippocampus and neocortex, 
less frequent in subcortical regions, and rare in the brainstem and spinal cord 
(Figure 21B) (Ash et al., 2013; Gendron et al., 2013; Mann et al., 2013). They 
produce toxic effects in vitro and in vivo (Kwon et al., 2014; Mizielinska et al., 
2014; Wen et al., 2014). Analyses of DPR interactomes reveal preferential 
interactions between proteins involved in proteasomal degradation (May et 
al., 2014; Zhang et al., 2018), RBPs, and components of membrane-less 
organelles, such as RNA stress granules, nucleoli, spliceosomes and the 
nuclear pore complex (NPC) (Lee et al., 2016; Boeynaems et al., 2017). A 
significant number of these organelle-related proteins, such as FUS, hnRNP-
A1 and TIA1, possess low complexity sequence domains (LCDs) which mediate 
the assembly of membrane-less organelles. In order for membrane-less 





achieved by the concentration of the organelle components and the formation 
of a network of weak multi-valent interactions, a process known as liquid-
liquid phase separation (LLPS) (Hyman et al., 2014). DPRs are able to interact 
with the LCD of these proteins, thus disrupting LLPS and altering their 
biophysical properties (Lee et al., 2016). Therefore, DPRs may contribute to 
toxicity by upsetting the composition of membrane-less organelles. 
 
Both RNA foci and protein aggregates may produce gain of function toxicity in 
neurons, which, in addition to the C9ORF72 transcript reduction, may promote 
neurodegeneration. Reduced C9ORF72 expression in sALS and sFTLD with 
normal repeat ranges implies that reduced C9orf72 levels may be a common 
pathogenic factor in ALS or a consequence of the disease process (Ciura et al., 
2013). Several studies support the idea that we cannot conclusively prove that 
RNA foci or DPRs alone or in combination act as the main drivers of C9orf72 
toxicity (Mackenzie et al., 2013; Davidson et al., 2014 and 2016; Gami et al., 
2015; Gomez-Deza et al., 2015; Schuldi et al., 2015). Rather, a combination of 
the two, together with other factors, contributes to the pathogenesis.  
 
3.6. Animal models of FTLD-TDP 
 
Several models recapitulate the initial proteinopathy and other pathological 
features linked to the human disorder. A summary of different C9orf72 FTLD 
animal models is shown in Table VI (Picher-Martel et al., 2016). Some models 
develop neurodegenerative cascades, but it remains uncertain whether the 
entire sequence of pathophysiologic events that occur in the human disease 
is fully captured (Dawson et al., 2018).  
 
Studies in the nematode C. elegans have contributed to our understanding of 





programmed cell death, and to mechanisms underlying human diseases such 
as cancer and neurodegeneration. The genes linked to familial forms of FTLD 
including PGRN, VCP and TDP-43, have homologs in C. elegans (only CHMP2B 
and FUS do not) (Boxer et al., 2012). 
 
Homologues of several genes causing human autosmal FTD syndromes 
including valosin-containing protein (VCP) and TDP-43 occur in Drosophila. 
Drosophila models are particularly useful for dissecting the pathogenic 
mechanisms associated with particular mutations and identifying possible 
therapeutic targets, because they are relatively inexpensive to produce and 

















  Mice 80 TRE none normal N N 
  Ubiquitin-positive 








nd 24 nd nd Y 
  Nuclear RNA foci, 
pTDP43 inclusions, 
cytosolic and nuclear 




  100-1000 BAC none normal N N   RNA foci, DPR, no NCI N 
  500 BAC none normal N N   RNA foci, DPR, no NCI N 
  450 BAC 52 normal N Y 
  RNA foci, DPR, age-
dependent protein 
accumulation, no 
motor deficits or MN 
loss, age dependent 
cognitive deficit, no 
TDP43 mislocalitzation 
N 
  500 BAC 16 20-40 Y Y 
  NMJ loss, reduced 
axonal size, MN loss, 
RNA foci, DPR, TDP43 
NCI 
Y 
  Fruit flies 36-103 elav-GS nd 4 nd nd 
  RNA foci, DPR, toxicity 
linked to DPR 
nd 
  160 
actin5C-
Gal4 
none normal N nd 
  RNA foci, DPR, toxicity 






Table VI. Summary of C9ORF72 animal models. Abbreviations: Y: yes; N: no; nd: not described; 
n/a: not applicable, BAC: Bacterial artificial chromosome (include C9ORF72 exons with 
promoter); CS: cognitive symptoms; DPR: dipeptide repeat; G: gliosis; NCI: neuron 
cytoplasmatic inclusions; MN: motor neuron; NMJ: neuromuscular junction; P: paralysis; PND: 
post-natal day. Adapted from Picher-Martel et al., 2016. 
 
However, among the different FTLD animal models, C9orf72 mutants have 
acquired relevance due to the high prevalence of this mutation in ALS and 
FTLD. In recent years, mice carrying 80 “GGGGCC” repeat expansions 
controlled under TRE promoter have been generated (Hukema et al., 2014). 
After doxycycline induction, mice develop ubiquitin-positive inclusion but not 
DPR; however, behavioral analyses are not available on these mice. 
Additionally, knockout of C9orf72 in mice does not result in any motor neuron 
degeneration or modification in life expectancy, thus suggesting that loss of 
function is not sufficient to cause disease (Koppers et al., 2015).  
 
More recently, an AAV vector expressing either 2 or 66 repeats of G4C2 was 
injected into the CNS of postnatal-day-0 mice (Chew et al., 2015). RNA nuclear 
foci occurred in mice carrying 66 repeats but not in mice carrying only two 
repeats. Moreover, rare pTDP-43 aggregates occurred in the nucleus and 
cytosol of cortex and hippocampus regions. These aggregates were not 
positive for poly(GA) but 75% of cells containing TDP-43 NCI were positive for 
poly(GA) inclusions. (G4C2)66 mice exhibit anxiety behavior in an open field 
test and motor impairment in the second day of rotarod testing at 6 months 
of age as compared to control mice.  
 
 
  30 
Ok371-
Gal4 
4 nd nd nd 
  Decreased locomotor 
activity 
nd 
  58 
Ok371-
Gal4 
nd nd nd nd 
  Decreased locomotor 
activity, NMJ loss DPR 
nd 
  Nematodes n/a alfa-1 2 nd Y nd 
  MN loss, paralysis in 
60% of worms 
nd 
  Zebrafish 
C9ORF72-
KO 
n/a nd nd nd nd 







3.7. Molecular alterations in FTLD-TDP 
 
ALS, FTLD and ALS-FTLD reflect a clinicopathological spectrum sharing similar 
disease mechanisms linked to pathological TDP-43 (Lomen-Hoerth et al., 
2002). Consequently, a wide range of cellular pathways linked to ALS occurs in 
FTLD-TDP. C9orf72 loss of function and toxic gain of function mechanisms and 
TDP-43 alterations in sporadic forms can affect RNA processing and 
metabolism pathways, with alterations in transport granule function and 
stress granule formation and vesicular trafficking. They can lead to nucleolar 
dysfunction, affecting RNA splicing and transcription, and causing DNA 
damage. Proteostasis pathways including autophagy and lysosomal function 
impairment, unfolded protein response, endoplasmic reticulum, and 
ubiquitin-proteasome system altered in ALS also occur in FTLD. Other cellular 
processes, including mitochondrial function, can be impaired. In addition, 
neuron-specific processes, such as hyperexcitability and hypoexcitability, 
glutamate excitotoxicity, axonal transport, and neuronal branching defects, 
occur in C9orf72-associated FTLD and c9FTD/ALS. Finally, loss of C9orf72 























































































































2. General objective 
 
The main aim of this doctoral thesis is the identification of new molecular 
alterations underlying motor and cognitive changes in post-mortem human 
spinal cord and frontal cortex in amyotrophic lateral sclerosis and in the frontal 
cortex in frontotemporal lobar degeneration TDP-43, both diseases within the 
spectrum of TDP-43 proteinopathies.  
 
2.1. Specific objectives 
 
Objective 1: To identify molecular alterations underlying brain alterations in 
frontal cortex of sporadic amyotrophic lateral sclerosis without 
frontotemporal dementia and their possible implications in frontotemporal 
lobar degeneration. 
 
- To identify transcriptomic alterations using microarray technology in 
the spinal cord and frontal cortex area 8 in sALS without cognitive 
alterations.  
- To validate altered pathways at mRNA and protein levels in the spinal 
cord and frontal cortex area 8, using RT-qPCR, western blotting and 
immunohistochemistry. 
- To analyze whether alterations in spinal cord samples are similar to 
those found in frontal cortex area 8 of the same cases. 
- To identify effectors of altered pathways as key players in disease 
etiology and/or disease progression, and at the same time postulating 






Objective 2: To identify and evaluate the possible alterations of the immune 
response at early stages of sALS in blood samples to learn about systemic 
responses to the disease. 
 
- To identify alterations in the peripheral immune response by 
detecting altered mRNA levels in samples of peripheral whole-blood 
cells from patients with sALS at early stage of the disease. 
- To analyze the predictive capacities of the possible alterations as 
biomarkers of disease progression.  
- To identify possible therapeutic candidates in peripheral blood 
samples at early stages of the disease.   
 
Objective 3: To evaluate and validate the chitinase-3-like protein 1/YKL-40 
molecule in the CSF as a possible biomarker in sALS. 
 
- To identify and characterize YKL-40 molecule by detecting mRNA and 
protein levels in post-mortem tissue of sALS, including spinal cord and 
frontal cortex area 8 compared with values in healthy controls. 
- To quantify and establish YKL-40 protein levels in cerebrospinal fluid 
of sALS cases as a diagnostic or prognostic marker of the disease. 
- To correlate YKL-40 levels with different clinical and biochemical 
parameters to promote its possible validity as a biomarker. 
 
Objective 4: To evaluate and validate axonemal transport effectors as possible 
biomarkers in sALS based on the axonal transport alterations previously 







- To identify and characterize DNAAF1 by detecting mRNA and LRRC50 
protein levels in spinal cord of sALS cases compared with healthy 
controls. 
- To characterize LRRC50 alterations in different neuronal nuclei, 
including dorsal nucleus of the vagus nerve, hypoglossal nuclei and 
oculomotor nuclei of the brain stem at terminal stages of ALS 
compared to controls. 
- To characterize LRRC50 in the spinal cord of hSOD1-G93A transgenic 
mice at pre-clinical and clinical stages of ALS, and study its possible 
implication in disease pathogenesis.  
 
Objective 5: To characterize molecular alterations in frontal cortex area 8 in 
sFTLD-TDP cases compared to control cases, and establish their possible 
relationship with cognitive alterations in sALS. 
 
- To identify transcriptomic alterations using microarray techniques in 
frontal cortex area 8 post-mortem samples of sFTLD-TDP. 
- To validate the altered pathways at mRNA and protein levels. 
- To verify enzymatic alterations by assessing enzymatic activity of 
complexes of the electron transport chain. 
- To explore possible relationships between alterations in sFTLD-TDP 
and sALS in frontal cortex area 8. 
 
Objective 6: To characterize molecular alterations in frontal cortex area 8 of 
fFTLD-TDP linked to C9orf72 mutations. 
 
- To identify mRNA and protein alterations using combined ‘omics’ in 






- To validate the altered pathways by measuring mRNA and protein 
levels using RT-qPCR and western blotting. 
- To determine possible correlations between transcriptomics and 
proteomics in the same region (area 8) and in the same individuals 
- To establish a possible relationship between fFTLD-TDP linked to 
C9orf72 mutations and alterations in sALSs and sFTLD-TDP frontal 
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In the present thesis, we have examined several molecular alterations 
underlying distinct TDP-43 proteinopathies within the ALS-FTLD spectrum in 
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4.1. Transcriptomic study of molecular alterations associated to ALS in 
spinal cord and frontal cortex area 8 
 
As shown in Figure 22, the starting point of this thesis was the publication of 
the manuscript “Amyotrophic lateral sclerosis, gene deregulation in the 
anterior horn of the spinal cord and frontal cortex area 8: implications in 
frontotemporal lobar degeneration”. In this study, we studied the whole-
transcriptomic profiles of frontal cortex area 8 and the anterior horn of the 
spinal cord in sALS patients without cognitive impairment and concluded that 
transcriptomic profiles in sALS are region-dependent. Whole transcriptome 
arrays showed that major up-regulated clusters in the anterior horn were 
related with innate inflammatory and adaptative inflammatory responses; 
genes involved in homeostasis and ion transport formed a small up-regulated 
group. The major group of down-regulated genes in the anterior horn was 
linked to the neuronal cytoskeleton. In contrast, the majority of differentially 
up-regulated transcripts in sALS in frontal cortex area 8 were linked with 
neurotransmission, ion channels and ion transport, synapses, and axon and 
dendrite maintenance. Down-regulated genes in frontal cortex area 8 were 
linked to oligodendrocyte development and function, myelin regulation, and 
membrane lipid metabolism. 
 
Altered gene expression was validated by RT-qPCR in 58 of 66 assessed genes. 
These observations extended the list of genes that are de-regulated in the 
anterior horn of the spinal cord, and they provided, for the first time, robust 
evidence of gene de-regulation in frontal cortex area 8 in sALS without 
cognitive impairment. Additionally, increased inflammatory response in the 
anterior horn and increased expression of selected neurotransmitter markers 






Gene validations indicated up-regulation of several genes involved in 
inflammatory response in the anterior horn of the spinal cord in sALS. AIF1 
and CD68 genes coding for reactive microglial proteins were highly up-
regulated in this region. In addition, high levels of transcripts coding for Toll-
like receptors (TLRs) expressed in glial cells (Arroyo et al., 2011), whose 
activation, in turn, activates phagocytosis (Iribarren et al., 2005; Chen et al., 
2006; Tahara et al., 2006) and pro-inflammatory responses (Facci et al., 2014), 
were up-regulated as well. Moreover, up-regulation of genes coding for pro-
inflammatory effectors was found in the anterior horn of the spinal cord, 
involving interleukin-1B (IL1B), interleukin-10 (IL10), interleukin-10RA 
(IL10RA), interleukin-10RB (IL10RB), tumor necrosis factor alpha (TNFA), 
catepsin C and S, (CTSC and CTSS, respectively), major histocompatibility 
complex, class II, DR beta 1/5 (HLA-DRB-1/5), programmed cell death 1 ligand 
2 (PDCD1LG2), interferon-gamma (INFG) and interleukin-33 (IL33), among 
others. This general view was in contrast with certain astrocitary markers, 
such as glial fibrillary acidic protein and voltage dependent anion channel, in 
which levels of mRNA were not modified. Moreover, IL6 mRNA, which encodes 
one specific pro-inflammatory cytokine with regenerative and anti-
inflammatory activities in particular settings (Simpson et al., 1997; Locksley et 
al., 2001; Schellera et al., 2011; Pal et al., 2014), was not modified. 
 
Increased inflammatory response in the anterior horn of the spinal cord was 
further documented by immunohistochemistry, showing increased expression 
of IBA-1, CD68, HLADRB1 and HLA-DRB5 in reactive microglia. Reactive 
microglia had a round, amoeboid morphology and is localized, as expected, in 
the anterior horn, and the lateral and anterior pyramidal tracts. IL-10 and TNF-
α were mainly localized in neurons of the spinal cord, and their expression was 
increased in remaining motor neurons of the spinal cord in sALS. In contrast, 





pointed to a cross-talk between microglia and neurons in sALS. GFAP 
immunoreactivity was clearly increased in reactive astrocytes, as already 
reported in classical neuropathological studies.  
 
In the anterior horn of the spinal cord, RTq-PCR results confirmed the reduced 
expression of axonemal genes identified in microarrays. The expression levels 
of genes coding for dynein heavy chain components and dynein assembly 
factors (DNAAF1) were down-regulated, thus suggesting impairment of motor 
ATPases involved in the transport of various cellular cargoes by ‘walking’ along 
cytoskeletal microtubules towards the minus-end of the microtubule (Asai and 
Brokaw, 1993; Chapelin et al., 1997; McKenney et al., 2014). However, mRNA 
levels of NEFH, which codes for neurofilament heavy polypeptide protein 
(Figlewicz et al., 1994) and acts as a rail for this kind of transport, were 
preserved in ALS. 
 
Regarding frontal cortex area 8, validations indicated up-regulation of 
neurotransmission-related genes and synaptic cleft genes. Genes involved in 
glutamatergic and GABAergic transmission were up-regulated in the frontal 
cortex in sALS. This applies to genes encoding the ionotropic glutamate 
receptor AMPA 1 (GRIA1), glutamate ionotropic receptor NMDA type subunit 
2A (GRIN2A), the glutamate ionotropic receptor NMDA type subunit 2B 
(GRIN2B) and glutamate metabotropic receptor 5 (GRM5). Regarding the 
GABAergic system, GAD1, coding for glutamate decarboxylase 1, a rate-
limiting enzyme that acts in the decarboxylation of glutamate essential for the 
conversion reaction of GABA from glutamate, was up-regulated, as were 
GABRA1, GABRD and GABRB2, which code for different subunits of ionotropic 
GABA-A receptors. GABBR2, that codes for the metabotropic receptor 





heterodimers with GABBR1, resulting in the formation of the G-protein 
coupled receptor for GABA, was also up-regulated (Burmakina et al., 2014).  
 
In line with increased expression of neurotransmitter-related genes, several 
genes encoding molecules linked to the synaptic cleft were also up-regulated 
in sALS, including: 
 
- BSN: Bassoon, a pre-synaptic cytoskeletal matrix (PCM) protein acting as 
a scaffolding protein and essential for the regulation of neurotransmitter 
release in a subset of synapses (Hallermann et al., 2010; Davydova et al., 
2014).  
- PCLO: Piccolo protein, a component of the PCM assembled in the active 
zone of neurotransmitter release (Fenster et al., 2000; Fenster and 
Garner, 2002).  
- FRMPD4: PSD-95-interacting regulator of spine morphogenesis protein, 
which regulates dendritic spine morphogenesis and is required for the 
maintenance of excitatory synaptic transmission (Matosin et al., 2016).  
- DDN and NRN1: dendrin and neuritin 1 proteins, respectively, which are 
involved in the remodeling of the postsynaptic cytoskeleton and neuritic 
outgrowth (Naeve et al., 1997; Kremerskothen et al., 2006; Shimada et 
al., 2016).  
 
Moreover, de-regulation of neurotransmitters and receptors was further 
supported by the demonstration of a significant increase in the protein levels 
of GluR-1 and a tendency to increase in those of GABAAB2 in frontal cortex 
area 8 in sALS when compared with controls. It is worth stressing that only a 






As an important regional difference related to neurotransmission and 
excitotoxicity, the expression of glutamate transporters was markedly 
different in the anterior horn of the spinal cord and frontal cortex area 8. 
SLC1A2 and SLC17A7 mRNA expression was significantly decreased in the 
anterior horn of the spinal cord, whereas SLC1A2 was significantly increased 
in frontal cortex area 8. SLC1A2 encodes the solute carrier family 1 member 2 
or excitatory amino acid transporter 2 (EAAT2) which clears glutamate from 
the extracellular space at synapses in the central nervous system. 
Immunohistochemistry showed decreased SLC1A2 protein expression in the 
membrane of neurons and neuropil of the anterior horn in sALS. SLC17A7 
encodes the vesicular glutamate transporter 1 (VGLUT1) which is a vesicle-
bound, sodium-dependent phosphate glutamate transporter expressed in the 
synaptic vesicles. Decreased expression of these proteins is linked to increased 
excitotoxity, which is postulated as a primary factor triggering motor neuron 
degeneration in sALS (Rothstein, 1995 and 2009). 
 
Finally, the expression of several myelin-related genes and oligodendrocyte 
genes was down-regulated in frontal cortex area 8: 
 
- MYRF: Myelin transcription factor regulates oligodendrocyte 
differentiation and is required for central nervous system myelination 
(Cahoy et al., 2008; Emery et al., 2009; Koenning et al., 2012; Li et al., 
2013).  
- OLIG2: The basic loop-helix protein OLIG2 mediates motor neuron and 
oligodendrocyte differentiation (Lederer et al., 2007; Sun et al., 2011). 
- SOX10: High mobility group protein SOX10 modulates myelin protein 
transcription (Leblanc et al., 2007; Li et al., 2007).  
- NKX2.2: NKX2.2 homeodomain transcription factor is a key regulator of 





- TF: Transferrin participates in the early stages of myelination (Connor, 
1994; Erikson et al., 1997).  
- PLP1: Proteolipid protein 1 plays a role in the compaction, stabilization 
and maintenance of myelin sheaths, as well as in oligodendrocyte 
development and axonal survival (Diehl et al., 1986; Griffiths et al., 1998).  
- MBP: Myelin basic protein is the second most abundant myelin-
associated protein, constituting about 30% of the total myelin proteins 
(Marty et al., 2002).  
- MOBP: Myelin-associated oligodendrocyte basic protein constitutes the 
third most abundant protein in CNS myelin and acts by compacting and 
stabilizing myelin sheaths (Montague et al., 2006).  
- MOG: Myelin oligodendrocyte glycoprotein is a cell surface marker of 
oligodendrocyte maturation (Roth et al., 1995).  
- MAG: Myelin-associated glycoprotein is a type I membrane protein and 
member of the immunoglobulin superfamily involved in the process of 
myelination and certain myelin-neuron cell-cell interactions (Lossos et al., 
2015).  
- MAL: Mal T-cell differentiation protein is involved in myelin biogenesis 
(Kim et al., 1995).  
- CNP1: 2',3'-cyclic nucleotide 3' phosphodiesterase participates in early 
oligodendrocyte differentiation and myelination (Kasama-Yoshida et al., 
1997; Lappe‐Siefke et al., 2003; Kursula, 2008). 
 
RTq-PCR gene validation, western blotting and immunohistochemestry results 









4.2. Inflammatory alterations associated to ALS 
 
Based on the data obtained in this first work, one block of the subsequent 
studies was oriented toward searching for novel molecular alterations and 
candidate biomarkers, taking into account the reported alterations in the 
inflammatory response pathways and axonal transport components in the 
anterior horn of the spinal cord. Concretely, the second work of this thesis, 
entitled “Inflammatory gene expression in whole peripheral blood at early 
stages of sporadic amyotrophic lateral sclerosis”, was focused on the study of 
early inflammatory alterations in whole peripheral blood of sALS cases.  
 
Inflammation involving microglial cells, macrophages, T cells, astrocytes and 
neurons, and mediated by a plethora of mediators of the immune response, 
occurs in the anterior horn of the spinal cord and, to a lesser extent, in other 
brain regions in ALS (Sta et al., 2011; McCombe and Henderson, 2011; Philips 
and Robberecht, 2011; Evans et al., 2013; Hooten et al., 2015; Komine and 
Yamanaka, 2015; Puentes et al., 2016; Liu and Wang, 2017; Article I). However, 
peripheral inflammatory responses are common, but poorly defined, in 
human neurodegenerative diseases. Several studies have focused on 
inflammatory responses in spinal cord and blood in sALS (Graves et al., 2004; 
Henkel et al., 2004; Shi et al., 2007; Casula et al., 2011; Sta et al., 2011; Rentzos 
et al., 2012; Johann et al., 2015; Puentes et al., 2016; Article I). We aimed to 
gaining information about inflammatory gene expression profiles in whole 
blood in a series of sALS patients at the beginning of clinical symptoms and not 
treated with riluzole to avoid bias related to treatment.  
 
Our observations complement data from previous studies and point to the 
activation of mechanisms facilitating extravasation of white blood cells (WBC) 





expression of leukocyte adhesion molecules, chemokines and cytokines (Ley, 
2002; Nathan, 2006). Increased expression of ITGB2 and a tendency of ICAM1 
to increase in blood suggest that adhesion and trans-endothelial migration of 
leukocytes were facilitated in sALS (Smith et al., 1989; Lefort and ley, 2012; 
Hua, 2013). Selectin 1, encoded by SELL, participates in leukocytes’ binding to 
endothelial cells and facilitates migration of WBC (Ley et al., 2007; Marki et 
al., 2015); SELL expression showed a tendency to increase in sALS. Increased 
expression of MMP9 observed in sALS favors degradation of extracellular 
matrix components and facilitation of leukocyte migration. MMP9 is usually 
secreted in conjunction with TIMP-1, a specific inhibitor, which controls its 
proteolytic activity (Kurzepa et al., 2014). A balance between MMP9 and 
TIMP-1 proteins regulates excessive tissue degradation in chronic 
inflammation (Amalinei et al., 2010). In contrast, other effectors involved in 
cell extravasation were not modified in WBC of sALS. mRNA expression levels 
of cathepsins, also involved in extracellular matrix degradation  (Fonović and 
Turk, 2014), were not modified in blood of ALS cases when compared with 
blood samples from controls. Expression levels of CCL2 and CCL3, the products 
of which modulate monocyte attraction (Paavola et al., 1998; Sanadgol et al., 
2016), were not modified in sALS. Finally, increased INPP5D mRNA expression 
favored a negative regulation of myeloid cell proliferation (Hakim et al., 2012). 
 
Regarding the state of lymphocyte cells, reduced expression of CCR5, CCL5 and 
CXCR5 supports reduced activation of B-cells (Le et al., 2004). CCL5 and CCR5 
encode T-cell chemo-attractant and regulatory molecules (Siveke and 
Hamann, 1998; Rabin et al., 1999). The product of CD2 expressed in T-cells 
modulates T-cell proliferation (The et al., 1997), whereas the product of TRBC1 
is implicated in T-cell activation (MacLean and Gibson, 1997). Our 
observations showed decreased expression of CD2, coding for CD2 molecule, 





expression of CD8 mRNA, coding for CD8 molecule, and preserved CD4 mRNA 
expression, coding for CD4 molecule; both T-cell markers as well. Reduced 
mRNA expression of these markers suggests inhibition of T-cell signaling. 
However, additional studies are needed to elucidate these discrepancies in 
larger series. 
 
As to pro- and anti-inflammatory cytokines, results indicated down-regulation 
of these molecules in sALS. Toll-like receptors are involved in the initiation of 
the inflammatory process (Trinchieri and Sher, 2007). Reduced levels of TLR3 
accompanied by a tendency to increased TLR4 and TLR2 mRNA expression 
pointed to ambiguous activation signaling by Toll-like receptors. TGFB2, IL10 
and IL6 mRNAs were down-regulated, and IL10RA and TNFA had tendency to 
decrease in blood in sALS when compared with controls. Expression levels of 
IL10RB, TGFB1, IL1β, IL6ST, INFG and VEGFA were not modified in sALS. 
Expression levels of assessed colony-stimulating receptors and CSF3R did not 
differ from control values. Only increased expression levels were reported in 
TNFR1S mRNA. 
 
With the aim of assessing our results at a clinical level, correlation studies were 
performed. Positive correlation between MMP9 and age, and negative 
correlation between age and CCL5, CCR5, and TRBC1, were observed in sALS 
but not in controls. No correlation was found between present observations 
and first clinical manifestation, gender and disease progression. Therefore, the 
present findings have little prognostic value. There was only positive 
correlation between TNFA mRNA expression and creatinin kinase (CK) levels. 
Although TNFA mRNA expression in blood was lower in sALS cases when 
compared with controls, higher TNFA mRNA values correlated with higher CK 
protein levels. This observation pointed to the possibility of a link between 





Previous studies showed that muscular pathology is accompanied by 
increased expression of systemic inflammatory markers (Lu et al., 2016). 
Moreover, increased expression of inflammatory markers, including IL-1β and 
TNF-α, has been found in the skeletal muscle at symptomatic and end-stages 
of SOD1(G93A) transgenic mice (Van Dyke et al., 2016). However, these 
individual data are not sufficient to allow us to advance any definitive 
conclusion. Transcriptome studies at early clinical stages in SOD1(G93A) 
transgenic mice in spinal cord, muscle and sciatic nerve have shown common 
deregulated pathways associated with T cell activation, two with macrophage 
activation and one pathway with genes involved in co-stimulatory regulation 
of the adaptive and innate immune systems; but blood did not show 
representation of these altered pathways (Lincecum et al., 2010).  
 
Thus, these results point to involvement of peripheral blood cells in the 
inflammatory response in the spinal cord in ALS. Present observations showed 
systemic inflammatory responses linked to extravasation of leukocytes and 
remodeling of extracellular matrix at early stages of sALS. 
 
Following our interest on improve the knowledge about the involvement of 
inflammatory mechanisms in ALS pathogenesis, the third work presented in 
this thesis, entitled “YKL40 in sporadic amyotrophic lateral sclerosis: 
cerebrospinal fluid levels as a prognosis marker of disease progression,” was 
focused on studying the neuroinflammatory response in the central nervous 
system. Specifically, we evaluated the astrocitary molecule YKL40 in the 
anterior horn of the spinal cord and frontal cortex area 8 of sporadic ALS cases 
and its possible role as a disease biomarker.  
 
Increased levels of selected inflammatory markers are found in blood and 





correlate with disease progression (Zhang et al., 2005; Shi et al., 2007; Cereda 
et al., 2008; Mantovani et al., 2009; Rentzos et al., 2012; Henkel et al., 2013; 
Sidaway, 2017; Zhao et al., 2017). All these observations strongly support a 
role for inflammation in the pathogenesis of sALS. However, the identification 
of a biomarker of inflammation with practical prognosis value has been limited 
because of individual variation and variations between methods and 
laboratories. 
 
Previous studies of ALS showed YKL40 mRNA up-regulation in the motor 
cortex (Sanfilippo et al., 2017) and increased YKL40 protein levels in the CSF 
correlating with disease progression (Illán-Gala et al., 2017; Thompson et al., 
2018). Regarding brain tissue, our present observations showed significant 
YKL40 mRNA up-regulation in the anterior horn of the spinal cord and frontal 
cortex area 8, accompanied by significantly increased YKL40 protein levels in 
the frontal cortex and a tendency to increased YKL40 in the spinal cord in sALS. 
Importantly, YKL40 was expressed in astrocytes, in agreement with other 
observations (Bonneh‐Barkay et al., 2010; Bonneh‐Barkay et al., 2012; Wiley 
et al., 2015; Ferrer, 2017; Llorens et al., 2017; Querol-Vilaseca et al., 2017), 
but in contrast to another description ascribing YKL40 expression to brain 
macrophages (Thompson et al., 2018). 
 
Up-regulation and increased YKL40 expression occcur in parallel with 
increased levels of microglia markers in the spinal cord but not in the frontal 
cortex area in sALS, and with increased GFAP protein levels in the spinal cord 
and frontal cortex but not with GFAP mRNA up-regulation in these regions. 
 
Based on these findings, increased YKL40 protein levels in the CSF mirror 
YKL40 changes in the central nervous system, and they can be interpreted as 





analysis of a possible correlation between YKL40 brain and spinal cord values, 
or disease progression/survival, was feasible in the present series because of 
the lack of sufficient clinical data. However, YKL40 CSF values negatively 
correlated with patient survival, indicating that higher YKL40 in the CSF likely 
occurs in patients with rapid disease progression. 
 
We do not know at this time what the functional implications of elevated 
YKL40 expression in ALS and other neurological diseases are. Nor do we know 
whether YKL40, even considering this particular chitinase as a marker of 
astrocyte inflammation, has beneficial or deleterious effects. In this line, chi3l1 
KO mice have increased astrocytic responses (GFAP staining) and increased 
IBA1 microglial expression when compared with wild-type animals following 
traumatic brain injury, suggesting that YKL40 limits the extent of astroglial and 
microglial neuroinflammation (Wiley et al., 2015). If this is the case then 
increased YKL40 expression per se would not be dangerous but rather a 
manifestation of increased beneficial response in the face of a more 
aggressive facet of ALS in a subgroup of patients. 
 
Previous studies showed increased levels of neurofilaments in the CSF of ALS 
cases (Oeckl et al., 2016; Weydt et al., 2016; Steinacker et al., 2016; Feneberg 
et al., 2018). NF heavy chain levels in CSF are negatively correlated with 
disease duration and ALS-FRS-R slope, and NF-L light chain levels in CSF are 
negatively correlated with disease duration. Thus, NF heavy and light chain 
levels have potential use as markers of neural degeneration in ALS (Xu et al., 
2016; Rossi et al., 2018). Increased NF-L levels in the CSF are not specific for 
the disease, but they are more likely useful as measures of disease progression 
(Xu et al., 2016; Rossi et al., 2018). In the present work, YKL40 levels in the CSF 
were assessed in parallel with levels of NF light chain. As expected, our results 





were significantly increased in ALS and levels negatively correlated with 
disease progression and ALS-FRS-R slope in our series. 
 
Thus, the present findings in this third work reveal that YKL40 and NF-L levels 
in CSF constitute a valuable combination of biomarkers for improving accuracy 
in the prognosis of patients with sALS. 
 
4.3. Alterations in axonal transport and dynein assembly in ALS 
 
Finally, as to altered pathways in the anterior horn of the spinal cord of sALS 
post-mortem tissue, the fourth paper included in the present thesis, entitled 
“Altered dynein axonemal assembly factor 1 expression in C-boutons in bulbar 
and spinal cord motor-neurons in sporadic amyotrophic lateral sclerosis,” 
describes for the first time novel specific changes in dynein-mediated axonal 
transport mechanisms. 
 
Neuronal retrograde transport, mediated by dyneins, is required to maintain 
homeostasis by removing aging proteins and organelles from the distal axon 
for degradation and recycling of components (Roberts et al., 2013; Maday et 
al., 2014). Dynein processing and localization varies in different cell types and 
clusters in distinct subcellular organelles (Vancoillie et al., 2000; Chuang et al., 
2001; Jha and Surrey, 2015; Twelvetrees et al., 2016). In the central nervous 
system, dyneins are largely localized at the axon terminals (Twelvetrees et al., 
2016) and their assembly is modulated by a heterogeneous group of dynein 
axonemal assembly factor DNAAFs that act, in most instances, in combination 
with particular chaperones to promote cytoplasmic pre-assembly of dyneins 
(Omran et al., 2008; Tarkar et al., 2013; Inaba et al., 2016; Jaffe et al., 2016; 





DNAAF1 gene and the encoded protein, leucine-rich repeat-containing protein 
50 (LRRC50), in motor-neurons and in the context of sALS. 
 
In agreement with our previous gene transcription results (Article 
I), DNAAF1 mRNA expression was reduced in the spinal cord anterior horn in 
sALS cases. Reduced DNAAF1 mRNA expression can be the result of mere 
motor neuron demise. However, LRRC50 immunoreactivity was drastically 
reduced at the surface of the remaining spinal and bulbar motor neurons in 
parallel with reduced numbers of C-boutons in sALS. Our study identified the 
presence of LRRC50-immunoreactive boutons at the surface of motor neurons 
of the spinal cord and motor nuclei of the brain stem in humans and mice; 
these are identified as C-boutons on the basis of single 
immunohistochemistry, and double- and triple-labeling immunofluorescence 
and confocal microscopy. C-boutons are pre-synaptic terminals of cholinergic 
interneurons, which modulate motor neuron activity. They are localized in the 
spinal cord and in most of the motor nuclei of the cranial nerves excepting the 
oculomotor nuclei of the brainstem (Conradi, 1969; Hellstrom et al., 1999; 
Miles et al., 2007; Frank, 2009; Zagoraiou et al., 2009; Gallart-Palau et al., 
2014; Casanovas et al., 2017). They contain VAChT and synaptic vesicle 
markers, and are in contact with postsynaptic components including M2 
muscarinic receptors and S1R; neuregulin 1-ErB retrograded signaling is also 
differentially compartmentalized in C-type boutons (Miles et al., 2007; 
Mavlyutov et al., 2010; Gallart-Palau et al., 2014; Casanovas et al., 2017). 
Therefore, LRRC50 reduction is not the mere reflection of motor neuron 
demise but a reduction in the number of LRRC50-immunoreactive boutons in 
the remaining motor neurons in sALS. 
 
This decline occurs independently of the aberrant formation of TDP-43-





et al., 2011; Ince et al., 2015). Nor does this decline correlate with the 
appearance of dynein-dynactin-immunoreactive deposits in motor neurons, 
which are neither related with skein-like inclusions, in the spinal cord in sALS 
(Ateh et al., 2007). However, LRRC50 reduction in C-boutons was 
accompanied by perinuclear LRRC50 immunoreactivity in some remaining 
motor neurons, suggesting some kind of alteration in the transport of this 
protein. 
 
Loss of cholinergic synapses in the spinal cord motor-neurons in sALS was 
reported many years ago (Nagao et al., 1998). This pioneering observation was 
partially refuted in SOD1 transgenic mice (Pullen and Athanasiou, 2009; 
Herron and Miles, 2012), due, in part, to different markers used to detect C-
boutons in SOD1 transgenic mice. A significant increase in the number of 
VAChT-positive boutons is observed at the beginning of the symptomatic 
stage, which is followed by a marked decrease at the final stages of the 
disease. Our present observations showed a marked reduction in LRRC50-
immunoreactive boutons in motor neurons of the ventral horn in hSOD1-G93A 
transgenic mice aged 150 days, which was accompanied by a parallel decrease 
in S1R-immunoreactive boutons. The presence of the remaining S1R seems to 
be protective of motor neurons, as the knocking-out of S1R in hSOD1-G93A 
transgenic mice exacerbates motor neuron disease progression (Casas et al., 
2013). Early pre-symptomatic alterations in C-boutons have also been 
reported in SOD1(G93A) transgenic mice (Mavlyutov et al., 2013).  
 
Our combined study in human sALS not linked to SOD1 mutations and in 
transgenic mice bearing high copy numbers of the mutated form of human 
SOD1 showed common responses regarding C-boutons in motor neurons. The 
number of LRRC50-immunoreactive structures was decreased in motor 





early or late events, transgenic mice at pre-clinical, early clinical and late 
clinical stages were examined. A decrease in LRRC50 immunoreactivity 
occured at preclinical stages in hSOD1-G93A transgenic mice, suggesting that 
LRRC50 alteration is an early event in the course of the disease. Moreover, a 
trend to decrease was observed at the age of 120 days and a significant 
decrease was manifested at the age of 150 days. 
 
Comparing, the pattern of C-bouton response in sALS and Tg mice differs from 
that seen after nerve peripheral nerve axotomy in mice. Reduced expression 
of VAChT and NRG1 immunoreactivity together with a reduction in size of C-
boutons starting at 24 hours is followed by practical recovery by 30 days 
postlesion (Sumner, 1975; Casanovas et al., 2017). Therefore, the changes 
observed here in motor neuron disease are hardly due to peripheral axotomy. 
 
However, whether LRRC50 in motor neurons is essential for the maintenance 
of C-boutons cannot be addressed by neuropathological approach. Yet this is 
an important point for understanding the role of this protein in motor neuron 
maintenance and neurodegeneration. 
 
4.4. Molecular alterations underlying cognitive impairment in 
frontotemporal lobar degeneration TDP-43 
 
The second block of this thesis was focused on the study of molecular 
alterations in frontal cortex area 8 underlying sporadic and familial forms of 
FTLD-TDP pathology, and their comparison with those observed in frontal 
cortex area 8 of sALS. The first study included in this block is entitled “Gene 







This manuscript was based on whole-transcriptome microarray hybridization 
and showed down-regulation of several genes in frontal cortex area 8 in sFTLD-
TDP clustered in pathways involved in neurotransmission and synapsis, 
neuronal architecture, cytoskeleton of axons and dendrites, vesicle trafficking, 
purine metabolism, mitochondria and energy metabolism. 111 selected genes 
from predicted altered pathways based on Gene Ontology (GO) database were 
validated by RT-qPCR. The expression of 81 genes was significantly 
deregulated in this cortical region in sFTLD-TDP when compared with controls. 
From those, 24 coded proteins were analyzed with western blotting and 8 of 
them resulted altered in sFTLD-TDP. Our results demonstrated that 
neurotransmission is markedly affected in sFTLD-TDP since several of the 
down-regulated genes were related to glutamate decarboxylase, several types 
and subunits of ionotropic and metabotropic glutamate and GABA receptors, 
neuronal vesicular and soluble glutamate transporters, and various synaptic 
proteins, together with loss of calbindin expression. This provides robust 
support to preliminary morphological observations using the Golgi method 
and calbindin immunohistochemistry showing decreased numbers, 
amputation, and proximal swellings of dendritic branches and loss of synaptic 
spine pyramidal cells, and loss of calbindin-immunoreactive neurons with 
atrophy of remaining neurons in layers II and III of the frontal cortex in FTLD 
(Ferrer, 1992). Protein expression studies showing decreased levels of 
synaptic markers are also in line with previous observations demonstrating 
reduced levels of several synaptic and presynaptic plasma membrane proteins 
in the frontal cortex, but not in the posterior parietal cortex assessed in 
parallel, in FTLD (Ferrer, 1999). 
 
In contrast to the marked decrease in the expression of cytoskeletal and 
synaptic markers, tau mRNA and protein levels were preserved in the present 





contrast with early reports pointing to decreased tau protein levels in FTLD 
with ubiquitin inclusions (presumably FTLD-TDP), which suggested that FTLD-
U could be a novel ‘inverse’ tauopathy because of the reduced levels of tau 
(Zhukareva et al., 2001; Zhukareva et al., 2003). Reduced tau mRNA and 
protein levels have been reported in FTLD-TDP linked to GRN mutations but 
not in other FTLD-TDP subtypes such as sporadic FTLD-TDP and FTLD-TDP-
C9ORF72 (Papegaey et al., 2016). 
 
Mitochondrial alterations compromise mRNA expression of several subunits 
of the mitochondrial complexes. Moreover, they were accompanied by 
altered protein expression of several subunits and with reduced activity of 
complexes I, IV, and V in sFTLD-TDP. Importantly, in addition to mitochondrial 
subunits encoded by genomic DNA, expression levels of MT-CO1 encoded by 
mitochondrial DNA were reduced in sFTLD-TDP. Therefore, mitochondrial 
alterations in sFTLD-TDP have both genomic and mitochondrial components. 
Other genes involved in energy metabolism were down-regulated as well, 
indicating functional energy metabolism failure in sFTLD-TDP. Gene-specific 
mitochondrial dysfunction has been described in human fibroblasts bearing 
mutations in TARDBP and C9ORF72 (Onesto et al., 2016). Mitochondrial 
dysfunction has also been documented in a transgenic knock-in mouse model 
for TDP-43 (Stribl et al., 2014). Therefore, mitochondrial alterations seem to 
be common to different forms of sFTLD-TDP and fFTLD-TDP. 
 
Purines and pyrimidines are components of a large number of key molecules. 
The primary purines adenine and guanosine, and pyrimidines cytosine, 
thymidine, and uracyl, are the core of DNA, RNA, nucleosides, and nucleotides 
involved in energy transfer (ATP, GTP) and coenzymes (NADH, FADH2) (Ipata 
et al., 2011; Ansoleaga et al., 2015). Alterations in the expression of genes 





metabolic processes in sFTLD-TDP. It can be argued that differences in the 
percentage of neurons, astrocytes, oligodendroglia and microglia lie beyond 
distinct patterns of gene expression, protein levels, and mitochondrial 
enzymatic activities in sFTLD-TDP. Certainly, neuron loss, spongiosis in the 
upper cortical layers and variable astrocytic gliosis are typical morphological 
alterations in sFTLD-TDP (Hortobagyi et al., 2015; Lashley et al., 2015; Mann 
and Snowden, 2017). Present findings complement morphological 
observations with biochemical data that identify damage of particular 
components of vital molecular pathways and essential modulators of synaptic 
transmission. 
 
Comparison of the present findings with our previous observations in frontal 
cortex area 8 in sALS using the same methods shows that most down-
regulated genes in sFTLD-TDP are up-regulated in frontal cortex area 8 in sALS 
cases without dementia (Article I). This suggests a primary response linked to 
synaptic and neurotransmission disturbances in frontal cortex area 8 at 
preclinical stages of frontal degeneration in sALS (sALS cases without apparent 
cognitive impairment), which may decay with disease progression and 
dementia in FTLD-TDP. Reduced expression of genes encoding actin, actin-
related members, kinesin and microtubule-associated protein further suggest 
cytoskeletal damage in sALS and sFTLD-TDP. 
 
Finally, the last part of the second block of this thesis was focused on the study 
entitled “Combined transcriptomics and proteomics in frontal cortex area 8 in 
frontotemporal lobar degeneration linked to C9ORF72 expansion,” in which 
mRNA and protein expression in frontal cortex area 8 was analyzed in fFTLD-






This study revealed altered gene transcription related to DNA recombination, 
RNA splicing regulation, RNA polymerase transcription, myelin synthesis, 
calcium regulation and ubiquitin-proteasome system in c9FTLD. Proteomics 
performed in the same tissue samples identified altered protein expression 
linked to apoptosis, inflammation, metabolism of amino acids, metabolism of 
carbohydrates, metabolism of membrane lipid derivatives, microtubule 
dynamics, morphology of mitochondria, neuritogenesis, neurotransmission, 
phagocytosis, receptor-mediated endocytosis, synthesis of ROS, and calcium 
signaling in c9FTLD. 
 
Genes and proteins did not match in the two lists of deregulated mRNAs and 
proteins in c9FTLD. However, a protein interactome map constructed using 
the IPA software showed deregulation of cross-linkers between DNA/RNA 
regulation systems and ubiquitin-proteasome systems, suggesting an 
imbalance in cellular transcription processes and protein degradation 
mechanisms, which makes sense in light of gene transcription observations of 
the main contributors to the pathogenesis of neurodegenerative diseases with 
abnormal protein aggregates. This is in line with the function of TDP-43 and 
C9orf72. Together, this combined transcriptomics-proteomics analysis 
supported the list of separately reported altered pathways linked to C9orf72 
mutations, including those involved in DNA recombination and transcription, 
RNA splicing, endoplasmic reticulum and mitochondria, synaptic transmission, 
protein degradation, calcium homeostasis, and inflammation (Kaus and 
Sareen, 2015; Dafinca et al., 2016; Budini et al., 2017; Gao et al., 2017; Palluzzi 
et al., 2017; Frick et al., 2018; Hermann and Parlato, 2018; Lau et al., 2018; 
Evans and Holzbaur, 2019). Additional alterations involved altered metabolism 
of amino acids and carbohydrates, membrane lipid derivatives, and 
microtubule dynamics, and synthesis of reactive oxygen species. Links 





damage and docosahexaenoic acid have previously been reported in the spinal 
cord in ALS, and in frontal cortex in FTLD-TDP (Ilieva et al., 2007; Martinez et 
al., 2008; Ayala et al., 2011a).  
 
Regarding TDP-43 and C9orf72, major pathologic components in c9FTLD, 
TARDBP mRNA expression was preserved but total TDP-43 protein showed 
increased levels in c9FTLD when compared with controls. This is in accordance 
with the abnormal deposition of this protein in intracellular inclusions and 
threads characteristic of this disease. In contrast, C9orf72 mRNA expression 
was significantly decreased in c9FTLD. However, the C9orf72 long isoform was 
significantly reduced and the C9orf72 short isoform significantly increased in 
c9FTLD. Reduced C9ORF72 protein levels were found in previous reports 
(Belzil et al., 2013a; Ciura et al., 2013; Xi et al., 2013; Waite et al., 2014). The 
functional implications of the reduced levels of the long C9orf72 isoform are 
not known, but quantitative mass spectrometry-based proteomics used to 
identify interacting proteins in motor neurons has shown that the long isoform 
complex stabilizes SMCR8, a protein which acts as an autophagic regulator 
(Jung and Behrends, 2017; Zhang et al., 2018). Therefore, reduced levels of 
the long isoform may interfere with normal autophagy and lysosomal 
processing (Zhang et al., 2018). C9orf72 also binds to several proteins 
including members of the Rab family, endoplasmic reticulum and synapses; 
nuclear and cytoplasmic transport, endoplasmic reticulum stress and altered 
synaptic function have all been reported in association with pathogenic 
C9ORF72 expansions (May et al., 2014; Zhang et al., 2014; Freibaum et al., 
2015; Jovicic et al., 2015; Gao et al., 2017; Frick et al., 2018; Vatsavayai et al., 
2019).  
 
An interesting deregulated cluster is composed of genes linked to several 





small nucleolar RNA (SCARNA2), and long noncoding RNAs such as X-inactive 
specific transcript (XIST) and the long intergenic non-coding RNAs LINC1476, 
LINC1140, and LINC00499. miRNAS participate in a large number of variegated 
processes including mRNA silencing and regulation of gene transcription 
(Ambros, 2004; Bartel, 2004). SCARNA2 localizes to Cajal bodies, the process 
of binding of its box C/D being modulated by coilin (Enwerem et al., 2015). 
Long intergenic non-coding RNAs are mainly localized in the nucleus where 
they modulate chromatin and genome architecture, in addition to RNA 
stabilization and transcription regulation (Ransohoff et al., 2018). XIST is 
localized in the X-chromosome and participates in the inactivation of 
chromosome X (Chow et al., 2005). The consequences of XIST deregulation in 
C9orf72 remain elusive.  
 
Our studies using a similar transcriptomics approach in frontal cortex area 8 in 
sFTLD-TDP have shown down-deregulation of genes linked to 
neurotransmission and synapses, neuronal architecture, cytoskeleton of 
axons and dendrites, vesicle trafficking, purines, mitochondria, and energy 
metabolism. Additional protein and enzymatic studies have revealed altered 
mitochondrial function and oxidative phosphorylation. Using the same 
methods, we observed up-regulated gene clusters in frontal cortex area 8 in 
sALS involving neurotransmission, synaptic proteins, and vesicle trafficking, 
and down-regulated genes clustering into oligodendrocyte function and 
myelin-related proteins. Curiously, some down-regulated clusters related 
mainly to synapses and neurotransmission in frontal cortex in sFTLD-TDP were 
up-regulated in frontal cortex in sALS without dementia. The present 
observations in c9FTLD reveal some commonalities with sFTLD-TDP in altered 
clusters but not in particular genes. Down-regulation of genes linked to 







Recent studies have shown oligodendrocytes as key players in 
neurodegenerative diseases with abnormal protein aggregates (Ferrer, 2018). 
Oligodendrogliopathy is common in sALS and FTLD-TDP. Phosphorylated-TDP-
43-immunoreactive oligodendroglial inclusions are found in, in addition to 
spinal cord motor neurons, the motor, sensory and premotor cortex, but not 
the corpus callosum, cingulum or lateral tracts of the spinal cord (Neumann et 
al., 2007). TDP-43 oligodendroglial inclusions are common in the deep layers 
of the cerebral cortex and white matter in FTLD-TDP (Fatima et al., 2015). The 
functional effects of oligodendroglial TDP43 inclusions are not known, but 
present findings indicate altered oligodendroglial gene expression in the 
frontal cortex in c9FTLD. Particular features are linked to C9orf72 
hexanucleotide repeat expansion (Bigio, 2011, 2012), and TDP-43-dependent 
or TDP43-independent oligodendroglial dysfunction might be a characteristic 
trait linked to C9orf72 hexanucleotide repeat expansion. In contrast, although 
astrocytes play key pathogenic roles in ALS (Ferrer, 2017), TDP-43-
immunoreactive inclusions are rare in sALS and FTLD-TDP (Kovacs et al., 2017).  
 
Comparisons with other studies performed in different types of FTLD-TDP 
showed disparate results. One gene expression analysis in fFTLD linked to GRN 
mutations identified abnormal regulated processes associated with lipid 
metabolism, MAPK signaling pathway, and transport (Chen-Plotkin et al., 
2008), while lysosomal dysfunction was identified in another (Evers et al., 
2017). Another study recognized synapse-, cytoskeletal/filament-, 
microtubule/axon-, and proteasome-related pathways in FTLD-TDP when 
compared with controls, and cytoskeletal protein-, mitochondria/energy-, 
synapse-, microtubule/axon-, and ubiquitin-proteasome-associated 
deregulation when comparing FTLD-TDP with FTLD associated with motor 





FTLD-ALS spectrum (Conlon et al., 2018). However, weighted co-expression 
network proteomic analysis has recently revealed 15 modules of co-expressed 
proteins, eight of which differed significantly across the ALS-FTD disease 
spectrum. Interestingly, a module enriched with astrocyte and microglia 
proteins was significantly increased in the frontal cortex in ALS cases carrying 
the C9orf72 mutation compared to sporadic ALS cases, suggesting that the 
genetic expansion is associated with inflammation in the brain (Umoh et al., 
2018). Increased levels of proteins linked to inflammation were also identified 
in the frontal cortex in C9orf72 in our study.  
 
The present dual ‘omics’ approach, like the majority of molecular studies 
carried out in the post-mortem human brain, is based on the relative 
abundance of particular mRNAs and proteins or ratios of two absolute 
concentrations (fold-change) representing concentrations relative to 
reference samples. Moreover, the agonal state and postmortem delay may 
differentially interfere with transcription and protein synthesis/degradation. 
Therefore, when analyzing postmortem brain samples, a non-steady-state 
condition is always the real scenario. This statement is important when 
assessing transcripts and proteins separately, but it is especially critical when 
analyzing RNA and protein correlations of particular genes in human 
postmortem brain (Marguerat et al., 2012; Vogel and Marcotte, 2012; Liu et 
al., 2016).  
 
Moreover, distinct cell populations are usually mingled, and rates and scales 
of RNA and corresponding encoded proteins may be cell type-dependent. 
These facts, together with particular characteristics of samples, and 
differences in the procedures and methods, may account for the non-
homogeneous results in different laboratories. Although the original samples 





similar and complementary using a combination of transcriptomics and 
proteomics, it is worth stressing that different RNAs and proteins were 
identified by these methods. Combined nontargeted ‘-omics’ seems to be a 
valuable approach to deciphering altered molecular pathways in FTLD 
provided that observations are viewed cautiously when assessing human 



























































































































































I. Altered regulation of transcription is observed in sALS in a region-
dependent manner in frontal cortex area 8 and the anterior horn of 
the spinal cord in the same cases. 
 
II. The expression of synaptic and neurotransmission related genes is up-
regulated, whereas myelin and lipid related genes are down-regulated 
in frontal cortex area 8 in sALS cases without apparent cognitive 
impairment. In contrast, in the spinal cord, most up-regulated genes 
belong to inflammatory response, whereas the main down-regulated 
genes are involved in axonal transport.  
 
III. Alterations in the regulation of transcription related to synapses and 
neurotransmission in frontal cortex area 8 in the absence of overt 
clinical symptoms of cognitive impairment are particularly important 
to identify early molecular alterations in frontal cortex within the 
spectrum of ALS/FTLD-TDP. 
 
IV. Inflammatory markers analysis in peripheral whole-blood shows a 
complex scenario at early clinical stages of sALS, including, on the one 
hand, up-regulation of genes whose products are involved in 
leukocyte extravasation and extracellular matrix remodeling, and, on 
the other, down-regulation of chemokines, anti- and pro-
inflammatory cytokines, and lymphocyte modulators. 
 
V. Increased YKL40 levels in the CSF are not disease-specific but are a 
good biomarker of sALS progression. Co-detection of YKL40 and NF-L 





improving accuracy in determining the prognosis of patients with 
sALS. 
 
VI. LRRC50 is described for the first time in motor-neurons and is a 
component of C-boutons involved in dynein assembly and retrograde 
axonal transport. 
 
VII. LRRC50-immunoreactive boutons are reduced in the remaining motor 
neurons in the anterior horn of the spinal cord, and motor nuclei of 
the vagus and hippoglossus nerves in sALS. Interestingly, oculomotor 
nuclei of the brainstem, which are not affected in sALS, do not have 
LRRC50-positive boutons.  
 
VIII. Transgenic mice bearing high copy numbers of the mutated form of 
human SOD1 show decreased numbers of LRRC50-immunoreactive 
boutons at early, preclinical stages of the disease, highlighting 
decreased LRRC50-immunoreactive structures as an early event in ALS 
pathogenesis. 
 
IX. Marked decrease in the expression of genes coding for cytoskeletal 
and neurotransmission components is found in sFTLD-TDP. In 
contrast, tau mRNA and protein levels are preserved, and tau 
phosphorylation is not increased in sFTLD-TDP.  
 
X. Impairment of mitochondrial activity affecting several mitochondrial 
complexes, as well as down-regulation of selected genes and reduced 
proteins implicated in mitochondrial function and energy metabolism, 






XI. Comparing results in frontal cortex area 8 in sALS and sFTLD-TDP, most 
down-regulated genes in sFTLD-TDP are up-regulated in frontal cortex 
area 8 in sALS cases without dementia. This suggests a primary 
response to synaptic and neurotransmission disturbances in frontal 
cortex area 8 at preclinical stages of frontal degeneration in sALS 
which decays with disease progression and dementia.  
 
XII. c9FTLD transcriptomic study in frontal cortex area 8 reveals altered 
gene transcription related to DNA/RNA mechanisms, myelin synthesis, 
calcium regulation and ubiquitin-proteasome system.  
 
XIII. c9FTLD proteomics performed in the same tissue samples identifies 
altered protein expression linked to apoptosis, inflammation, synaptic 
structure and function, morphology of mitochondria, endocytosis 
mechanisms and synthesis of ROS. 
 
XIV. Down-regulated clusters related mainly to synapses and 
neurotransmission in frontal cortex in sFTLD-TDP are up-regulated in 
frontal cortex in sALS without dementia. c9FTLD reveal some 
commonalities within the spectrum of sFTLD-TDP in altered clusters 
but not in specific genes. Additionally, down-regulation of genes 
linked to oligodendrocytes and myelin in frontal cortex area 8 is 
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Additionally, during the PhD student period, the author has also contributed 
in the following publications: 
 
Cannabinoid receptor 2 participates in Aβ processing in a mouse 
model of Alzheimer’s disease but plays a minor role in the therapeutic 
properties of a cannabis-based medicine 
 
Aso E, Andrés-Benito P, Carmona M, Moreno J, Maldonado R, Ferrer I. 
Journal Alzheimer’s Disease. 2016 Feb 6; 2016, 51 (2): 489-500.  
doi: 10.3233/JAD-150913.  
 
ABSTRACT 
The endogenous cannabinoid system represents a promising therapeutic 
target to modify neurodegenerative pathways linked to Alzheimer's disease 
(AD). The aim of the present study was to evaluate the specific contribution of 
CB2 receptor to the progression of AD-like pathology and its role in the 
positive effect of a cannabis-based medicine (1:1 combination of Δ9-
tetrahidrocannabinol and cannabidiol) previously demonstrated to be 
beneficial in the AβPP/PS1 transgenic model of the disease. A new mouse 
strain was generated by crossing AβPP/PS1 transgenic mice with CB2 knockout 
mice. Results show that lack of CB2 exacerbates cortical Aβ deposition and 
increases the levels of soluble Aβ40. However, CB2 receptor deficiency does 
not affect the viability of AβPP/PS1 mice, does not accelerate their memory 
impairment, does not modify tau hyperphosphorylation in dystrophic neurites 
associated to Aβ plaques, and does not attenuate the positive cognitive effect 
induced by the cannabis-based medicine in these animals. These findings 
suggest a minor role for the CB2 receptor in the therapeutic effect of the 
cannabis-based medicine in AβPP/PS1 mice, but also constitute evidence of a 
link between CB2 receptor and Aβ processing. 
 
KEYWORDS: Alzheimer’s disease; AβPP/PS1 mice; amyloid; cannabinoid 









Delineating the efficacy of a cannabis-based medicine at advanced 
stages of dementia in a murine model 
 
Aso E, Andrés-Benito P, Ferrer I. 
Journal Alzheimer’s Disease. 2016 Oct 4; 54 (3): 903-912. 
doi: 10.3233/JAD-160533.  
 
ABSTRACT 
Previous reports have demonstrated that the combination of Δ9-
tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) botanical extracts, 
which are the components of an already approved cannabis-based medicine, 
reduce the Alzheimer-like phenotype of AβPP/PS1 transgenic mice when 
chronically administered during the early symptomatic stage. Here, we 
provide evidence that such natural cannabinoids are still effective in reducing 
memory impairment in AβPP/PS1 mice at advanced stages of the disease but 
are not effective in modifying the Aβ processing or in reducing the glial 
reactivity associated with aberrant Aβ deposition as occurs when 
administered at early stages of the disease. The present study also 
demonstrates that natural cannabinoids do not affect cognitive impairment 
associated with healthy aging in wild-type mice. The positive effects induced 
by Δ9-THC and CBD in aged AβPP/PS1 mice are associated with reduced 
GluR2/3 and increased levels of GABA-A Rα1 in cannabinoid-treated animals 
when compared with animals treated with vehicle alone. 
 

















Transcriptional network analysis in frontal cortex in Lewy body 
diseases with focus on dementia with Lewy bodies 
 
Santpere G and Garcia-Esparcia P, Andres-Benito P, Lorente-Galdós B, 
Navarro A, Ferrer I. 
Brain Pathol. 2017 Mar 21, 28(3):315-333. 
doi: 10.1111/bpa.12511.  
 
ABSTRACT 
The present study investigates global transcriptional changes in frontal cortex 
area 8 in incidental Lewy Body disease (iLBD), Parkinson disease (PD) and 
Dementia with Lewy bodies (DLB). We identified different coexpressed gene 
sets associated with disease stages, and gene ontology categories enriched in 
gene modules and differentially expressed genes including modules or gene 
clusters correlated to iLBD comprising upregulated dynein genes and taste 
receptors, and downregulated innate inflammation. Focusing on DLB, we 
found modules with genes significantly enriched in functions related to RNA 
and DNA production, mitochondria and energy metabolism, purine 
metabolism, chaperone and protein folding system and synapses and 
neurotransmission (particularly the GABAergic system). The expression of 
more than fifty selected genes was assessed with real time quantitative 
polymerase chain reaction. Our findings provide, for the first time, evidence 
of molecular cortical alterations in iLBD and involvement of several key 
metabolic pathways and gene hubs in DLB which may underlie cognitive 
impairment and dementia. 
 
KEYWORDS: GABA; Lewy body diseases; axonema; cerebral cortex; 
chaperones; dementia with Lewy bodies; dynein; mitochondria; 













Locus coeruleus at asymptomatic early and middle Braak stages of 
neurofibrillary tangle pathology 
 
Andrés-Benito P, Fernández-Dueñas V, Carmona M, Escobar LA, Torrejón B, 
Aso E, Ciruela F, Ferrer I. 
Neuropathol Appl Neurobiol. 2017 Aug; 43 (5): 373-392.  
doi: 10.1111/nan.12386.  
 
ABSTRACT 
AIMS: The present study analyses molecular characteristics of the locus 
coeruleus (LC) and projections to the amygdala and hippocampus at 
asymptomatic early and middle Braak stages of neurofibrillary tangle (NFT) 
pathology. METHODS: Immunohistochemistry, whole-transcriptome arrays 
and RT-qPCR in LC and western blotting in hippocampus and amygdala in a 
cohort of asymptomatic individuals at stages I-IV of NFT pathology were used. 
RESULTS: NFTs in the LC increased in parallel with colocalized expression of 
tau kinases, increased neuroketal adducts and decreased superoxide 
dismutase 1 in neurons with hyperphosphorylated tau and decreased voltage-
dependent anion channel in neurons containing truncated tau were found. 
These were accompanied by increased microglia and AIF1, CD68, PTGS2, IL1β, 
IL6 and TNF-α gene expression. Whole-transcriptome arrays revealed 
upregulation of genes coding for proteins associated with heat shock protein 
binding and genes associated with ATP metabolism and downregulation of 
genes coding for DNA-binding proteins and members of the small nucleolar 
RNAs family, at stage IV when compared with stage I. Tyrosine hydroxylase 
(TH) immunoreactivity was preserved in neurons of the LC, but decreased TH 
and increased α2A adrenergic receptor protein levels were found in the 
hippocampus and the amygdala. CONCLUSIONS: Complex alteration of several 
metabolic pathways occurs in the LC accompanying NFT formation at early and 
middle asymptomatic stages of NFT pathology. Dopaminergic/noradrenergic 
denervation and increased expression of α2A adrenergic receptor in the 
hippocampus and amygdala occur at first stage of NFT pathology, suggesting 
compensatory activation in the face of decreased adrenergic input occurring 
before clinical evidence of cognitive impairment and depression. 
 
KEYWORDS: Alzheimer's disease; amygdala; hippocampus; locus coeruleus; 






MicroRNA expression in the locus coeruleus, entorhinal cortex, and 
hippocampus at early and middle stages of braak neurofibrillary 
tangle pathology 
 
Llorens F and Thüne K and Andrés-Benito P, Tahir W, Ansoleaga B, 
Hernández-Ortega K, Martí E, Zerr I, Ferrer I. 
J. Mol. Neurosci. 2017 Oct; 63(2): 206-215.  
doi: 10.1007/s12031-017-0971-4.  
 
ABSTRACT 
The present study analyzes by RT-qPCR the expression of microRNA (miRNA)-
27a-3p, miRNA-124-3p, miRNA-132-3p, and miRNA-143-3p in the locus 
coeruleus (LC), entorhinal cortex (EC), CA1 region of the hippocampus (CA1), 
and dentate gyrus (DG) of middle-aged (MA) individuals with no brain lesions 
and of cases at Braak and Braak stages I-II and II-IV of neurofibrillary tangle 
(NFT) pathology. The most affected region is the LC in which miRNA-27a-3p, 
miRNA-124-3p, and miRNA-143-3p show a trend to increase at stages I-II and 
are significantly up-regulated at stages III-IV when compared with MA. Only 
miRNA-143-3p is up-regulated in the EC at stages III-IV when compared with 
MA and with stages I-II. No modifications in the expression levels of miRNA-
27a-3p, miRNA-124-3p, miRNA-132-3p, and miRNA-143-3p are found in CA1 
at any stage, whereas miRNA-124-3p is significantly down-regulated in DG at 
stages I-II. Accompanying in situ hybridization reveals miRNA-27a-3p, miRNA-
124-3p, and miRNA-143-3 localization in neurons, indicating that changes in 
miRNA expression are not a direct effect of changes in the numbers of neurons 
and glial cells. Present observations show for the first time important miRNA 
de-regulation in the LC at the first stages of NFT. Since the LC is the main 
noradrenergic input to the cerebral cortex, key regulator of mood and 
depression, and one of the first nuclei affected in aging and Alzheimer's 
disease (AD), these findings provide insights for additional study of the LC in 
aging and AD. 
 
KEYWORDS: Alzheimer disease; Entorhinal cortex; Hippocampus; Locus 








Altered regulation of KIAA0566, and katanin signalling expression in 
the locus coeruleus with neurofibrillary tangle pathology 
 
Andrés-Benito P, Delgado-Morales R, Ferrer I. 
Front. Cell Neurosci. 2018 May 17; 12:131.  
doi: 10.3389/fncel.2018.00131.  
 
ABSTRACT 
The locus coeruleus (LC), which contains the largest group of noradrenergic 
neurons in the central nervous system innervating the telencephalon, is an 
early and constantly vulnerable region to neurofibrillary tangle (NFT) 
pathology in aging and Alzheimer's disease (AD). The present study using 
whole genome bisulfite sequencing and Infinium Human Methylation 450 
BeadChip was designed to learn about DNA methylation profiles in LC with age 
and NFT pathology. This method identified decreased DNA methylation of 
Katanin-Interacting Protein gene (KIAA0566) linked to age and presence of 
NFT pathology. KIAA0566 mRNA expression demonstrated with RT-qPCR 
significantly decreased in cases with NFT pathology. Importantly, KIAA0566 
immunoreactivity was significantly decreased only in LC neurons with NFTs, 
but not in neurons without tau pathology when compared with neurons of 
middle-aged individuals. These changes were accompanied by a similar 
pattern of selective p80-katanin reduced protein expression in neurons with 
NFTs. In contrast, p60-katanin subunit expression levels in the neuropil were 
similar in MA cases and cases with NFT pathology. Since katanin is a major 
microtubule-severing protein and KIAA0566 binds and interacts with katanin, 
de-regulation of the katanin-signaling pathway may have implications in the 
regulation of microtubule homeostasis in LC neurons with NFTs, thereby 
potentially interfering with maintenance of the cytoskeleton and transport. 
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Altered gene transcription in astrocytes and oligodendrocytes in 
frontal cortex in Creutzfeldt-Jakob disease MM1 and VV2 
 
Andrés-Benito P, Domínguez-González M, Ferrer I.  
Prion 2018 Jul 15. 12(3-4):216-225.  
doi: 10.1080/19336896.2018.1500076.  
 
ABSTRACT 
Targeted expression of genes coding for proteins specific to astrocytes, 
oligodendrocytes and myelin was performed in frontal cortex area 8 of 
Creutzfeldt-Jakob disease methionine/methionine and valine/valine (CJD 
MM1 and VV2, respectively) compared with controls. GFAP (glial fibrillary 
acidic protein) mRNA was up-regulated whereas SLC1A2 (solute carrier family 
1 member 2, coding for glutamate transporter 1: GLT1), AQ4 (aquaporin 4), 
MPC1 (mitochondrial pyruvate carrier 1) and UCP5 (mitochondrial uncoupled 
protein 5) mRNAs were significantly down-regulated in CJD MM1 and CJD VV2, 
and GJA1 (connexin 43) in CJD VV2. OLIG1 and OLIG2 (oligodendocyte 
transcription factor 1 and 2, respectively), SOX10 (SRY-Box10) and 
oligodendroglial precursor cell (OPC) marker NG2 (neuronal/glial antigen) 2 
were preserved, but GALC (coding for galactosylceramidase), SLC2A1 (solute 
carrier family 2 member 1: glucose transporter member 1: GLUT1) and MCT1 
(monocarboxylic acid transporter 1) mRNA expression levels were significantly 
reduced in CJD MM1 and CJD VV2. Expression levels of most genes linked to 
myelin were not altered in the cerebral cortex in CJD. Immunohistochemistry 
to selected proteins disclosed individual variations but GFAP, Olig-2, AQ4 and 
GLUT1 correlated with mRNA levels, whereas GLT1 was subjected to individual 
variations. However, MPC1, UCP5 and MCT1 decrease was more closely 
related to the respective reduced neuronal immunostaining. These 
observations support the idea that molecular deficits linked to energy 
metabolism and solute transport in astrocytes and oligodendrocytes, in 
addition to neurons, are relevant in the pathogenesis of cortical lesions in CJD. 
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PPARɣ agonist-loaded PLGA-PEG nanocarriers as a potential 
treatment for Alzheimer's disease: in vitro and in vivo studies 
 
Silva-Abreu M, Calpena AC, Andrés-Benito P, Aso E, Roig D, Espina M, García 
ML, Ferrer I, Romero IA, Male D. 
Int. J. Nanomedicine. 2018 Sep 20; 13:5577-5590.  
doi: 10.2147/IJN.S171490. IF: 4.30 
 
ABSTRACT 
OBJECTIVE: The first aim of this study was to develop a nanocarrier that could 
transport the peroxisome proliferator-activated receptor agonist, pioglitazone 
(PGZ) across brain endothelium and examine the mechanism of nanoparticle 
transcytosis. The second aim was to determine whether these nanocarriers 
could successfully treat a mouse model of Alzheimer's disease (AD). 
METHODS: PGZ-loaded nanoparticles (PGZ-NPs) were synthesized by the 
solvent displacement technique, following a factorial design using poly (lactic-
co-glycolic acid) polyethylene glycol (PLGA-PEG). The transport of the carriers 
was assessed in vitro, using a human brain endothelial cell line, cytotoxicity 
assays, fluorescence-tagged nanocarriers, fluorescence-activated cell sorting, 
confocal and transmission electron microscopy. The effectiveness of the 
treatment was assessed in APP/PS1 mice in a behavioral assay and by 
measuring the cortical deposition of β-amyloid. RESULTS: Incorporation of PGZ 
into the carriers promoted a 50x greater uptake into brain endothelium 
compared with the free drug and the carriers showed a delayed release profile 
of PGZ in vitro. In the doses used, the nanocarriers were not toxic for the 
endothelial cells, nor did they alter the permeability of the blood-brain barrier 
model. EM indicated that the nanocarriers were transported from the apical 
to the basal surface of the endothelium by vesicular transcytosis. An efficacy 
test carried out in APP/PS1 transgenic mice showed a reduction of memory 
deficit in mice chronically treated with PGZ-NPs. Deposition of β-amyloid in 
the cerebral cortex, measured by immunohistochemistry and image analysis, 
was correspondingly reduced. CONCLUSION: PLGA-PEG nanocarriers cross 
brain endothelium by transcytosis and can be loaded with a pharmaceutical 
agent to effectively treat a mouse model of AD. 
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Genetic deletion of CB1 cannabinoid receptors exacerbates the 
Alzheimer-like symptoms in a transgenic animal model 
 
Aso E, Andrés-Benito P, Ferrer I. 
Biochemical Pharmacology. 2018 Nov; 157: 210-216. 
doi: 10.1016/j.bcp.2018.08.007.  
 
ABSTRACT 
Activating CB1 cannabinoid receptor has been demonstrated to produce 
certain therapeutic effects in animal models of Alzheimer's disease (AD). In 
this study, we evaluated the specific contribution of CB1 receptor to the 
progression of AD-like pathology in double transgenic APP/PS1 mice. A new 
mouse strain was generated by crossing APP/PS1 transgenic mice with CB1 
knockout mice. Genetic deletion of CB1 drastically reduced the survival of 
APP/PS1 mice. In spite that CB1 mutant mice bearing the APP/PS1 transgene 
developed normally, they suddenly died within the first two months of life 
likely due to spontaneous seizures. This increased mortality could be related 
to an imbalance in the excitatory/inhibitory transmission in the hippocampus 
as suggested by the reduced density of inhibitory parvalbumin positive 
neurons observed in APP/PS1 mice lacking CB1 receptor at 7 weeks of age. We 
also evaluated the AD-like phenotype of APP/PS1 mice heterozygous for the 
CB1 deletion at 3 and 6 months of age. The memory impairment associated to 
APP/PS1 transgene was accelerated in these mice. Neither the soluble levels 
of Aβ or the density of Aβ plaques were modified in APP/PS1 mice 
heterozygous for CB1 deletion at any age. However, the reduction in CB1 
receptor expression decreased the levels of PSD-95 protein in APP/PS1 mice, 
suggesting a synaptic dysfunction in these animals that could account for the 
acceleration of the memory impairment observed. In summary, our results 
suggest a crucial role for CB1 receptor in the progression of AD-related 
pathological events. 
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Wnt signaling alterations in the human spinal cord of ALS cases: 
spotlight on Fz2, Fz5 and Wnt5a 
 
González-Fernández C, González P, Andrés-Benito P, Ferrer I, Rodríguez FJ. 




Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with 
no cure, and elucidation of the mechanisms mediating neuronal death in this 
neuropathology is crucial to develop effective treatments. It has recently been 
demonstrated in animal models that the Wnt family of proteins is involved in 
this neuropathology, although its potential involvement in case of humans is 
almost unknown. We analyzed the expression of Wnt signaling components in 
healthy and ALS human spinal cords by quantitative RT-PCR, and we found 
that most Wnt ligands, modulators, receptors, and co-receptors were 
expressed in healthy controls. Moreover, we observed clear alterations in the 
mRNA expression of different components of this family of proteins in human 
spinal cord tissue from ALS cases. Specifically, we detected a significant 
increase in the mRNA levels of Wnt3, Wnt4, Fz2, and Fz8, together with several 
non-significant increases in the mRNA expression of other genes such as 
Wnt2b, Wnt5a, Fz3, Lrp5, and sFRP3. Based on these observations and on 
previous reports of studies performed in animal models, we evaluated with 
immunohistochemistry the protein expression patterns of Fz2 and Fz5 
receptors and their main ligand Wnt5a in control samples and ALS cases. No 
substantial changes were observed in Fz5 protein expression pattern in ALS 
samples. However, we detected an increase in the amount of Fz2+ astrocytes 
in the borderline between gray and white matter at the ventral horn in ALS 
samples. Finally, Wnt5a expression was observed in neurons and astrocytes in 
both control and ALS samples, although Wnt5a immunolabeling in astroglial 
cells was significantly increased in ALS spinal cords in the same region where 
changes in Fz2 were observed. Altogether, these observations strongly 
suggest that the Wnt family of proteins, and more specifically Fz2 and Wnt5a, 
might be involved in human ALS pathology. 
 






Involvement of oligodendrocytes in Tau seeding and spreading in 
tauopathies 
 
Ferrer I, Aguiló García M, Carmona M, Andrés-Benito P, Torrejón-Escribano 
B, Garcia-Esparcia P, Del Rio JA. 




INTRODUCTION: Human tau seeding and spreading occur following 
intracerebral inoculation into different gray matter regions of brain 
homogenates obtained from tauopathies in transgenic mice expressing wild 
or mutant tau, and in wild-type (WT) mice. However, little is known about tau 
propagation following inoculation in the white matter. OBJECTIVES: The 
present study is geared to learning about the patterns of tau seeding and cells 
involved following unilateral inoculation in the corpus callosum of 
homogenates from sporadic Alzheimer's disease (AD), primary age-related 
tauopathy (PART: neuronal 4Rtau and 3Rtau), pure aging-related tau 
astrogliopathy (ARTAG: astroglial 4Rtau with thorn-shaped astrocytes TSAs), 
globular glial tauopathy (GGT: 4Rtau with neuronal tau and specific tau 
inclusions in astrocytes and oligodendrocytes, GAIs and GOIs, respectively), 
progressive supranuclear palsy (PSP: 4Rtau with neuronal inclusions, tufted 
astrocytes and coiled bodies), Pick's disease (PiD: 3Rtau with characteristic 
Pick bodies in neurons and tau containing fibrillar astrocytes), and 
frontotemporal lobar degeneration linked to P301L mutation (FTLD-P301L: 
4Rtau familial tauopathy). METHODS: Adult WT mice were inoculated 
unilaterally in the lateral corpus callosum with sarkosyl-insoluble fractions or 
with sarkosyl-soluble fractions from the mentioned tauopathies; mice were 
killed from 4 to 7 months after inoculation. Brains were fixed in 
paraformaldehyde, embedded in paraffin and processed for 
immunohistochemistry. RESULTS: Tau seeding occurred in the ipsilateral 
corpus callosum and was also detected in the contralateral corpus callosum. 
Phospho-tau deposits were found in oligodendrocytes similar to coiled bodies 
and in threads. Moreover, tau deposits co-localized with active 
(phosphorylated) tau kinases p38 and ERK 1/2, suggesting active tau 
phosphorylation of murine tau. TSAs, GAIs, GOIs, tufted astrocytes, and tau-





often associated with slight myelin disruption and the presence of small PLP1-
immunoreactive globules and dots in the ipsilateral corpus callosum 6 months 
after inoculation of sarkosyl-insoluble fractions from every tauopathy. 
CONCLUSIONS: Seeding and spreading of human tau in the corpus callosum of 
WT mice occurs in oligodendrocytes, thereby supporting the idea of a role of 
oligodendrogliopathy in tau seeding and spreading in the white matter in 
tauopathies. Slight differences in the predominance of threads or 
oligodendroglial deposits suggest disease differences in the capacity of tau 
seeding and spreading among tauopathies. 
 


























Cannabidiol-enriched extract reduced the cognitive impairment but 
not the epileptic seizures of a Lafora’s disease animal model 
 
Aso E, Andrés-Benito P, Grau-Escolano J, Caltana L, Brusco A, Sanz P, Ferrer 
I.  




Lafora disease (LD) is a rare form of progressive infantile epilepsy in which a 
rapid neurological deterioration occurs as the disease advances, leading the 
patients to a vegetative state and then death, usually within the first decade 
of disease onset. Based on the capacity of the endogenous cannabinoid 
system (ECS) to modulate several cellular processes commonly altered in 
many neurodegenerative processes, as well as the antiepileptic properties of 
certain natural cannabinoids, the aim of the present study was to evaluate the 
role of the ECS in LD progression and to test whether a natural cannabis 
extract highly enriched in cannabidiol (CBD) might be effective in curbing the 
pathological phenotype of malin knockout (KO) mice as an animal model of 
LD. Our results reveal for the first time that alterations in the ECS occur during 
the evolution of LD, mainly at the level of CB1, CB2 and GPR55 receptors 
expression, and that a CBD-enriched extract is able to reduce the cognitive 
impairment exhibited by malin KO mice. However, in contrast to what has 
previously been reported for other kinds of refractory epilepsy in childhood, 
the CBD-enriched extract does not reduce the severity of the epileptic seizures 
induced in this animal model of LD. 
 















Relevance of host tau in tau seeding and spreading in tauopathies 
 
Ferrer I, Zelaya MV, Aguiló García M, Carmona M, López-González I, Andrés-
Benito P, Lidón L, Gavín R, Garcia-Esparcia P, Del Rio JA. 




Introduction: Human tau seeding and spreading occur following intracerebral 
inoculation of brain homogenates obtained from tauopathies in transgenic 
mice expressing natural or mutant tau, and in wild-type (WT) mice. Objectives: 
The present study was geared to learning about the patterns of tau seeding, 
the cells involved, and the characteristics of tau following intracerebral 
inoculation of homogenates from primary age-related tauopathy (PART: 
neuronal 4Rtau and 3Rtau), aging-related tau astrogliopathy (ARTAG: 
astrocytic 4Rtau), and globular glial tauopathy (GGT: 4Rtau with neuronal 
deposits and specific tau inclusions in astrocytes and oligodendrocytes). 
Methods: Young and adult WT mice were inoculated unilaterally in the 
hippocampus or in the lateral corpus callosum with sarkosyl-insoluble 
fractions from PART, ARTAG, and GGT cases, and were killed at variable 
periods of three to seven months. Brains were processed for 
immunohistochemistry in paraffin sections. Results: Tau seeding occurred in 
the ipsilateral hippocampus and corpus callosum and spread to the septal 
nuclei, periventricular hypothalamus and contralateral corpus callosum, 
respectively. Tau deposits were mainly found in neurons, oligodendrocytes, 
and threads; the deposits were diffuse or granular, composed of 
phosphorylated tau, tau with abnormal conformation, and 3Rtau and 4Rtau 
independently of the type of tauopathy. Truncated tau at the aspartic acid 421 
and ubiquitination were absent. Tau deposits had the characteristics of pre-
tangles. A percentage of intracellular tau deposits co-localized with active 
(phosphorylated) tau kinases p38 and ERK 1/2. Conclusions: Seeding and 
spreading of human tau into the brain of WT mice involves neurons and glial 
cells, mainly oligodendrocytes, thereby supporting the idea of a primary role 
of oligodendrogliopathy, together with neuronopathy, in the progression of 
tauopathies. Human tau inoculation modifies murine tau metabolism with the 
production and deposition of 3Rtau and 4Rtau, and by activation of specific 





tauopathy, aging-related tau astrogliopathy, globular glial tauopathy, seeding, 
spreading. 
 
KEYWORDS: tau, tauopathies, primary age-related tauopathy, aging-related 






































Nuclear lipidome is altered in amyotrophic lateral sclerosis: a 
preliminary study 
 
Ramirez-Nuñez O, Jové M, Torres P, Sol J, Fontdevila L, Romero-Guevara R, 
Ayala V, Rossi C, Boada J, Povedano M, Andrés-Benito P, Ferrer I, Pamplona 
R, Portero-Otín M. 
Under revision. (Submitted 25/06/2019) 
 
ABSTRACT 
In this pilot study, we show that nuclei in spinal cord from ALS patients exhibit 
a differential lipidomic signature. Among the differential lipid species we could 
annotate 41 potential identities. These comprise membrane-bound lipids such 
as phosphatidylethanolamines -including plasmalogens- and 
phosphatidylcholines but also other lipid classes such as glycosphingolipids, 
diacylglycerols, and triacylglycerides (potentially present as nuclear lipid 
droplets). These results were orthogonally validated by showing loss of 
alkyldihydroxyacetonephosphate synthase (AGPS), a key peroxisomal enzyme 
in plasmalogen synthesis, both in ALS necropsy samples, in human motor 
neurons derived from iPSC from ALS patients and in hSOD-G93A transgenic 
mice. Further, diacylglycerol content changes were associated to ALS-linked 
variations in related-enzymes, such as phospholipase C βI (PLCβI), the source 
of nuclear diacylglycerol, and protein kinase CβII (PKCβII), whose function 
partially depends on nuclei concentration of diacylglycerol. These results point 
out for not only a role of nuclear membrane lipids but also to lipids present in 
the nucleoplasm, suggesting an undisclosed role for this part of the subcellular 
lipidome in ALS pathophysiology. 
 














A non-canonical senescence profile in the spinal cord of the ALS model 
hSOD1-G93A 
 
Torres P, Anerillas C, Encinas M, Povedano M, Andrés-Benito P, Ferrer I, 
Ayala V, Pamplona R, Portero-Otín M 
Under revision. (Submitted 08/05/2019) 
 
The present study was addressed to explore cellular senescence mechanisms 
and senescence-associated secretory phenotype (SASP) markers in the familial 
amyotrophic lateral sclerosis (ALS) transgenic mouse model hSOD1-G93A. We 
evaluate senescence biomarkers, including p16 and p21 by reverse-
transcriptase quantitative PCR (RT-qPCR), immunofluorescence (IF) and 
immunohistochemistry (IHC), as well as senescence associated beta 
galactosidase (SA-beta-gal) activity in the lumbar spinal cords (LSC) of this 
model. We also quantified the mRNA levels of SASP markers and its 
association with the potential dysfunction of TAR-DNA binding of 43 kDa (TDP-
43). Our results show an atypical senescence-profile in LSC from transgenic 
mice, with an increase of p16 and p21 mRNA and protein levels in glial cells 
with a mostly cytoplasmic pattern, without the canonical increase of SA-beta-
gal activity. Consistent with enhanced SASP, there is an increase of Il1a and Il6. 
TDP43 splicing activity is compromised in this ALS model and it is significantly 
associated with the p16 mRNA increase. Globally, our findings support the 
existence of a non-canonical profile of senescence biomarkers in the LSC of 
the ALS model hSOD1-G93A. 
 
KEYWORDS: Cell senescence; amyotrophic lateral sclerosis; motor neuron; 
cryptic exon; senescenceassociated secretory phenotype; cell cycle 
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